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Abstract 
CD40 is a member of the Tumour Necrosis Factor (TNF)-Receptor superfamily and plays an 
important role in maturation and differentiation of dendritic cells and B cells. In B cells, 
CD40 provides a costimulatory signal and facilitates differentiation, germinal centre 
formation and isotype switching. So far it has been shown that TNF-Receptor Associated 
Factors (TRAFs) and cellular Inhibitor of Apoptosis Proteins (cIAPs) are important mediators 
of CD40 signalling and needed for the activation of Nuclear Factor-κB (NF-κB) and Mitogen-
Activated Protein Kinase (MAPK) signalling pathways. However, the exact function of these 
components and their biochemical interplay are still unknown. Hence, our understanding of 
the CD40-Receptor Signalling Complex (RSC) which initiates CD40 signal transduction is 
incomplete. 
In order to understand the biochemical processes that initiate CD40 signalling a new 
technique suitable to identify core components of the CD40-RSC was developed in this thesis. 
This technique is based on the employment of a tandem-tagged recombinant version of CD40 
ligand to purify the CD40-RSC in two separate steps. This resulted in higher purity of the 
receptor complex and allowed for determining the composition of the CD40-RSC by mass 
spectrometry. 
This established protocol revealed the recruitment of three novel constituents to the CD40-
RSC. HOIL-1, HOIP and SHARPIN are able to form the Linear Ubiquitin Chain Assembly 
Complex (LUBAC) which catalyses the formation of linear ubiquitin chains. This complex 
was only recruited to the CD40-RSC when highly ubiquitinated cIAP2 was also present. It 
was then shown that HOIL-1 and HOIP can bind to ubiquitin chains in vitro and that cIAPs 
are required for LUBAC recruitment to the CD40-RSC. Specific suppression of LUBAC 
components by RNA interference or by genetic ablation resulted in an inhibitory effect on 
CD40 signal transduction, gene induction and isotype switching caused by a defect in NF-κB 
and MAPK signalling. 
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Chapter 1. Introduction 
1.1 The immune system 
Humans are constantly surrounded by microzoa, viruses and other microorganisms which are 
able to infiltrate the body and cause disease. Evolution has therefore equipped living 
organisms with a defence mechanism, the immune system. This system is able to distinguish 
infiltrating organisms from the body (self/non-self discrimination) and in most cases it can 
eliminate the foreign invaders. In addition, the system is able to recognise altered host cells 
which may lead to cancer. 
The understanding of the immune system has largely improved since the 1790’s when Edward 
Jenner made use of the body’s host defences by challenging them. He deliberately infected a 
boy with the virus responsible for cowpox and, in doing so, protected him against the human 
disease smallpox. Although this new technique, termed vaccination, spread quickly 
throughout Europe, it was another hundred years until Louis Pasteur developed a vaccine 
against fowl cholera. Paul Ehrlich’s work on diphtheria serum inspired his side chain theory, a 
precursor idea that cells express surface molecules for binding antigens. Studies by Elie 
Metchnikoff on phagocytosis identified macrophages as cellular components of the immune 
system which play an important role in the elimination of foreign material. These findings 
were honoured with the Nobel Prize in 1908 for Ehrlich and Metchnikoff, and it became clear 
that the immune system can be divided into two parts which we refer to as adaptive and innate 
immunity (Kaufmann, 2008). Today it is well established that the immune system is quite 
complex and that a large variety of cells and molecules contributes to the effects observed by 
these early pioneers (Silverstein, 2009). 
Innate immunity is the first line of defence and comprises molecular and cellular mechanisms. 
All components are pre-existing and do not adapt during an infection, however, it provides 
immediate protection against foreign components. In contrast, adaptive immunity is activated 
more slowly than innate immunity, but provides a second, more specified line of defence. 
This system acts in a highly specific manner against pathogens by being able to adapt to the 
non-self. Additionally, the adaptive immunity establishes immunological memory of foreign 
antigen by being able to proliferate and differentiate into long lived cells.  
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1.1.1 The innate immune response 
The innate immunity is the most ancient defence mechanism of vertebrates against microbes. 
In fact, some forms of innate immunity can be found in all multicellular plants and animals 
whereas the adaptive immune system has evolved more recently and was long thought to be 
restricted to jawed vertebrates; however, recent findings also showed an existence in jawless 
vertebrates, such as hagfish and lampreys (Boehm, 2011). Importantly, innate immunity also 
provides the basis for the the development of an effective adaptive immune response. 
Pathogens escaping the first line of defence provoke a weaker response of the adaptive 
immunity showing that for a proper immune response both systems must cooperate (Murphy 
et al, 2008). 
1.1.1.1 The first barriers for pathogens 
All surfaces of the human body exposed to pathogens have developed an active mechanical 
barrier to protect it against invasion by pathogens. These mechanisms include maintaining 
unfavourable pH levels such as pH 5 on the skin and pH 1 in the stomach. In addition, anti-
bacterial molecules are produced by keratinocytes into the extracellular matrix and the layer 
of corneocytes, such as lysozyme, dermcidin, psoriasin or RNases (Elias, 2007). Moreover, 
the skin and the intestine are covered with commensal bacteria which while resistant to these 
protection mechanisms also provide protection against settlement of pathogens. The lower 
respiratory tract produces mucus which traps pathogens and is removed by hair-like 
protrusions, called cilia. Finally, coughing, sneezing and tearing are mechanical mechanisms 
that expel foreign items (Delves et al, 2006). 
1.1.1.2 Molecular components of innate immunity 
Once a pathogen breaches the anatomical barriers of the host, it will immediately be 
recognised by cells and molecules from the innate immune system via so-called pattern 
recognition receptors (PRRs) that, as the name suggests, are molecular receptors for certain 
pathogen-associated molecular patterns (PAMPs) expressed by the invading organism. PRRs 
can be either soluble or membrane bound. The detection of pathogens by PRRs initiates a 
multitude of expression and signalling events, such as the immediate production of soluble 
mannose-binding lectin (MBL) and the C-reactive protein (CRP). MBL binds to mannose, a 
carbohydrate which is expressed on bacteria, and CRP binds to phosphocholine which is 
expressed on dying cells and some bacteria. Both these proteins are able to activate the 
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complement system, which is a family of proteases whose cleavage products are able to 
activate immune responses and lyse microorganisms by forming holes in their membranes 
(Delves et al, 2006).  
Another important group of PRRs are the membrane bound Toll like receptors (TLRs). 
Interestingly, TLRs were first associated with dorsal-ventral development in Drosophila, but 
later on a role in the anti-fungal immune response in Drosophila was described by Jules 
Hoffmann and Bruno Lemaitre in 1996 (Lemaitre et al, 1996). One year later, a connection 
between the homologous proteins in humans and host defence mechanisms was made by 
Ruslan Medzhitov and Charles Janeway (Medzhitov et al, 1997). This class of PRRs 
recognises PAMPs such as lipopolysaccharide (LPS), single-stranded RNA (ssRNA), double-
stranded RNA (dsRNA) and flagellin. They can either be localised in the plasma membrane or 
in internal compartments like the phagolysosome, and are also expressed on cells of the 
adaptive immune system, e.g. B cells. Once TLRs bind to their ligands, they trigger gene 
expression and the release of pro-inflammatory mediators (Kumar et al, 2009).  
Pro- and anti-inflammatory mediators are combined in a group of signalling molecules called 
cytokines. Cytokines have a wide spectrum of activities as they can be pleiotropic or specific 
to a cell type; they can act locally or on distant organs. One example of a cytokine which acts 
locally is Interleukin-8 (IL-8), a chemoattractant which induces proximal endothelial tissue 
vasodilatation and promotes neutrophil recruitment. Tumour necrosis factor (TNF) and IL-6 
are examples of cytokines that can also act systemically, beside their local effects, and induce 
expression of acute phase response proteins in the liver, such as CRP and components of the 
complement cascade (Delves et al, 2006). 
1.1.1.3 Cellular components of innate immunity 
Cells of the innate immune system are the first to encounter pathogens and try to clear the 
infection locally. Macrophages are one such cell type and reside in different parts of the body 
in order to act at the site of invasion. They are able to engulf, or phagocytose, microbes and 
produce non-specific but highly reactive chemicals. Macrophages express the Nicotinamid-
adenin-dinukleotid-phosphat (NADPH) phagosome oxidase enzyme complex and the 
inducible nitric oxide synthetase (iNOS) which allow them to produce reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) respectively. After phagocytosis, the 
microbes are sequestered inside the macrophages but separated from the cytosol in 
phagosomes; the production of ROS and RNS inside the phagosome lead to the killing of the 
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pathogen therein. Additionally, macrophages release inflammatory mediators to establish the 
site of inflammation and recruit more cells from the circulation. The majority of immune cells 
recruited by this process are neutrophils which are specialised in eliminating pathogens via 
phagocytosis and the production of antimicrobial substances, such as ROS and RNS (Delves 
et al, 2006). 
Dendritic cells (DC) are another type of innate immune cells, and are important for 
connecting innate and adaptive immunity. After DC have engulfed pathogens, they are able to 
process and present molecular fragments derived from pathogens, termed antigens, on their 
surface in the context of surface protein called the major histocompatibility complex (MHC). 
MHC molecules can be recognised by cells of the adaptive immune system and are therefore 
important for the development of an adaptive immune response. Two general classes of MHC 
molecules can be distinguished: MHC class I and MHC class II. MHC class I molecules are 
found on all nucleated cells and present peptides on the cell surface which are recognised by 
cytotoxic cells. MHC class II molecules are expressed solely on antigen presenting cells 
(APC), such as DCs, macrophages and B cells, and only they are able to present pathogen-
derived antigens in the context of MHC class II molecules to cells of the adaptive immune 
system. DCs are considered professional APCs because they have the ability to migrate to 
secondary lymphoid tissues after antigen uptake and present antigens effectively at the site at 
which an adaptive immune response develops (Murphy et al, 2008). 
Another cellular constituent of the innate immune system are natural killer (NK) cells. NK 
cells provide a line of defence against viral infections. Since infected cells express less surface 
MHC class I molecules than non-infected cells, NK cells are able to distinguish between 
infected and non-infected cells. The loss of inhibitory surface signals for NK cells is the 
trigger to target infected cells for killing. NK cells also produce Interferon-γ (IFNγ) and TNF 
which are potent activators of both innate and adaptive immune responses, thereby showing 
again how these systems are interlocked (Murphy et al, 2008).  
1.1.2 The adaptive immune response 
The adaptive branch of the immune response acts more slowly than the innate branch to an 
infection (Figure 1.1) because it involves cell selection, expansion and maturation. However, 
it is more specific than innate immunity and it is able to “remember” antigens, creating the 
possibility to rapidly defeat a second infection by the same pathogen.  
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B cells and T cells are the main players within this part of the immune system. Both cell types 
reside in lymphoid organs until they are activated to differentiate and proliferate by the 
presentation of antigen by cells of the innate immune system. T cells and B cells have 
receptors which are specific for antigens and are called the T cell receptor (TCR) or B cell 
receptor (BCR) respectively. The TCR can only bind to antigens which are presented in the 
context of MHC class I or II molecules. Different subsets of T cells can be identified by the 
expression of surface markers and cytokine expression. The first important differentiation is 
via the surface expression of the cell differentiation markers CD4 or CD8. These marker 
proteins are involved in binding of the T cell to the APC via MHC molecules. Whereas the 
TCR binds to the MHC molecule in the region of the antigen, the CD4 and CD8 molecules 
recognise a different part of the MHC molecules. CD8+ T cells are stimulated by MHC class I 
molecules on APCs, while CD4+ T cells bind to, and are stimulated by, MHC class II 
molecules on APCs (Murphy et al, 2008).  
CD8+ T cells are referred to as cytotoxic T cells because they are able to lyse infected or 
dysfunctional somatic cells. Upon activation, cytotoxic lymphocytes release perforin and 
granzymes. Whereas perforin forms pores in the membrane of target cells, granzymes exhibit 
protease activity and lead to cell death (Anthony et al, 2010). Thereby they are able to destroy 
intracellular pathogens such as viruses. CD4+ T cells recognise MHC class II molecules on 
Removal of
infectious agent
Removal of
infectious agent
Clonal expansion
and
differentiation to
effector cells
Removal of
infectious agent
Innate Immunity
(immediate: 0-4 
hours)
Early induced
innate response
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hours)
Adaptive immune 
response (late: 
>96 hours)
Recognition by
preformed, 
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associated
molecular
patterns
Recognition by
naive B and T 
cells
Transport of
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Figure 1.1: The response to an initial infection. 
The activation of the immune response can be seen as a process of different 
compartments of the immune system: the immediate innate immunity, the early induced 
innate response and the late adaptive immune response. The first two phases are 
immediate but unspecific wereas the last one is highly specific but needs time to be 
activated. (adapted from (Murphy et al, 2008)) 
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APCs. These T cells provide additional signals for APC that serve to magnify or strengthen 
the response and are therefore called “T-helper cells”. The CD4+ T cell population can again 
be divided thus far into four subclasses: TH1, TH2, TH17 and Treg cells. TH1 cells enable an 
protective immunity against intracellular viral and bacterial infections. They mainly produce 
IFNγ, TNF and LT-α which are potent stimulators of macrophages and cytotoxic lymphocytes 
(Szabo et al, 2003). In contrast, TH2 cells are able to stimulate the humoral immune response 
by providing additional signals to B cells, such as the cytokines IL-4, IL-5, IL-9 and CD40L. 
Thereby, TH2 cells provide help for neutralising extracellular pathogens but are also important 
for expelling parasitic worms, such as helminths. Moreover, they are involved in allergic 
reactions (Paul & Zhu). In 2000, a new class of T cells was identified, now referred to as TH17 
cells. They mainly secrete IL-17, IL-6, TNF and the chemokine (C-X-C-motif) ligand-1 
(CXCL1). These cytokines are important for the early recruitment of neutrophils to the site of 
an infection (Infante-Duarte et al, 2000; Ouyang et al, 2008). The regulatory T cells, or Treg 
cells, produce IL-10 and TGF-β which are cytokines with immune suppressive functions. 
Therefore this cell type is able to negatively regulate an immune response and induce 
peripheral tolerance (Vignali et al, 2008). 
1.2 B cells 
The major role of B cells is the production of antibodies which are able to bind specific 
antigens, thereby neutralising their activity and opsonising them for either phagocytosis or 
clearance from the body. B cell development takes place in the bone marrow and 
subsequently leads to their release to the circulation. These cells make first contact with 
antigens in the secondary lymphoid tissue which initiates their maturation into antibody-
producing plasma cells or memory cells. 
1.2.1 B cell development 
B cell development in the bone marrow can be categorised in several characteristic stages. 
Development and expression of the immunoglobulin heavy and light chains that comprise the 
BCR define crucial stages in B cell maturation. Productive chromosomal gene rearrangements 
must occur in order for a functional BCR to be expressed, and hence B cell development to 
proceed.  
Arising from pluripotent haematopoietic stem cells in the bone marrow, B cells maintain close 
contact with stromal bone marrow cells which provide important growth factors such as stem-
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cell factor (SCF) and IL-7. Lymphoid progenitor cells are the first subpopulation which can 
be distinguished from the myeloid progenitor cells, and go on to differentitate into pro-B 
cells. At this stage, the pro-B cells already express the Igα/Igβ chains of the BCR, which are 
needed for signalling. Furthermore, these cells express several surface markers, such as 
CD45R, CD19 and IL-7R, and the intracellular proteins recombination activating genes -1 
and -2 (RAG-1 and RAG-2). RAG-1 and RAG-2 are needed for gene rearrangement to 
produce the BCR heavy chain. Gene rearrangement for the heavy chain involves three 
different gene segments, the Variable, the Diverse and the Joining gene segments (VDJ loci), 
each with multiple gene segments. The rearrangement for the light chain involves only gene 
segments of the V and J loci. One gene from each locus will be rearranged randomly with a 
gene from the other loci to achieve higher diversity. The first rearrangement is between the D 
and JH loci of the heavy chain at the late pro-B cell stage. A subsequent rearrangement 
bringing the VH and the DJH loci together should, in the case of a productive rearrangement, 
result in the expression of the immunoglobulin µ heavy chain on the cell surface. At this pre-
B cell stage, the heavy chain is tested for its functionality; the pre-BCR is formed by the 
expression of two surrogate chains encoded by non-rearranging genes, λ5 and VpreB. The 
interaction of these surrogate chains with the heavy chain marks an important checkpoint in 
the development of B cells: without a functional pre-BCR no further development occurs. 
Signalling via this receptor also enforces allelic exclusion, which means that the second allele 
is excluded from producing a heavy chain (Melchers, 2005; Murphy et al, 2008).  
Pre-B cells are large in size and undergo multiple cell divisions to produce a repertoire of 
smaller pre-B cells for rearrangement of the light chain. The light chain is produced by 
joining the VL to JL segment; in the case of unproductive rearrangements this procedure can 
be repeated. Rearrangement is attempted on the same allele again, and if this does not lead to 
a successful rearrangement, the second allele is used. This second rearrangement produces a 
large number of immature B cells, each expressing only one type of receptor but with a high 
diversity for antigen specificity among the cells. Immature B cells express membrane-bound 
immunoglobulin (Ig)M on the surface and are tested in the bone marrow for self tolerance. In 
the case a cell binds to self antigen it does not receive the necessary signals for maturation and 
either rests or dies. Finally, mature B cells are released into the circulation expressing IgM but 
also IgD. Interestingly, a subset of B cells is formed and called B1 cells. B1 cells account for 
approximately 5% of B cells in humans. These cells can be distinguished from other B cells 
because they express none or only low levels of IgD but in most cases CD5. CD5 attenuates 
BCR signalling, therefore allowing only very strong stimuli to activate these B cells. 
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Additionally, B1 cells are self-renewing. Whereas conventional B cells are found in the 
secondary lymphoid tissues (e.g. spleen and lymph nodes) and are able to change their 
antibody repertoire after antigen challenge from IgM/IgD to IgG in a process known as 
isotype-switching, B1 cells do not have this possibility and mainly reside in the peritoneal and 
pleural cavities (Melchers, 2005; Murphy et al, 2008).  
1.2.2 Follicular B cells versus marginal zone B cells 
Bone marrow derived B cells undergo further differentiation after arrival in the spleen: they 
differentiate either to follicular B cells or marginal zone B cells. As the names suggest, these 
two B cell lineages are defined by their location within the spleen, either the B cell follicles or 
the marginal zone, but they can also be differentiate from another by the expression of 
different sets of surface markers. 
B cell follicles contain naive B cells which are recirculating to get in contact with antigens. 
This compartment also contains activated, proliferating and maturing B cells in the germinal 
centres (GCs). Follicles are adjacent to T cell zones facilitating cell-to-cell contact between 
the different activated lymphocytes. This provides the basis for T cell-dependent immune 
response to antigens. However, the follicular B cells also recirculate to the bone marrow 
where they aggregate next to special slow-flowing blood vessels, allowing them to respond to 
blood-borne pathogens in a T cell-independent manner. Most mature follicular B cells express 
high levels of IgD, lower levels of IgM and intermediate levels of CD21. CD21 is also known 
as the complement receptor type 2 and binds components of the activated complement 
cascade, leading to B cell activation (Pillai & Cariappa, 2009).  
Marginal zone B cells are characterised by high expression levels of CD21 (CR2), CD35 
(CR1) and CD1d. High levels of CD1d facilitate the presentation of lipid antigens to invariant 
natural killer T (iNKT) cells and it is probable that splenic marginal zone B cells are an 
important source of lipid-specific antibodies (Barral et al, 2008; Leadbetter et al, 2008). High 
expression levels of CD21 on these cells might facilitate the transport of immune complexes 
from the circulation to the follicular zone, thereby exposing them to follicular DCs and B 
cells. Marginal zone B cells are generated as naive B cells that show some properties of 
memory cells, e.g. a pre-activated phenotype, the ability to self-renew and to survive for the 
life-span of the host (Pillai & Cariappa, 2009).  
To date, four different categories of mutations in mice are known to result in a defect in 
marginal zone development: mutations involving negative regulators of BCR signalling, 
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mutations involving the B cell activating factor (BAFF) receptor and the canonical nuclear 
factor-κB (NF-κB) pathway (see section 1.3.4.2), mutations in the Notch pathway, and 
mutations involving signalling molecules that are linked to integrin or chemokine activation. 
Interestingly, the strength of BCR stimulation seems to regulate the B cell fate during 
development into a follicular or marginal zone B cell. Weak stimulation of the BCR favours 
the development of the marginal zone B cell lineage whereas strong stimulation induces 
development towards follicular B cells (Pillai & Cariappa, 2009). 
1.2.3 Activation of B cells in secondary lymphoid organs 
Mature B cells circulate to secondary lymphoid tissues where they make contact with 
antigens. In the case no cognate antigen has bound, these B cells leave the lymphoid organ via 
the lymphatic system and return to the bloodstream to start a new cycle of circulation. This 
increases the chance for B cells to make contact with antigens in different parts of the body. 
A local infection with a pathogen may result in the invasion by the pathogen into the lymph 
and transit to the proximal draining lymphoid organ. If a local infection cannot be brought 
under control, it may spread systemically by reaching the spleen through the blood. Naive 
follicular B cells residing in the B cell follicles in different lymphoid organs can either 
directly encounter antigens (Pape et al, 2007) or indirectly be exposed to antigen via 
presentation by tissue-resident DCs homing to the lymphoid organs (Bergtold et al, 2005; 
Pape et al, 2007). DCs can deliver native antigens which are not processed and able to bind 
the BCR of cognate naive follicular B cells (Bergtold et al, 2005). Importantly, DCs do not 
only present antigens to B cells but they also present processed antigens in the context of 
MHC class II to TH cells in the T cell zones of secondary lymphoid organs. DCs and T cells 
engage in an immunological dialogue in which T cells transiently express CD40L and are 
thereby able to interact with CD40 on DCs. Engagement of CD40 on DCs is essential for their 
maturation and survival. In turn, the CD40-dependent maturation of DCs leads to the 
sustained expansion and differentiation of antigen-specific T cells which have the capacity to 
stimulate B cells (Grewal & Flavell, 1996).  
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Figure 1.2: Interaction between B cell and T helper cell. 
The B cell interaction with a T helper cell involves several steps, first the B cell must 
be stimulated with a cognate antigen. This will result in the presentation of an antigen 
fragment in the context of a MHCII molecule on the cell surface. Second, a T cell can 
bind with its TCR to the immobilised antigen and becomes stimulated. Third, the 
stimulated T cell produces cellular (e.g. CD40) and extracellular (e.g. IL-4) biological 
agents to stimulate B cells. Only if the B cell gets this additional stimulatory signal it 
will start to proliferate and differentiate to produce an immune response (adapted 
from (Murphy et al, 2008)). 
CD40L
CD40
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TCR
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B cell
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B cells are activated when an antigen is able to crosslink the BCR, enabling downstream 
signalling within the B cell. In most cases help from activated T cells is needed to fully 
potentiate the B cell response. These antigens are called thymus-dependent (TD) antigens. 
Some antigens are able to initiate a B cell response without any further help from T cells and 
these antigens are called thymus-independent (TI) antigens. One example for a TI antigen is 
LPS, which is not only able to bind to its cognate BCR but also to TLR4, thereby activating B 
cells via two independent pathways (Lanzavecchia & Sallusto, 2007). 
The activation of B cells via TD antigens is quite complex (Figure 1.3). On binding the BCR, 
the antigen is internalised by receptor-mediated endocytosis and processed via the endocytic 
pathway into peptides. The activated BCR also triggers the presentation of antigens in the 
context of MHC class II and the upregulation of B7 on the B cell surface, which is a co-
stimulator for T cells. Indeed, a TH cell can bind via its TCR to the presented antigen on 
B cells, which in turn stimulates the T cell to upregulate CD40L. The importance of a 
membrane-bound protein for the interaction between B cells and T cells was shown in 1990 
by Hodgkin et al. They were able to stimulate naive B cells with membrane fractions from 
stimulated CD4+ T cells but not with unstimulated T cells (Hodgkin et al, 1990). Later, CD40 
was identified as the T-cell-contact-dependent stimulus for B cells by experiments in which 
CD40-Ig fusion proteins were used to antagonise the ability of T cell-derived plasma 
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membranes to activate B cells in vitro (Noelle et al, 1992). In addition, CD40 signalling on B 
cells is required for the generation of high titres of isotype-switched, high affinity antibodies 
and for the development of humoral immune memory. CD40 engagement on B cells by 
CD40L on activated T cells triggers B cell intercellular adhesion, sustained proliferation, 
expansion, differentiation and antibody isotype switching in vitro. Additionally, this 
engagement is required in vivo for GC formation and progression, and the generation of 
memory B cells and long-lived plasma cells (Elgueta et al, 2009).  
Beside CD40L another important B cell stimulus is provided by IL-4 which is secreted by 
TH2 cells following stimulation. Both molecules synergise in driving B cell proliferation and 
differentiation. Additionally, B cells express factors such as CD80, CD86 and 4-1BB ligand 
which bind to CD28 and 4-1BB on T cells respectively. The soluble cytokine BAFF is 
secreted by DCs and macrophages to stimulate B cell proliferation and survival. Cytokines 
important for B cell differentiation into plasma cells are IL-5 and IL-6, which are also 
secreted by TH cells (Murphy et al, 2008). 
It was shown that the interaction of activated T cells and B cells does not occur randomly but 
that activated TH cells are able to home towards B cell follicles and position themselves at the 
border of B cell follicles and the T cell zone (Garside et al, 1998). This enables them to 
encounter and activate B cells in a defined sequence of temporally ordered events in which 
the CD40-CD40L engagement plays a decisive role. It was shown that the blockade of this 
interaction inhibits the differentiation of naive follicular B cells into plasmablasts (Foy et al, 
1993). This interaction can be readily observed as a response to TD antigens. Shortly 
thereafter, B cells enter the cell cycle; these proliferating cells then differentiate into 
plasmablast secreting germline-encoded IgM and later IgG. These plasmablasts are located 
outside of B cell follicles, approximately two to twelve days post-immunisation (Elgueta et al, 
2009).  
In contrast to the TD immune response, abrogation of the CD40-CD40L pathway has no 
impact on the TI antibody response. Mice immunised against TI-type II antigen TNP-Ficoll 
do not show a difference in the humoral immune response when treated with antagonistic 
anti-CD40 antibodies or control antibodies (Foy et al, 1993). Similar results were observed in 
studies comparing the immune response to TNP-Ficoll between CD40L knockout mice and 
wild-type littermates (Xu et al, 1994). In summary, CD40 signalling is essential for B cell 
differentiation into plasmablasts when stimulated with TD, but not TI, antigens.  
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1.2.4 Germinal centre formation 
Beside the formation of plasmablasts as a quick response, a subset of oligoclonal antigen-
responding naive follicular B cells can colonise the B cell follicles to form GC structures. 
GCs are specialised microenvironments in which B cells can mutate their BCRs to undergo 
affinity maturation. Whether a responding B cell differentiates into a plasmablast or 
participates in GC formation is determined by a number of B cell intrinsic and extrinsic 
factors (Elgueta et al, 2009). The major intrinsic factor is defined by the affinity of the initial 
interaction between the BCR and antigen; the stronger the interaction, the more likely the 
B cell will be driven into the plasmablast lineage. In contrast, a lower initial affinity of the 
BCR leads to the formation of GCs (Benson et al, 2007; O'Connor et al, 2006; Paus et al, 
2006). One important extrinsic factor is the availability of CD40L; stimulation via CD40L-
CD40 clearly modifies B cell fate. Inactivation of this interaction with an anti-CD40L 
antibody in vivo resulted in absence of GCs (Foy et al, 1994). Interestingly, in the presence of 
enhanced CD40 stimulation during a primary immune response, differentiation of B cells 
down the plasmablast lineage and diversion from the GC response is favoured (Erickson et al, 
2002). This was tested by additional application of agonistic anti-CD40 antibodies to a 
primary stimulus. It was observed that all antigen-responding B cells uniformly differentiated 
into plasmablasts and were located outside of the follicular B cell zone. These results point to 
an essential role for the strength and duration of CD40L-CD40 ligation in B cell fate during 
humoral immune response development. 
Once a B cell is committed to the GC lineage, it gets in close contact with a specialised subset 
of activated TH cells, so-called T follicular helper cells (TFH cells). TFH cells are characterised 
by their high expression of the chemokine receptor CXCR5, CD40L, ICOS and the secretion 
of IL-21. Binding of CXCL13 to CXCR5 enables TFH cells to home into B cell follicles and 
GCs. The other signals keep the GC reaction going and stimulate B cell proliferation, isotype 
switching and differentiation into plasma cells (King et al, 2008).  
During maturation, GCs polarise into dark and light zones. The dark zone is characterised by 
a high density of rapidly dividing B cells which are called GC centroblasts. This is the site of 
somatic hypermutation (SHM) and due to the large nucleus of cells, this zone has a dark 
appearance in histological analyses (Rogerson et al, 1991). The light zone is the point of 
antigen entry and contains follicular dendritic cells (FDCs), on which antigen complexes are 
tethered by binding the complement receptors CD21 and CD35, and FcγRII (Liu et al, 1997). 
Together with light zone stromal cells, FDCs secret CXCL13; thereby recruiting TFH cells to 
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this area. B cells residing in this zone are called GC centrocytes and, like TFH cells, they also 
express CXCR5. The light zone is a place of critical interaction between antigens, TFH cells 
and centrocytes. Depending on the affinity between the BCR and antigen, decisive survival 
signals are provided to centrocytes with high affinities to antigens. In this context, CD40 also 
serves as a survival signal from TFH cells to B cells, thereby protecting these cells from CD95-
induced apoptosis by up-regulation of anti-apoptotic proteins such as B-cell lymphoma extra 
large (Bcl-XL) and cellular FLICE-inhibitory protein (c-FLIP) (Hennino et al, 2001; Tuscano 
et al, 1996). Additional signals to BCR- and CD40-signalling are needed to drive centrocyte 
differentiation to plasma cells and memory B cells, whereas IL-21 plays again an important 
role. 
CD40 signals from activated T cells in the early phase of GC formation and from TFH cells 
during GC development are essential for the completion of the GC response. Blockade of 
CD40-CD40L interaction or genetic ablation of these genes prevents clonal proliferation of 
antigen-responding B cells (Foy et al, 1993). In this respect it was shown that anti-CD40L 
treatment at the peak of GC formation completely shuts down GC development (Foy et al, 
1994). Anti-CD40L antibody treatment leads to a decrease in Ig affinity in plasma cells in 
comparison with control-antibody treated mice (Takahashi et al, 1998). These results provide 
evidence that affinity maturation occurs in GCs and progresses over time in a CD40-CD40L 
dependent manner. In summary, these data provide evidence that CD40 signalling initiates 
and propagates GC formation and SHM. 
1.2.5 Somatic hypermutation and isotype switching of B cells 
B cells are able to produce five different types of immunoglobulins, namely IgM, IgD, IgG, 
IgA and IgE. In addition, different subclasses exist for IgG and IgA. The different types of 
antibodies execute different functions within the immune system. IgM is the first antibody 
class produced in a humoral immune response as it is generated without class switching. 
These antibodies form pentamers and therefore have a high avidity without having undergone 
affinity maturation. IgM antibodies are effective in binding to multivalent antigens and in 
activating the complement system.  
In contrast, IgG, IgA and IgE are much smaller molecules and only produced after class 
switch recombination (CSR). IgG and IgE are bivalent antibodies whereas IgA is tetravalent. 
As IgA is effectively transported across the epithelium, it is efficient in neutralising antigens 
in the extracellular space. IgG in contrast is present in the blood and extracellular fluid. It can 
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effectively opsonise pathogens for engulfment by macrophages and activates the complement 
system. IgE is normally not found directly in any fluids, but bound to receptors on mast cells 
which are located beneath the skin and mucosa, and along blood vessels. Antigen binding of 
these cells results in the release of strong chemical mediators which trigger coughing, 
sneezing and vomiting to eliminate infectious agents (Murphy et al, 2008).  
CSR, also known as isotype switching, occurs during the maturation of B cells in GCs. B cells 
which have left the bone marrow express both IgM and IgD. This is possible because both 
isotypes are transcribed from the same mRNA and expression can be achieved by alternative 
splicing. However, isotype switching to other classes requires irreversible chromosomal 
recombination which occurs only after B cell stimulation. For this process, the class switch 
regions play a decisive role in guiding the respective heavy chain segment to the VDJ 
segment. The switch region consists of highly repetitive DNA sequences and is located in 
front of the different gene segments. In stimulated B cells, these switch regions are recognised 
and used by protein complexes enabling the chromosomal recombination. The first complex 
comprises activation-induced cytidine deaminase (AID), which is also needed for SHM and 
can only be found in stimulated B cells. AID introduces deoxyuridine within the switch 
region, a chemical alteration that is recognised and removed by the base-excision-repair 
(BER) enzyme uracil-DNA glycosylase (UNG) to generate an abasic site. The processing of 
this site by the apurine/apyrimidinic endonuclease 1 (APE1) creates a nick at this site 
(Chaudhuri & Alt, 2004). The different nicks are brought together by another protein complex 
which includes DNA-protein kinase (DNA-PK). Interestingly, DNA-PK was shown to 
recombine all Ig heavy chains except IgG1 (Manis et al, 2002), suggesting a DNA-PK-
independent mechanism in this case. However, the double-stranded break repair machinery 
fuses the two switch regions from the µ-gene to the target gene, excluding a part of the 
chromosome. This brings the new constant heavy chain region into close proximity of the 
variable region and results in the expression of a new isotype with the same specificity 
because the V region is untouched throughout this process. 
CSR is regulated by the cytokine milieu with CD40L being one important trigger. The effect 
of a non-functional CD40L can be observed in humans suffering from the hyper IgM (HIGM) 
syndrome. These patients have low to non-existent levels of IgG, IgE and IgA and suffer from 
opportunistic infections such as Pneumocystis carinii (Fuleihan, 2001). HIGM syndrome is in 
most cases caused by mutations in the CD40L gene but can also be caused by mutations in 
proteins involved in CD40L-induced signalling pathways such as NEMO, or in proteins 
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directly involved in CSR such as AID (Lee et al, 2005). After induction of CSR, the presence 
of certain cytokines triggers the differentiation to various antibody-producing cells. IgA 
production, for example, is induced by TGF-β and augmented by IL-5, whereas the 
differentiation to IgG1-producing cells is induced by IL-4 and inhibited by IFNγ (McHeyzer-
Williams & McHeyzer-Williams, 2005). 
Like CSR, SHM only occurs in activated B cells and the enzymatic function of AID is again 
required in this process. SHM is specific for the V regions of light and heavy chains within 
BCR genes and creates a series of related B cell lineages that differ subtly in their specificity 
and affinity towards an antigen. This diversification and maturation of the antibody repertoire 
requires permanent selection for the antigen because many point mutations will result in 
unproductive receptors. B cells with unproductive receptors will undergo apoptosis because 
the mutation will either disrupt formation of a BCR or decrease the ability of the BCR to 
compete for antigens; both will result in a lack of survival signals. This process of maturation, 
selection and proliferation is repeated several times to ensure the generation of a highly 
effective humoral immune response (Frieder et al, 2006).  
The importance of AID in the two different processes is shown in AID-deficient mice and 
humans which results in immune deficiency with no SHM and CSR. The mechanisms of CSR 
and SHM are quite similar since both involve the activities of AID, UNG and APE1. 
However, in SHM neither double strand breaks occur nor is DNA excised. In this case, an 
extensive and error-prone repair mechanism through DNA replication leads to a higher 
mutation rate and results in affinity maturation when the BCR is positively selected (Frieder 
et al, 2006).  
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1.3 The TNF-Receptor superfamily member CD40 
The TNF-Receptor superfamily (TNF-RSF) consists of 29 proteins (Table 1.1) and is 
characterised by 1-6 cysteine rich domains (CRD) within the extracellular domain of the 
receptors. The receptors do not have any intrinsic enzymatic activity, however, they can be 
divided into three groups according to their intracellular domains. The first group includes 
members with a death domain (DD) in the cytosolic portion (e.g. TNF-Receptor 1, CD95 and 
TRAIL-Receptor 1 and 2). Stimulation with the cognate ligand induces the formation of 
receptor complexes and the activation of caspases, initiating cell death in a variety of cells.  
The second group includes several receptors which are incapable of signal transduction and 
are therefore referred to as decoy receptors (DcR3, TRAIL-R3 and OPG). These proteins 
might modulate the signals of functional receptors. 
All other members of the TNF-RSF possess a co-stimulatory function for the activation of 
immune cells. They possess an intracellular domain which is able to bind adaptor proteins 
among which the family of TNF receptor associated factors (TRAFs) is the most prominent. 
The binding domain for the TRAF family is the TRAF interacting motive (TIM); signal 
transduction via TRAFs leads to cell activation, differentiation and survival. This third group 
includes, among others, the receptors TNF-R2, 4-1BB, OX40 and CD40. 4-1BB, for example, 
is an important co-stimulator of T cells and leads to long term survival and formation of 
memory T cells. CD40 in contrast is more prominent on APCs and is needed on B cells for 
isotype switching and mediation of several survival signals. It is also expressed on DCs and 
leads to their differentiation and maturation. This receptor is discussed in more detail in the 
next chapter. 
 
Table 1.1: Members of the TNF-Receptor and Ligand superfamilies. 
Receptor 
Intracellular 
signalling motif 
Cytokine 
TNF-R1 DD TNF, LTα 
TNF-R2 TIM TNF, LTα 
CD95 (APO-1/Fas) DD CD95L 
DcR3 soluble VEGI, CD95L 
DR3 DD VEGI, LIGHT 
TRAIL-R1 (DR4) DD TRAIL 
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TRAIL-R2 (DR5) DD TRAIL 
TRAIL-R3 (DcR1) - TRAIL 
TRAIL-R4 (DcR2) - TRAIL 
DR6 DD, TIM unknown 
EDAR DD, TIM  EDA-A1 
NGFR DD, TIM NGF 
OPG soluble RANKL, TRAIL 
RANK TIM RANKL 
LTβR TIM LTα, LTβ, LIGHT 
FN14 TIM TWEAK 
HVEM TIM LIGHT, LTα 
CD27 TIM CD27L 
CD30 TIM CD30L 
CD40 TIM CD40L 
4-1BB TIM 4-1BBL 
OX40 TIM OX40L 
GITR TIM GITRL 
BCMA TIM BAFF, APRIL 
TACI TIM BAFF, APRIL 
BAFF-R TIM BAFF 
XEDAR TIM EDA-A2 
TROY TIM unknown 
RELT TIM unknown 
 
Legend: BAFF: B-cell-activating factor, BCMA: B-cell maturation antigen, RANK: receptor activator of NF-
κB, DD: death domain, EDA: ectodermal dysplasin, EDAR: ectodysplasin-A-receptor, FN14: fibroblast growth 
factor-inducible 14, GITR: glucocorticoid-induced TNF-R family receptor, HVEM: herpes virus entry mediator, 
LT: lymphotoxin, NGF: nerve growth factor, OPG: osteoprotegrin, RANKL: receptor activator of nuclear factor 
κB ligand, RELT: receptor expressed in lymphoid tissues, TACI: transmembrane activator and calcium-signal 
modulating cyclophilin ligand (CAML) interactor, TIM: TRAF-interacting motif, TNF: tumour necrosis factor, 
TRAIL: TNF-related apoptosis-inducing ligand, TWEAK: TNF-like weak inducer of apoptosis, VEGI: vascular 
endothelial cell-growth inhibitor, XEDAR: X-linked EDA-A2 receptor. 
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A comprehensive survey of ligand-receptor interactions and cross-species reactivity within 
human and mouse TNF-SF and TNF-RSF was achieved by the group of Pascal Schneider 
(Bossen et al, 2006). In this study, the extracellular domain of each receptor was anchored to 
the membrane via a glycosylated phosphatidylinositol link and the binding of soluble fusion 
ligands was analysed. The soluble fusion ligands comprised the extracellular domain of each 
ligand cloned to the Fc portion of human IgG1 for oligomerisation. All the tested interactions 
were strictly specific, although a weak interaction between human TNF and mouse TNF-R2 
was detected after oligomerisation of the ligand. Some ligand/receptor pairs were shown to be 
partially species−specific. For example, the mouse CD40L recognised both human and mouse 
receptors, but human CD40L was not able to bind mouse CD40. Finally, some TNF-RSF 
memebers were not bound by any known TNF-SF ligands, suggesting either that additional 
members of the TNF-SF remain to be identified (Bossen et al, 2006) or that these receptors 
bind non-TNF-SF members, as is the case for the low affinity nerve growth factor receptor 
(NGFR) (Micera et al, 2007). 
1.3.1 CD40 and its ligand 
The CD40 protein was described for the first time by Paulie and colleagues (Paulie et al, 
1984) and the human CD40 cDNA was isolated 5 years later from the human Burkitt 
lymphoma Raji cell line library (Stamenkovic et al, 1989). The open reading frame contains 
831 base pairs (bp) from which the translated product was predicted to be 277 amino acids 
(aa). The first 20 residues, predominantly hydrophobic, compose the signal peptide. The 
remaining sequence has characteristics of a type I membrane glycoprotein with a predicted 
molecular weight (MW) of 28.3 kDa.  
The extracellular domain consists of 193 residues, which include 22 cysteines and two 
potential N-linked glycosylation sites. The transmembrane region contains 22 hydrophobic 
residues; and the cytoplasmic region is 62 aa in size (Figure 1.4). The extracellular domain 
has four cysteine-rich residues which are characteristic for the TNF-RSF. Beside these 
domains, two asparagine-linked glycosylation sites (N153, N180) and a pre-ligand assembly 
domain (PLAD) were described. The latter is able to induce oligomerisation in the absence of 
ligand binding. However, ligand-binding promotes the association of receptors to higher order 
oligomers and thereby leads to proper signal induction. Oligomerisation is achieved more 
efficiently by multimeric CD40Ls as these have been found to provide a stronger stimulus 
(Haswell et al, 2001; Morris et al, 1999). 
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Figure 1.3: Domain structure of CD40 and CD40L. 
Scheme of the gene loci of CD40 (top) and CD40L (bottom) with introns and exons on 
the respective chromosome. The structure of the resulting protein is shown 
underneath. CD40 is a type I transmembrane protein with the N-terminus outside the 
cell, whereas CD40L is a type II transmembrane protein. TMD: transmembrane 
domain. 
I II III IV V VI VII VIII IX3‘ 5‘Chromosome 20,
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Mouse CD40 cDNA was cloned from B lymphocytes stimulated with LPS and IL-4, and its 
sequence shares many characteristics with human CD40. However, the murine version 
comprises 305 aa residues, with a hydrophobic leader sequence of 21 aa, followed by a 172 aa 
cysteine-rich extracellular domain, a 22 aa transmembrane domain and a 91 aa intracellular 
domain (Torres & Clark, 1992). The MW of the mature form was calculated to be 31.4 kDa. 
Only one potential N-glycosylation site appears in the mouse form. The extracellular domains 
of CD40 from the two species share 62% identity, with the 22 cysteines being conserved, and 
the identity within the cytoplasmic domain of the two proteins is 78% (Torres & Clark, 1992). 
CD40 is expressed on different cell types within, and outside, the immune system (Table 1.2 
summarises CD40 expression on different cell types). CD40 is essential for the proper 
development and functioning of B cells which express CD40 in almost every stage of 
development. Haematopoietic progenitor cells of the B cell lineage express CD40, as do B 
cells regardless of their function (naive B cells, centroblasts, plasmablasts, plasma cells and 
memory B cells) or location (bone marrow, tonsil, spleen, primary/secondary follicle). 
The cDNA coding for murine CD40L was isolated from the murine EL-4 thymoma cell line 
after enrichment of cells binding to a CD40-Fc fusion protein. The murine cDNA predicts a 
type II transmembrane protein of 260 aa consisting of a 22 aa cytoplasmic domain, a 24 aa 
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Cell type Functional Consequenses 
Pre-B cells proliferation CD23 expression 
Naive mature B cells proliferation, differentiation, isotype switch 
Germinal center B cells proliferation, differentiation, Fas expression, selection 
Plasma cells IL-6 production 
Monocytes/macrophages cytokine secretion, NO production, production metalloproteinases, 
monocyte procoagulant activity and tissue factor expression 
Synovial monocytes TNF secretion 
Alveolar macrophages high-level CD40 expression in sarcoidosis 
Dendritic cells / Langerhans cells growth and survival; expression costimulatory molecules 
enhanced; cytokine production  
CD34 precursors Proliferation, development dendritic cells  
T cells proliferation, CD25 expression, cytokine production  
Eosinophils enhanced survival, GM-CSF production 
Endothelial cells 
-HUVEC 
 
 
- Microvascular endothelial 
- Vascular EC (saphenous veins) 
 
up-regulation CD54, CD62E, CD106, increased tissue 
factor/thrombomodulin expression, and proagulant activity, T cell 
costimulation increased production LIF, IL-6, GM-CSF  
CD40 expression increased by HIV 
increased IL-1, IL-6, IL-8 production 
Epithelial cells 
-Thymic epithelial cells 
- Kidney epithelial cells 
 
-Keratinocytes 
-Carcinomas and transformed 
epithelial cells 
 
GM-CSF production 
cytokine/chemokine secretion; IL-6, LIF, GM-CSF IL-8, MCP-1, 
RANTES enhanced expression CD54, Bcl-x 
IL-8 secretion 
growth inhibition/apoptosis 
Fibroblasts 
- Synoviocytes 
- Lung fibroblasts 
-Dermal, Thyroid fibroblasts 
Gingival fibroblasts  
 
Proliferation, cytokine production (GM-CSF, MIP-1α) 
increased IL-6, IL-8, NF-κB, Cox-2, PGE2 
increased IL-6, IL-8, NF-κB 
increased IL-6, IL-8 
Follicular dendritic cells Growth; CD54 expression 
Vascular smooth muscle cells increased MMP-1, MMP-3, MMP-9, MMP-2, activation ICE (IL-1β 
converting enzyme) induction stromelysin-3 (MMP-11) 
Hepatocytes induction of Fas-L expression 
(van Kooten & Banchereau, 2000) 
 
Table 1.2 Cells expressing CD40 and functional consequences of in vitro CD40 activation. 
transmembrane domain, and a 214 aa extracellular domain with four cysteines (Armitage et 
al, 1992). 
The human CD40L cDNA was isolated by screening stimulated human blood T cell libraries 
with the murine CD40L probe, and by another study from an activated human T cell library 
(Hollenbaugh et al, 1992; Spriggs et al, 1992). Human CD40L is a type II transmembrane 
protein that is 261 aa in size. The intracellular portion is 22 aa long, the transmembrane 
domain 24 aa, and the extracellular domain 215 aa, including five cysteine residues. CD40L is 
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encoded on the X chromosome, explaining why the genetic mutation of this protein is also 
referred to as X-linked HIGM syndrome (Villa et al, 1994). 
Although initial studies suggested a molecular mass of 39 kDa (and hence the original name 
gp39 for CD40L), on most cell types the apparent molecular weight of CD40L is 32–33 kDa. 
The amino acid backbone predicts a protein of 29 kDa; the higher molecular weight is due to 
posttranslational modifications. A conserved, single N-linked glycosylation site was found in 
human, murine, and bovine CD40L. A comparison of human and mouse CD40L showed that 
both sequences exhibit 78% identity in their aa sequences. Furthermore, 75% identity is found 
between the extracellular domain, 96% between the transmembrane region and 81% between 
the cytoplasmic domains (van Kooten & Banchereau, 2000). Beside the transmembrane form 
of CD40L, shorter forms and soluble forms were described with MWs of 31, 18, and 14 kDa 
(Graf et al, 1995; Ludewig et al, 1996; Mazzei et al, 1995; Wykes et al, 1998). The soluble 
forms of CD40L are biologically active but play minor roles in the immune response. It also 
became clear that a higher order crosslinking of this ligand strongly improves signal 
transduction (Haswell et al, 2001). 
1.3.2 Engagement of CD40: antibody and ligand 
Stimulation of CD40 can be achieved by using agonistic antibodies as a cross linking agent or 
with the natural ligand. However, the quality of the signal initiation strongly depends on the 
level of oligomerisation by the stimulating agent. 
This finding is based on early studies using anti-CD40 F(ab’)2 fragments which showed cell 
stimulatory activity (Ledbetter et al, 1987). In contrast, a monovalent anti-CD40 F(ab’) is 
significantly less potent (Paulie et al, 1989), pointing towards the need for crosslinking of 
more than one receptor molecule to induce signal transduction. Interestingly, monovalent anti-
CD40 F(ab’) was able to block the signal-inducing effects of the bivalent antibody (Paulie et 
al, 1989). Gordon et al. have used a second-layer antibody to crosslink the anti-CD40 
antibody and demonstrated higher levels of proliferation and RNA synthesis on resting B 
lymphocytes compared with that induced by “monomeric” antibodies (Gordon et al, 1988). 
The ultimate demonstration of the CD40 cross-linking theory came from Banchereau and co-
workers. By using a transgenic CDw32 L mouse cell line expressing Fc-γ receptor for optimal 
crosslinking of anti-CD40 antibodies in solution, they obtained long-term growth of primary 
human B cells in culture (Banchereau et al, 1991). 
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Morris et al. studied the proliferation of B cells when stimulated with recombinant CD40L 
compared with that stimulated with a recombinant CD40L fused to a leucine zipper motif. 
This leucine zipper motif promotes trimerisation of the ligand, which then stimulates B cells 
more efficiently (Morris et al, 1999). These observations were confirmed later by 
overexpression studies of monomeric, dimeric and trimeric forms of the intracellular domain 
of CD40. It was observed that only the trimeric fusion protein was able to effectively induce 
NF-κB activity (Werneburg et al, 2001). Another study investigated the effect of higher 
crosslinked CD40L complexes by using a dodecameric form of CD40L. This dodecameric 
form of CD40L was produced by replacing the lectin domains of surfactant protein (SP-D) 
with the C-terminal extracellular domain of murine CD40L (Haswell et al, 2001). Cells 
stimulated with the dodecameric CD40L showed higher rates of proliferation and surface 
protein expression as compared with that stimulated by trimeric CD40L. In addition, it was 
shown that membrane-bound CD40L has an even higher ability to stimulate CD40 on B cells 
and is therefore different in its effectiveness to soluble CD40L. Whereas soluble CD40L 
increased expression of Bcl-6 and phosphorylation of p38, membrane-bound CD40L led to 
decreased expression of Bcl-6 but to a prominent stimulation of p38, c-Jun N-terminal kinase 
(JNK) and extracellular signal related kinase (ERK) (Batlle et al, 2009). 
These reports suggest a wide spectrum in effectiveness of CD40-stimulating agents depending 
on their crosslinking status. Furthermore, it reveals that it is important to use stimulating 
agents with higher-order crosslinking for investigating CD40 signalling because these mimic 
best the natural system within organisms. 
1.3.3 The CD40 Receptor signalling complex  
Based on the structural homologies within the TNF-SF, CD40L is predicted to form trimeric 
structures. As mentioned previously, higher-order CD40 oligomerisation is crucial for 
effective CD40-mediated signal transduction. 
Early investigations on CD40 signalling in Raji cells focused on the phosphorylation of the 
receptor itself (Paulie et al, 1989). Subsequent studies with mutation and deletion of 
threonine 234 within the intracellular domain of murine CD40 showed an important role for 
this residue in CD40 signal transduction (Clark & Shu, 1990; Hostager et al, 1996). As the 
cytoplasmic domain of CD40 is only 62 aa long and does not contain an enzymatically active 
domain, this suggests that separate kinases/phosphatases are activated and/or that additional 
signalling proteins associate with the intracellular region upon CD40 stimulation. 
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The most important signalling proteins that interact with CD40, as well as with many other 
members of the TNF-R family, are the TRAF proteins. The TRAF family is a 
phylogenetically conserved group of scaffold proteins that activate signalling cascades after 
the receptors of the TNF-R and Toll/IL-1 family bind to their ligands. To date, seven 
members (TRAF1 – 7) have been identified in mammals, with homologues in Drosophila 
melanogaster and Caenorhabditis elegans (Xu et al, 2004). The C-terminus of TRAF proteins 
can be divided into two domains: TRAF-N and TRAF-C. The TRAF-N domain is helical and 
is organised as a coiled-coil which allows oligomerisation. All TRAFs contain a TRAF-N 
domain. The TRAF-C domain contributes to oligomerisation and to recruitment to TRAF-
binding domains within the intracellular domains of the above-mentioned receptors or of 
other cytoplasmic factors following their stimulation (Ha et al, 2009). TRAF7 is the only 
TRAF protein which does not contain a TRAF-C section. The N-termini of all TRAF proteins 
- except TRAF1 - contain a RING (really interesting new gene) finger motif, which is 
essential for E3 ubiquitin ligase activity; TRAFs are therefore potential E3 ubiquitin ligases. 
Zinc finger binding motifs are also a common feature in all TRAF molecules, again apart 
from TRAF1 (Ha et al, 2009).  
The first member of the TRAF family identified in association with CD40 was TRAF3; this 
was observed in a yeast-two hybrid system by the groups of Vishva Dixit (Hu et al, 1994), 
David Baltimore (Cheng et al, 1995) and John Reed (Sato et al, 1995). TRAF3 is a 62-kDa 
intracellular protein that is expressed in almost all cell types. The protein contains several 
functional domains involved either in signal transduction (such as the RING finger domain, 
isoleucine zipper and zinc finger) or in protein-protein interactions either to associate with 
CD40 or to form homo-/heterodimers. Interestingly, TRAF3 knockout mice have almost 
normal B cell signalling, whereas T cell activation is impaired (Xu et al, 1996).  
Kuhné et al. described the isolation of a CD40 receptor signalling complex (CD40-RSC) after 
stimulation with the cognate ligand. They provided data for the recruitment of TRAF3 and 
TRAF2 to the intracellular domain of CD40 following stimulation with CD40L and 
precipitation with an anti-CD40 antibody (Kuhne et al, 1997). The role of TRAF2 for CD40 
signalling was confirmed in an elegant study by Monroe and Bishop in 2004. By using a 
TRAF2 knockout B cell line they were able to detect a defect in CD40-mediated JNK 
phosphorylation (Munroe & Bishop, 2004). Recently it was shown that TRAF2 forms a 
heterotrimeric complex with TRAF1 which is more stable than homotrimeric complexes of 
each molecule (Zheng et al, 2010). This is in line with earlier experiments by Bishop and 
Chapter 1: Introduction 
24 
 
Figure 1.4: Sceme of the cytoplasmic domain of CD40 and the activation of 
different signalling pathways. 
The amino acid sequence of the cytoplasmic domain of CD40 is shown with different 
binding domains for proteins which were mapped with deletion mutants. The activation 
of different signalling pathway emerging from the domains is also indicated. Modifed 
from (van Kooten & Banchereau, 2000). TM: transmembrane domain 
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colleagues who identified cooperation between TRAF1 and TRAF2 for CD40 signalling. 
Knockdown of either TRAF1 or TRAF2 decreased phosphorylation of JNK, while knockout 
of both proteins simultaneously abrogated all signalling events (Xie et al, 2006). 
TRAF5 and TRAF6 were also described to bind to the CD40-RSC after CD40L stimulation. 
An overexpression study by Ishida et al. revealed that TRAF6 indeed plays a role in CD40 
signalling (Ishida et al, 1996a). Furthermore, this group mapped the binding domain of 
TRAF2 to a distal region of CD40, whereas TRAF6 binds proximally (Figure 1.4). TRAF5 
was first described by Ishida and colleagues to bind to CD40 in vitro. They mapped the 
binding for TRAF5 to residues 230 - 269 (Ishida et al, 1996b). Accordingly, the functional 
requirement for TRAF5 in CD40 signalling was confirmed by Nakano and colleagues using 
TRAF5 knockout cells (Nakano et al, 1999). A comprehensive interaction study using 
recombinant baculovirus-expressed proteins was carried out by Pullen and colleagues in 1998. 
This study mapped the interactions of TRAF2, TRAF3, TRAF6 and the as-yet-unknown 
TRAF1 to the CD40 intracellular domain in great detail (Figure 1.4).  
Interestingly, this study did not detect a direct interaction of TRAF5 with the receptor (Pullen 
et al, 1998) suggesting that the recruitment of TRAF5 most likely depends on other TRAF 
molecules. Another study by the same group investigated signal transduction of CD40 by 
comparing wild-type CD40 with CD40 containing mutations in the TRAF binding sites in 
stably transfected cells. They demonstrated that both TRAF binding sites on CD40 were 
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required for optimal NF-κB and JNK activation whereas p38 phosphorylation was mainly 
dependent on the TRAF6 binding site within CD40 (Pullen et al, 1999a). However, three 
years later Noelle and colleagues investigated CD40 signalling in CD40 knockout B cells 
from mice transgenic for either wt CD40 or CD40 with mutated TRAF-binding sites and 
observed that the phosphorylation of IκBα and p38 was similar between wt CD40 and CD40 
with a mutated TRAF6 binding site but diminished in CD40 with a mutated TRAF1, TRAF2 
and TRAF3 binding site. Interestingly, mice with a mutated TRAF6 binding site in CD40 
showed a defect in affinity maturation and generation of antigen-specific long-lived bone 
marrow derived plasma cells (Ahonen et al, 2002). Thus, even through these results it is not 
conclusively identified which TRAF molecules and TRAF-binding sites in CD40 are 
important for the activation of NF-κB or Mitogen activated protein kinase (MAPK) 
signalling, but show that both binding sites are needed for normal CD40 signalling. 
Werneburg et al. performed pulldown experiments with overexpressed trimeric CD40 and 
found TRAF2, TRAF3, TRAF5, TRAF6 and cIAP1 associated with the CD40 construct but 
were not able to detect cIAP2 (Werneburg et al, 2001). Furthermore, they were not able to 
detect cIAP1 recruitment to a CD40 mutant with altered TRAF binding sites supporting a role 
for TRAF proteins as adaptors for cIAP1. In contrast, the group of Harald Wajant found, in 
fluorescence microscopy-based colocalisation assays using overexpressed proteins, that 
cIAP2 does co-localise with TRAF2 after CD40 stimulation (Fotin-Mleczek et al, 2004). In 
2007, a study from Michael Karin’s lab showed that MEKK1 is recruited to the CD40-RSC 
and plays a role in CD40 signalling (Gallagher et al, 2007). Another extensive study from this 
lab one year later demonstrated the recruitment of TRAFs, cIAP1/2, TAK1, IKKα/β and 
NEMO to the CD40-RSC upon CD40L stimulation. Furthermore this report demonstrated that 
phosphorylation of most target proteins is strongly decreased or abolished when TRAF2 is 
missing, and in most cases decreased when TRAF6 is absent. However, loss of TRAF3 
resulted in the increased phosphorylation of MEKK1 and cJun. Interestingly, it was observed 
that the CD40-RSC is released from the membrane after 30 minutes, whereas TRAF3 needs to 
be ubiquitinated and degraded by the proteasome for the release of the membrane-bound 
complex into the cytosol. The authors therefore suggest that TRAF3 works as a “brake” in 
this system (Matsuzawa et al, 2008). 
To study the components of the CD40-RSC in an unbiased assay, the RSC can be 
immunoprecipitated as the native complex from cells, or as a complex from cell lines 
overexpressing CD40 and the components analysed by mass spectrometry. The latter 
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precipitation was performed by Hostager and colleagues with an antibody as stimulating agent 
(Hostager et al, 2010). The mass spectrometric analysis revealed a recruitment of not only 
known components (TRAF1, TRAF2, TRAF3, TRAF5, TRAF6 and cIAP1), but also three 
unknown proteins of the CD40-RSC: SMAC/DIABLO, HTRA2 and HOIP. 
Beside the well established role of TRAF proteins, some other proteins and families are 
brought in relation with CD40 signalling. Members of the Cbl family are also suggested to 
play a role in CD40 signal transduction (Arron et al, 2001). Depending on the cell type, Cbl 
proteins are thought to either positively or negatively regulate a wide range of kinases and 
adapter proteins such as phosphatidylinositol-3-kinase (PI3K), Rous sarcoma (Src) oncogene 
tyrosine kinase, spleen tyrosine kinase (STK), growth factor receptor bound protein 2, and Src 
homology 2 domain-containing transforming protein C1 (Arron et al, 2001). Cbl-b-deficient 
DCs stimulated in vitro with CD40L showed an ablation of Akt activation without affecting 
canonical NF-κB induction (Arron et al, 2001). In line with this, it was shown that Cbl-b 
induces Akt phosphorylation via PI3K and that blockade of PI3K activity before CD40 
engagement abrogates Akt activation (Davies et al, 2004). Physiologically, the blocking of 
PI3K drastically affected the survival of DCs (Yu et al, 2004). However, Davies et al. 
suggested another mechanism whereby PI3K is able to activate the mammalian target of 
rapamycin (mTOR), which in turn induces the expression of the anti-apoptotic protein cFLIP, 
leading to cell survival (Davies et al, 2004). 
In contrast to the results described above, B cells deficient in Cbl-b have an increased NF-κB 
and JNK activation, suggesting that in B cells Cbl-b is a negative regulator of these signalling 
pathways. In this case, Cbl-b is recruited through TRAF2, and once recruited, it is supposed to 
block further recruitment of TRAF2 because lack of Cbl-b resulted in increased TRAF2 
recruitment to CD40 (Qiao et al, 2007).  
Similar observations were made for the activation of Janus kinase 3 (Jak3) after CD40 
stimulation. Recruitment of Jak3 to the CD40-RSC was described in B cells (Hanissian & 
Geha, 1997) but phosphorylation of this protein could not be observed (Revy et al, 1999), 
suggesting that recruitment of Jak3 to the cytoplasmic domain does not accomplish any 
functions. However, CD40 engagement on monocytes was able to induce Jak3 
phosphorylation (Revy et al, 1999). In line with these observations, blockade of Jak3 in APCs 
upon CD40 stimulation inhibited maturation (Saemann et al, 2003; Saemann et al, 2002).  
Chapter 1: Introduction 
27 
 
In summary, these results reveal functional differences in CD40 signalling dependent on the 
cell type. While B cells signal mostly via TRAF molecules, it seems that other APCs may be 
able to use additional signalling pathways. 
1.3.4 CD40-RSC downstream signalling 
The trimerisation of the CD40 receptor and recruitment of signalling proteins to the CD40-
RSC results in the activation of different signalling cascades and transcription factors. The 
predominant pathways are the MAPK pathway, with its transcription factors activator 
protein-1 (AP-1), and the NF-κB pathway.  
1.3.4.1 The MAPK signalling 
The human genome contains 518 kinases which are important players in many signalling 
pathways. Signalling within the TNF-RSF depends on the activation of downstream effector 
kinases which mainly belongs to the MAP kinase subgroup of serine/threonine (S/T) kinases 
(Johnson & Hunter, 2005). The initiator kinase is activated at the receptor level and 
phosphorylates a downstream kinase which in turn phosphorylates another downstream 
kinase. This results in at least three levels of kinase activation before gene expression is 
triggered. The kinase on the bottom level which directly initiates transcription is the MAPK 
which is activated by a MAP kinase kinase (MAP2K). The MAP2K is in turn activated by a 
receptor-proximal MAP kinase kinase kinase (MAP3K). 
ERK, JNK and p38 are the most prominent MAPKs in CD40 signal transduction and they 
activate members of the transcription factor AP-1 (Figure 1.5). These transcription factors 
form a heterodimeric complex which is composed of proteins of the Jun (cJun, JunB and 
JunD), Fos (cFos, FosB, Fra-1 and Fra-2), JDP (JDP1 and JDP2) and ATF subgroups (CREB, 
ATF2, ATF3 and B-ATF) (Shaulian & Karin, 2002). Activation of ERK, JNK and p38 by 
their upstream kinases is thought to be a direct and fast process. MKK1 and MKK2 were 
found to activate ERK (Derijard et al, 1995) whereas JNK is activated by MKK4 and MKK7 
(Tournier et al, 1997). Interestingly, MKK4 is also able to phosphorylate p38, which is, 
however, mainly targeted by MKK3 and MKK6. Nevertheless, this redundancy and cross-talk 
between different pathways lends strength to cellular activation of transcription (Tournier et 
al, 1997).  
However, the detailed mechanism of activation by receptor complex signalling is not entirely 
understood. Studies using receptor mutants, including those with altered TRAF binding sites, 
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Figure 1.5: Scematic overview of CD40 induced MAPK signalling. 
CD40-RSC formation by CD40L results in the activation of a MAPK cascade activation 
which is schematically shown on the left side. The receptor complex is able to activate 
MAP4K or MAP3K. These initiator kinases TPL-2, TAK, GCK and MEKK1 in turn 
activate a broad spectrum of MAP2K. Finally the MAPK are activated and able to 
induce gene transcription by activating transcription factors of the AP-1 familiy.  
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yielded controversial results regarding the mechanism of activation. For example, although 
signalling via the kinase p38 appeared important for B cell proliferation and gene expression 
(Aicher et al, 1999; Craxton et al, 1998), a later report showed decreased gene expression 
following p38 activation (Dadgostar et al, 2002). Other studies investigating the mechanism 
by which p38 is activated showed that TRAF2 and TRAF3 are important for p38 signalling 
whereas TRAF6 is dispensable (Ahonen et al, 2002; Grammer et al, 1998). Furthermore, 
another group reported a main role for TRAF6 in p38 activation (Pullen et al, 1999a) in light 
of evidence that p38 can still partially be activated when all TRAF-binding sites are mutated 
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(Manning et al, 2002). Some of these controversies might be explained by the use of different 
cell types, as B cells and DCs behave differently upon CD40 stimulation (Schonbeck & 
Libby, 2001).  
Today it is believed that MAPK signalling within the CD40 signal pathway starts 
predominantly with MAP3K. However, it cannot be ruled out that MAP4Ks which are not yet 
identified also play an important role in this process. Interestingly, MAP4Ks that have been 
implicated in mediating JNK activation belong to a protein family which includes the 
germinal center kinase (GCK), germinal center-like kinase (GLK) and germinal center kinase 
related protein (GCKR) (Dempsey et al, 2003). All these proteins demonstrate the ability to 
activate MEKK1 and MKK4, suggesting that they are upstream of these MAP3Ks (Chin et al, 
1999; Shi et al, 1999). Chin et al. showed in an overexpression system that dominant negative 
GLK is able to block CD40 induced JNK activation, thereby pointing towards a role for GLK 
in CD40 signalling (Chin et al, 1999). 
TGF-β-activated kinase 1 (TAK1) is a MAP3K with a well described function in TNF-R1 
signalling. TAK1 is recruited to the TNF-RSC together with TAK1 binding proteins 2 and 3 
(TAB2 and TAB3) as a trimeric complex. The recruitment depends on the kinase RIP1 which 
becomes highly ubiquitinated upon TNF stimulation. Due to the ubiquitin binding properties 
of TAB2, the TAB/TAK1 complex is then recruited to the TNF-RSC (Cheung et al, 2004; 
Kanayama et al, 2004; Lee et al, 2003). The recruited TAB proteins facilitate the dimerisation 
or oligomerisation of TAK1, thereby promoting the transautophosphorylation and activation 
of TAK1 (Kanayama et al, 2004). In fact, Matsuzawa et al. showed a recruitment of TAK1 to 
the CD40-RSC thereby also indicating a role for TAK1 in CD40-induced signalling 
(Matsuzawa et al, 2008). TAK1 ablation led to an impairment of TNF and IL-1β-induced 
activation of NF-κB, JNK and p38 whereas this was not investigated in detail for CD40 
signalling. CD40-induced proliferation in TAK1-deficient B cells was significantly decreased. 
Moreover, TAK1 is important for B-1 B cell development but has no impact on the formation 
of follicular or marginal zone B cells (Sato et al, 2005). Hence, although there is growing 
evidence that TAK1 plays a role in CD40 signalling, it remains elusive which signalling 
pathways and B cell subtypes rely on this kinase.  
Tumour progression locus 2 (TPL-2) - also called cancer Osaka thyroid - was identified as a 
MAP3K expressed in many tumours and associated with the progression of lymphoma 
(Patriotis et al, 1993). In 2000 this protein was found in connection with the activation of 
ERK, JNK and p38 (Dumitru et al, 2000). The analysis of TPL-2 knockout mice revealed no 
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obvious phenotype but showed a defect in ERK phosphorylation after CD40 stimulation and 
lower IgE levels after immune challenge (Eliopoulos et al, 2003). Phosphorylation and 
activation of the two upstream kinases of ERK, MKK1 and MKK2, is blocked in TPL-2-
deficient cells upon CD40 stimulation. Overexpression of TRAF6 led to ERK 
phosphorylation in wt cells but not in TPL-2-ablated cells. This strongly suggests that TPL-2 
acts downstream of TRAF6. Interestingly, JNK and p38 signalling was not affected in Tpl-2 
deficient cells after CD40 and TNF stimulation, indicating that this MAP3K is specific for 
ERK activation (Eliopoulos et al, 2003).  
Another potent activator of MAPK signalling is MEKK1. MEKK1 activates JNK and p38 via 
their upstream kinases MKK3, MKK4, MKK6 and MKK7 (Karin & Gallagher, 2005). 
MEKK1 is thought to form a protein complex with the downstream molecules MKK4 and 
JNK1/2 (Xia et al, 1998). The role of MEKK1 in activation of the ERK signalling pathway 
remains to be solved. In-vitro experiments suggest that MEKK1, which has both a kinase 
domain and an E3 ligase domain, is able to trigger K48 ubiquitination and degradation of 
ERK (Lu et al, 2002). However, deletion of the kinase domain within MEKK1 effected only a 
minor decrease on ERK phosphorylation, whereas JNK and p38 phosphorylation appeared 
significantly affected after CD40 stimulation (Gallagher et al, 2007). This is in line with 
overexpression experiments showing that MEKK1 was able to stimulate the MAP2Ks in these 
two pathways. Importantly, MEKK1 was also found to be recruited to the CD40-RSC 
(Gallagher et al, 2007). As it was shown that MEKK1 can associate with oligomerised 
TRAF2 upon TNF stimulation (Baud et al, 1999), a similar mechanism may also apply to the 
CD40-induced recruitment of MEKK1. MEKK1-deficient mice exhibited defective B cell 
proliferation after immunisation with TD antigens, but not in response to TI antigens 
(Gallagher et al, 2007). A similar defect is exhibited in JNK2-deficient, but not JNK1-
deficient, cells, or B cells treated with a JNK inhibitor. Ex-vivo stimulation of kinase mutated 
MEKK1 cells showed reduced expression of the surface proteins ICAM-1, Fas and CXCR4 
after CD40 stimulation, but no difference was observed between wt and kinase-altered cells 
for other surface proteins, such as MHC class II, CD23, CD80, CD86 and LFA-1. 
Furthermore, these cells produced significantly less IL-6 but normal levels of TNF, and 
showed a defect in switching to IgG1 and IgG2a/b after CD40L and IL-4 treatment. In 
summary, these data suggest that MEKK1 plays an important role for the activation of distinct 
genes, but is not required in every respect of CD40-induced gene induction. 
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1.3.4.2 NF-κB signalling 
The NF-κB family is comprised of five molecules: NF-κB1 (p50 and its precursor p105), 
NF-κB2 (p52 and its precursor p100), c-Rel, RelA (p65) and RelB (Rothwarf & Karin, 1999). 
All five proteins share an N-terminal Rel homology domain (RHD) which enables 
dimerisation between proteins of this family, interaction with their inhibitors and binding to 
DNA (Hayden & Ghosh, 2004). NF-κB was first discovered in B cells as a protein bound to 
an enhancer element within the immunoglobulin κ light chain (Singh et al, 1986). It soon 
became clear that this factor plays an important role in almost all cells and that it is retained in 
the cytosol in unstimulated cells by the inhibitor of κB (IκB) (Ghosh et al, 1998). The IκB 
family consists of eight members which can be divided into three groups: first, the typical IκB 
proteins IκBα, IκBβ and IκBε, which are present in the cytoplasm of unstimulated cells and 
undergo stimulus-dependent degradation and resynthesis; second, the precursor proteins p100 
and p105 which can be processed to form active members of the family, p50 and p52; third, 
the atypical IκB proteins IκBγ, BCL-3 and IκBNS which are usually not expressed in 
unstimulated cells, but are induced following stimulation. These latter family members share 
characteristic ankyrin-repeats which form a large surface around the RHD of NF-κB dimers, 
thereby masking the nuclear localization sequence (NLS) (O'Dea & Hoffmann, 2010). The 
best studied IκB molecule is IκBα which forms a complex with NF-κB dimers (e.g. p50 and 
p65). After stimulation it undergoes rapid proteasomal degradation, thereby exposing the NLS 
of the dimer. The released dimer is able to translocate to the nucleus and bind to its respective 
κB promoter element to activate transcription (Hayden & Ghosh, 2008). Interestingly, one of 
the most sensitive genes activated by this mechanism is IκBα itself, providing a negative 
feedback loop which inhibits NF-κB signalling upon reexpression (Ghosh et al, 1998). 
Chapter 1: Introduction 
32 
 
Figure 1.6: Scheme for CD40 induced NF-κB signalling. 
CD40L engagement with its receptor results in the formation of a signalling complex 
and the activation of canonical and non-canonical NF-κB signalling. The activation of 
canonical NF-κB signalling is induced via TAK1 and mainly IKKβ within the IKK 
complex (consisting of NEMO, IKKα and IKKβ). Activation of IKKβ leads to the 
phosphorylation of IκBα and its subsequent degradation, thereby releasing p50/p65. 
The inactive non-canonical NF-κB pathway relies on the degradation of NIK by the 
cytosolic complex of cIAP1/2, TRAF2 and TRAF3. Once the receptor is stimulated, the 
degradation of this complex is initiated and NIK, IKKα and p100 can be activated. 
Stabilised NIK is able to activate IKKα within the IKK complex, resulting in the 
phosphorylation of p100. p100 is then partially degraded to p52.  
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Two different NF-κB pathways can be distinguished: the classical and the alternative 
pathway. Both pathways differ in their mechanisms of activation and the involved proteins. 
The classical pathway mainly relies on the degradation of IκBα which needs to be 
phosphorylated by the IκB kinase (IKK) complex. This complex consists of three proteins: 
IKKα, IKKβ and NF-κB essential modulator (NEMO, also called IKKγ). IKKβ was shown to 
be essential for the phosphorylation of IκBα. This phosphorylation serves as a signal for an E3 
ubiquitin ligase to add K48 linked ubiquitin chains, thereby promoting proteasomal 
degradation. Recently, all IKK complex components were observed to be recruited to the 
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CD40-RSC (Matsuzawa et al, 2008). These authors also demonstrated that TAK1 is recruited 
to the CD40-RSC and this event might contribute to the activation of the classical NF-κB 
pathway. The TAB/TAK complex promotes the transautophosphorylation and activation of 
TAK1 which in turn is able to activate IKKβ and initiate canonical NF-κB signalling by 
phosphorylation of IκBα (Kanayama et al, 2004). 
An alternative NF-κB activation pathway based on the role of NF-κB inducing kinase (NIK) 
in the activation and processing of p100 was first described in 2001 (Xiao et al, 2001). Later 
that year, a report by Senftleben et al. supported these findings by identifying a role for IKKα 
in this pathway (Senftleben et al, 2001), pointing towards an IKKα- and p100-dependent 
pathway. In contrast to the canonical pathway, activation of the non-canonical NF-κB 
pathway is triggered by few extracellular stimuli. CD40L and LT-β were the first described 
ligands (Coope et al, 2002) followed by BAFF (Claudio et al, 2002), TWEAK (Saitoh et al, 
2003; Wicovsky et al, 2009) RANK (Novack et al, 2003) and TNF-R2 (Munroe & Bishop, 
2004; Rauert et al, 2010). Coope et al. were first to show that CD40 and LT-β stimulation 
leads to the degradation of p100 to p52, a process that can be blocked by the proteasome 
inhibitor MG132, suggesting that proteasomal activity is responsible for the observed 
degradation. Moreover, these authors also provide evidence that this process is dependent on 
NIK which was already identified to be involved in p100 degradation (Xiao et al, 2001).  
NIK belongs to the MAP3K family; mutation of NIK in the alymphoplasia mice (aly) or 
complete abrogation of its expression in NIK knockout mice completely blocked p100 
processing (Shinkura et al, 1999; Xiao et al, 2001; Yin et al, 2001). To date, all identified 
inducers of non-canonical NF-κB signalling rely on NIK, establishing NIK as a central 
component of this pathway (Sun, 2011). Although NIK stimulates p100 phosphorylation in 
vivo, recombinant NIK was unable to directly phosphorylate p100 in vitro (Liang et al, 2006; 
Senftleben et al, 2001). Instead, activated NIK is able to phosphorylate the downstream kinase 
IKKα within the IKK complex (Senftleben et al, 2001). Consequently, inactivation of IKKα 
in mice lead to a phenotype similar to the observed in NIK knockout mice, including impaired 
B-cell maturation and defects in lymphoid organogenesis (Matsushima et al, 2001; Senftleben 
et al, 2001). Interestingly, IKKα induces p100 degradation less effectively than NIK (Xiao et 
al, 2001). It was suggested that NIK either facilitates binding of IKKα to p100 (Xiao et al, 
2004) or activates additional factors (Sun, 2011).  
Steady state levels of NIK were shown to be kept extremely low, thereby preventing 
processing of p100 in resting cells. Both knockdown of TRAF3 and TRAF3 knockout showed 
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increased levels of NIK compared with control cells, thereby suggesting that these low levels 
of NIK are due to posttranslational regulation by direct or indirect interaction (He et al, 2006; 
Liao et al, 2004). Indeed, deletion of the TRAF3 binding site in NIK resulted in its 
accumulation in cells (Liao et al, 2004). These results were surprising since TRAF3 itself 
does not possess any intrinsic K48 ligase activity. However, two independent groups showed 
that a complex consisting of TRAF3, TRAF2 and cIAP1/2 can be co-precipitated together 
with NIK (Vallabhapurapu et al, 2008; Zarnegar et al, 2008). Loss of any of these proteins 
resulted in the stabilization of NIK and processing of p100, suggesting that either TRAF2 or 
cIAP1/2 was responsible for the degradation of NIK. Furthermore, it was shown that receptor 
stimulation leading to non-canonical NF-κB signalling led to the receptor-induced 
degradation of TRAF2 and TRAF3, which is mediated by cIAP1 and cIAP2 (Vallabhapurapu 
et al, 2008). This suggests that cIAPs target NIK for ubiquitination and degradation under 
unstimulated conditions but redirect degradational activity towards TRAF2 and TRAF3 in 
response to receptor signals. A crucial trigger for this substrate switch might be the 
recruitment of the involved cIAPs and TRAFs to the receptor. This redirection of the substrate 
specificity of cIAPs results in NIK stabilisation, its ability to phosphorylate IKKα, and, 
probably in a dual activity, to phosphorylate p100. Subsequently, the two phosphorylated 
serine residues within p100 serve as binding platform for βTrCP (Fong & Sun, 2002; Liang et 
al, 2006) and the recruitment of the ubiquitin ligase SCFβTrCP to βTrCP (Karin & Ben-Neriah, 
2000). This activity results in K48 ubiquitination of a lysine residue within p100 which is 
situated in a region homologous to IκBα (Scherer et al, 1995). p100 is then targeted for partial 
degradation by the proteasome. The released p52 form can then dimerise with Rel-B and 
translocate to the nucleus to activate gene transcription. 
1.3.4.3 Abrogation of signal initiation 
Activated signal transduction leads to different biological effects which must be switched off 
again when their respective tasks are fulfilled. Interruption of signalling is regulated by many 
different parameters. Extracellularly this mainly relates to ligand availability. Within cells, the 
signal can be stopped by the presence or activation of counteracting enzymes such as 
phosphatases in the kinase system or deubiquitinases (DUBs; also known as deubiquitinating 
enzymes) in the ubiquitin system. Another important mechanism is the transcription of 
important inhibitory factors which can act either outside the cell to decrease the ligand 
concentration or inside the cell to stop signal transduction. 
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MAPK signalling is inactivated by a group of phosphatases belonging to the protein tyrosine 
phosphatase (PTP) family which are called MAP Kinase Phosphatases (MKPs) (Karin & 
Gallagher, 2005). To date, 10 different MKPs are known to counteract MAPK signalling (Li 
et al, 2009). Like other PTPs, MPK activity is specific for phosphotyrosine and 
phosphothreonine residues in the MAPK activation loop, and these enzymes contain a 
reactive cysteine residue which can be oxidised, leading to MPK inactivation. This offers a 
way to regulate MAPK activity in response to the redox-status of cells. At present it is not 
clear whether individual MKPs strongly discriminate between different MAPKs. For instance, 
several MPKs, including MKP1, MKP3, MKP5 and MKP7 were shown to be capable of JNK 
inactivation (Karin & Gallagher, 2005). 
Within the ubiquitin system two DUBs were described to play a role in CD40 signalling, A20 
and CYLD. Both proteins were first described to be important negative regulators of NF-κB 
signalling (Chen, 2005). Indeed, A20 knockdown experiments revealed an inhibitory effect of 
A20 on CD40 stimulation (Longo et al, 2003). Later, A20 was found to play a negative role in 
NF-κB activation in A20-ablated primary cells, however, a role in MAPK signalling was not 
observed (Tavares et al, 2010). In addition, surface expression of CD80, CD69 and CD95 
after CD40 stimulation was increased and proliferation enhanced in A20 knockout B cells 
(Tavares et al, 2010). In 2003, a role for CYLD in CD40 signalling was described in an 
overexpression system (Trompouki et al, 2003). CYLD ablation led to increased NF-κB 
activation whereas CYLD overexpression resulted in inhibition of the NF-κB pathway after 
CD40 overexpression. 
In summary, CD40 induces several genes which mediate cellular functions important for 
specific immune responses. However, it also triggers the expression of some inhibitory 
molecules which interfere with signal transduction and function in negative feedback loops. 
One of the most important genes in this respect is the NF-κB-driven expression of IκBα which 
inhibits NF-κB (Schonbeck & Libby, 2001). This is important for cells, as NF-κB can act as a 
tumour promotor and constitutive NF-κB signalling most likely results in tumour formation 
(Kirkin & Dikic, 2011). 
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Figure 1.7: Ubiquitin can form eight different linkage types. 
The three dimensional structure of ubiquitin shows the distribution of the seven lysine 
residues and M1, which can be used to form linear ubiquitin chains. Each lysine 
residue reaches into a different geometric space, providing more possibilities for the 
formation of a poly-ubiquitin chains. The abundance of the respective linkage types 
found in S. cerevisiae is shown in parentheses (Xu et al, 2009). Figure modified from 
(Komander, 2009). 
1.4 The ubiquitin system 
Postranslational protein modifications such as phosphorylation and ubiquitination are 
important regulators in many different cellular processes, from basic metabolism to cell cycle 
control and signalling events. Whereas phosphorylation involves the addition of negatively 
charged phosphate residues by kinases, addition of ubiquitin residues is more complex and 
involves a cascade of proteins. The possibility of forming different ubiquitin linkage types 
adds complexity to the system.  
1.4.1 Biology of the ubiquitin molecule 
Ubiquitin is a highly conserved and ubiquitously expressed protein in all eukaryotes from 
yeast to humans and is believed to have evolved from ancestral proteins containing β-grasp 
folds (Liu & Chen, 2011). Ubiquitin is encoded by four different genes. In two cases it is 
fused to the essential small and large ribosomal proteins, S27 and L40, respectively. 
Furthermore, the Ubb and Ubc genes consist of four and nine repeats of the mono-ubiquitin 
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coding sequence (Kimura & Tanaka, 2010). Disruption of the Ubc gene results in embryonic 
lethality in mice (Ryu et al, 2007) but disruption of the Ubb gene has no effect on embryonic 
viability, with neonates displaying normal Mendelian ratios (Ryu et al, 2008). Nevertheless, 
these mice develop adult-onset obesity due to the degeneration of hypothalamic neurons 
involved in controlling energy balance and feeding, the disruption of circadian rhythm and 
infertility due to defects in progression of meiosis (Ryu et al, 2010; Ryu et al, 2008). Each of 
the four fused ubiquitin proteins is cleaved by deubiquitinating enzymes (DUBs) into equal 
sized ubiquitin units of 76 aa. Depending on the cell type, these mono-ubiquitin units form 
0.1% to 5% of the cellular protein content and their level is regulated to keep a free pool of 
monomers available for various cellular processes (Kimura & Tanaka, 2010).  
Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48, K63) and each one of 
them can be used as acceptor for the C-terminus of another ubiquitin moiety to form ubiquitin 
chains (Figure 1.7). Additionally, it was recently discovered that the N-terminus can function 
as an acceptor for the C-terminus of another protein, thereby building M1-linked ubiquitin 
chains (also called head-to-tail or linear ubiquitin chains) (Ikeda & Dikic, 2008; Kirisako et 
al, 2006).  
Crystal structure analysis revealed different morphologies for different linkage types which is 
due to different geometric positions of the lysine residues within ubiquitin (Figure 1.7). 
Additionally, it was shown that different linkage types serve different functions in cells. For 
example, both K48-linked (the first and best studied linkage type) and K11-linked ubiquitin 
chains have a compact globular form but are still distinguishable in their structures (Bremm et 
al, 2010). When attached to proteins these two linkage types lead to proteasomal degradation 
of target proteins. In contrast, K63- and M1-linked ubiquitin chains have open, elongated 
structures. Because of the close proximity of the N-terminus and the K63 residue, these two 
chain types are relatively similar in their conformation. However, the molecular 
characteristics of the isopeptide linkage in K63-linked ubiquitin chains differ significantly 
from the peptide bond in linear chains. Due to the connecting peptide bond between the M1 
and the C-terminus, linear chains are conformationally restrained compared with the more 
flexible isopeptide linkage between the lysine residue of one ubiquitin and the C-terminus of 
another (Komander et al, 2009b). K63-linked ubiquitin chains were described to have a 
particular important role in signalling processes, but evidence is emerging that the M1-linked 
ubiquitin chains also play a decisive role in the quality of signal transduction. 
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Figure 1.8: The different ubiquitin linkage types. 
Ubiquitin linkage types can be categorised into three groups: monoubiquitination, 
multiple-monoubiquitination and polyubiquitination. In the case of polyubiquitination 
different scenarios are possible: the chain can consist of either a single linkage type 
(homotypic) or of different linkage types (heterotypic), where the latter can exhibit 
branched linkages. Each linkage type has different biochemical properties and 
influences cellular functions in a unique way. 
K KK
Target
K
Target
K
Target
K48
K48
K48
K48
K
Target
K63
K63
K63
K63
M1
K
Target
K63
K63
M1
K63
K
Target
K63
K11
K63
K63K27
Monoubiquitiation Multiple-monoubiquitination
Homotypic polyubiquitination
Heterotypic polyubiquitination
Mixed 
linkages
Branched
linkages
Beside the above-described ubiquitin linkage types, also all other possible lysine-linked chain 
types were identified to be present in yeast cells. However, we are only beginning to 
understand specific roles in cellular processes. In addition, recent studies describe the 
existence of mixed ubiquitin chains containing more than one ubiquitin linkage type (Figure 
1.8) (Ben-Saadon et al, 2006; Kim et al, 2007). Another possibility for protein modification 
with ubiquitin is based on mono- or multiple–mono-ubiquitination of target proteins 
respectively (Ikeda & Dikic, 2008). Modifications with monoubiquitin have been shown to be 
involved in the DNA-damage response and in receptor tyrosine kinase (RTK) signalling. In 
fact, it was demonstrated by the group of Ivan Dikic that multiple-monoubiquitination of 
RTKs is an important signal for their endocytosis and lysosomal degradation. 
Monoubiquitination is also the signal responsible for the migration of RTKs from the plasma 
membrane to the lysosome (Haglund et al, 2003a; Haglund et al, 2003b).  
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Figure 1.9: Mechanism for the formation of ubiquitin chains. 
The E1 forms a high energy thioester bond with Ubiquitin in an ATP-dependent 
manner. This activated Ubiquitin is then transferred to the E2 and the “recycled” E1 is 
released. In the case of an E3 RING protein, the E2 and the substrate is brought into 
close proximity and the reaction occurs with the facilitating function of the E3, finally 
releasing the ubiquitinated substrate. In the case of E3 HECT proteins, the ubiquitin is 
first transferred from the E2 to the E3 and finally transferred to the target protein.  
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1.4.2 Proteins involved in the ubiquitin system 
To attach ubiquitin covalently to proteins, a stepwise enzymatic reaction occurs involving 
three classes of enzymes, E1, E2 and E3 (Hershko & Ciechanover, 1998). First, the carboxyl 
group at the C-terminus of ubiquitin is activated with ATP by forming a high-energy mixed 
anhydride bond. This anhydride bond is targeted by the sulfhydryl group of the ubiquitin 
activating enzyme (E1) active site cysteine, which forms a high-energy thioester bond 
between E1 and ubiquitin and expels AMP (Figure 1.9). Within the ubiquitin system two E1 
proteins are known to date, Uba1 and Uba6. Activated ubiquitin is next transferred to an 
active site cysteine residue of the ubiquitin-carrier protein, E2. The family of E2s consists of 
approximately 50 proteins. The last step of the reaction, the transfer of the ubiquitin moiety 
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from E2 to the substrate, is catalysed by a ubiquitin conjugating enzyme, E3. E3 ligases 
facilitate the linkage of the C-terminus of ubiquitin to the ε-amino group of a lysine residue, 
thereby establishing an amide isopeptide bond (Figure 1.9). 
To date, over 700 E3 ligases have been identified, which can be divided into three families, 
HECT (homologous with E6-associated protein C-terminus), U-box and RING (Really 
Interesting New Gene). The family of HECT E3s takes an active part in the enzymatic process 
by covalently linking ubiquitin to a cysteine residue and then transferring it to the substrate. In 
contrast, the members of the U-box and RING family position the substrate and the activated 
E2-ubiquitin complex in close proximity to the substrate, thereby facilitating a direct transfer 
of the ubiquitin molecule (Deshaies & Joazeiro, 2009; Liu & Chen, 2011). However, a recent 
report by Rachel Klevit’s group shows that E3 ubiquitin ligases with a RING-in-between-
RING (RBR) domain covalently bind ubiquitin molecules with the second RING domain, 
meaning that E3 ligases also form an intermediate compound like that seen with HECT E3s 
(Wenzel et al, 2011). It was reported that E4 ubiquitin elongating factors can further elongate 
a ubiquitin oligomer (Hoppe, 2005). There is evidence that linkage specificity is determined 
by the E2 proteins (Christensen & Klevit, 2009), whereas substrate specificity depends on the 
E3 proteins (Ikeda & Dikic, 2008).  
Phosphorylation and ubiquitination are both post-translational modifications which can be 
reversed either by phosphatases or DUBs. These enzymes are far from being uniform in 
structure and function and are subject to multiple layers of regulation that modulate both their 
reactivity and specificity (Komander et al, 2009a). Indeed, it was shown that certain DUBs 
can have specificity for individual chain types but that other DUBs can cut chains 
promiscuously. For example, it was shown that Usp2 cleaves K48-, K63- and M1-linked 
ubiquitin chains whereas CYLD only cleaves K63- and M1-linked polymers with a preference 
for linear chains; AMSH (associatedmolecule with the SH3 (Src homology 3) domain of 
STAM (signal-transducing adaptor molecule)) cleaves K63- but not K48- and M1-linked 
chains (Komander et al, 2009b).  
The varied structures of poly-ubiquitin chains suggest that ubiquitin binding proteins and 
receptors have particular binding specificities. These proteins possess a ubiquitin binding 
domain (UBD) (Pickart & Fushman, 2004). So far 16 different types of UBDs have been 
identified to be encoded for in the eukaryotic genome. These include ubiquitin-associated 
(UBA) domains, ubiquitin interacting motifs (UIMs), Gga and Tom1 (GAT) domains, Npl-4 
zinc finger (NZFs) domains, coupling of ubiquitin conjugation to endoplasmic reticulum (ER) 
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degradation (CUE) domains, ubiquitin conjugating enzyme variant (UEV) domains, GRAM-
like ubiquitin-binding in Eap45 (GLUE) domains, Plextrin receptor for ubiquitin (Pru), VHS 
(Vps27, HRS, STAM) domains and polyubiquitin-associated zinc finger (PAZ) domains. In 
general, UBDs usually range in size from 20 aa to 150 aa and are therefore quite small. 
Interestingly, they exhibit a relatively weak affinity (KD ~ 10-500 µM) to monoubiquitin. 
However, they are usually able to bind certain polyubiquitin chains of one or the other linkage 
types at much higher affinities (Hicke et al, 2005). Whereas the structure and interface of 
UBDs are quite versatile and some of them do not seem to have any features in common, all 
described UBDs to date use the same ubiquitin interface. This part of ubiquitin includes 
residue I44 - in some cases L8 and G47 - and is characterised by its hydrophobicity. It plays a 
decisive role for the binding of UBDs to ubiquitin (Hicke et al, 2005). Additionally, these 
interactions are quite often supported by other factors or domains which are able to transform 
a promiscuous monoubiquitin-binding protein into a linkage-specific binding protein.  
The globular structure of K48-linked ubiquitin chains places the I44 interface in a completely 
different geometry compared with the elongated structure of K63-linked polymers. Therefore, 
UBDs are able to distinguish between the different chain types. For instance, the Pru domain 
in the proteasome receptor Rpn13 prefers to bind K48-linked tetra-ubiquitin (Husnjak et al, 
2008). On the other hand, there are also UBDs which specifically bind to K63-linked chains 
but only very weakly associate with linear and K48-linked chains, e.g. the NZF in TAB2 
(Kulathu et al, 2009; Sato et al, 2009). In contrast, the UBDs in ABIN and NEMO proteins 
(UBAN) bind linear ubiquitin chains at an approximate 100-fold higher affinity compared 
with the affinity for K63- and K48-linked chains (Lo et al, 2009; Rahighi et al, 2009). 
1.4.3 Physiological roles of differently linked ubiquitin chains 
A study by Xu et al. quantified the abundance of all ubiquitin chain types except M1-linked 
ubiquitin chains in yeast cells and found the following frequencies: K6 (11%), K11 (28%), 
K27 (9%) K29 (3%), K33 (3%) K48 (29%) and K63 (17%). This work also showed that all 
linkage types, save K63-linked chains, accumulate within cells after treatment with 
proteasome inhibitors, suggesting a role in protein degradation (Xu et al, 2009). Interestingly, 
the extensively studied K48- and K63-ubiquitin linkages comprised only about 50% of all 
chain types. Only recently, a number of reports have begun to elucidate the biological roles of 
the other, so called atypical ubiquitin chains: 
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K6-linked ubiquitin chains were found to be synthesised by the heterodimeric RING E3 
complex consisting of BRCA1 and BARD1. These proteins are localised at sites of DNA 
damage and mutation of BRCA1 leads to early-onset breast and ovarian cancer which are 
characterized by high genetic instability, suggesting a role for this chain type in DNA repair 
(Morris & Solomon, 2004; Nishikawa et al, 2004; Wu-Baer et al, 2003).  
The second most abundant ubiquitin linkage type, K11-linked ubiquitin chains, seem to be a 
potent signal for proteasomal degradation but are also employed in many other pathways 
(Komander, 2009). For example, K11-linked ubiquitin chains were shown to play a role in 
endoplasmic reticulum associated degradation (ERAD), in the mammalian cell cycle and, in 
signal transduction emanating from the TNF-RSC (Dynek et al, 2010; Matsumoto et al, 2010; 
Xu et al, 2009). The anaphase-promoting complex/cyclosome (APC/C) is the key E3 to 
generate K11-linked ubiquitin chains, and together with UbcH10, targets proteins for 
degradation during mitosis, suggesting an important role for this chain type in cell cycle 
progression (Jin et al, 2008; Matsumoto et al, 2010). Only recently, Vucic and colleagues 
provided evidence for the existence of K11-linked ubiquitin chains within the TNF-RSC and 
showed that NEMO is able to bind to K11-linked chains (Dynek et al, 2010). 
Two recent studies claim a role for K27 in cellular processes. Zucchelli et al. claims the 
existence of K27 ubiquitin chains on the misfolded proteins DJ-1 and L166P generated by 
TRAF6 (Zucchelli et al, 2010). A publication by Arimoto et al. suggests a role for K27 
ubiquitin chains in antiviral immune responses. In this paradigm, TRIM23 is supposed to 
generate K27-linked ubiquitin chains on NEMO and should be important for NF-κB mediated 
gene induction (Arimoto et al, 2010). 
K29 and K33 were shown to regulate protein kinases which are inactivated by the attachment 
of these ubiquitin polymers (Al-Hakim et al, 2008). The AMP-activated protein kinase-related 
kinases (AMPKs) regulate cell polarity and proliferation and are subjected to regulation by 
the DUB USP9X, which removes the ubiquitin residues and reestablishes kinase activity. 
Another role for regulating signalling events was found in the Notch signalling pathway, 
where one of the regulatory proteins was modified with K29-linked ubiquitin chains and 
subjected to lysosomal degradation rather than proteasomal degradation (Chastagner et al, 
2006; Chastagner et al, 2008). A recent report claimed a role for K33-linked polyubiquitin in 
T cell receptor activation. The modification is supposed to be mediated by Cbl-b and Itch and 
affects receptor phosphorylation and association with ζ-chain associated protein of 70 kDa 
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(Zap-70), resulting in augmented receptor activation in the absence of this chain type (Huang 
et al, 2010).  
It was believed that K48-linked polymers are the main chain type present in cells and this 
chain type was therefore referred to be the canonical chain type. Tetramers of this chain type 
are thought to be the minimal recognition motif for efficient activation of the proteasomal 
degradation pathway. However, ubiquitin itself is not degraded but recycled (Komander, 
2009). The proteasome consists of a core protease unit and two regulatory units forming a 
protein complex of approximately 2,000 kDa. This complex contains a variety of ubiquitin 
receptors and DUBs to regulate protein homeostasis and is responsible for more than 80% of 
the intracellular protein degradation (Wang & Maldonado, 2006). 
K63-linked ubiquitin chains were the only chain type in the study by Xu and colleagues which 
did not accumulate in yeast cells after treatment with a proteasome inhibitor, suggesting an 
exclusive role in non-degradative processes (Xu et al, 2009). Indeed, many earlier studies 
supported this hypothesis as roles in receptor internalisation, DNA damage response and 
cytokine signalling were described.  
By using K63A mutants of endogenous ubiquitin, early studies demonstrated a role for K63-
linked ubiquitin chains in sensitising cells to DNA damage (Hofmann & Pickart, 1999). 
Subsequently, the proliferating cell nuclear antigen (PCNA) was implicated in this process. 
When PCNA was mono-ubiquitinated, DNA replication was error-prone. However, 
elongation of these ubiquitin molecules by K63-linked ubiquitin chains changed the 
replication process to an error-free pathway (Moldovan et al, 2007). Additionally, histones 
were shown to be targeted by K63-linked ubiquitination after DNA damage, inducing 
recruitment of DNA-repair proteins, including p53-binding protein 1 (53BP1) and BRCA1 
(Panier & Durocher, 2009)  
The function of K63-linked ubiquitin chains are best studied in the context of cytokine 
signalling, as K63-linked chains are needed in different signalling pathways for the activation 
of a variety of transcription factors. This chain type was observed on TRAFs, RIP1, IL-1 
receptor-associated kinases (IRAKs) and on components of the TAB/TAK complex (Deng et 
al, 2000; Ea et al, 2006; Ordureau et al, 2008; Reiley et al, 2007). It was shown that activation 
of the IKK complex by TAK1 is dependent on K63-linked polymers, which are assembled at 
signalling complexes upon receptor stimulation, e.g. by TRAF E3 ligases (Deng et al, 2000; 
Komander, 2009). This scaffold of K63-linked ubiquitin chains is the basis for assembling 
recruiting the TAB/TAK complex and is mediated by the K63-specific ubiquitin-binding 
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domains of the TAB2 or TAB3 subunits. This oligomerisation is thought to trigger cross-
phosphorylation and activation of TAK1; however, it is also possible that ubiquitin plays an 
active allosteric role in TAK1 activation (Komander, 2009). An interdependent activation 
mechanism involving K63-linked polyubiquitin chains was shown for IL-1 signalling. A 
study from Cohen and colleagues showed that IRAK1 and IRAK4 phosphorylate Pellino to 
activate its E3 activity. Once activated, Pellino in turn is able to ubiquitinate IRAK1 and 
IRAK4 with K63-linked ubiquitin polymers, thereby providing an important initial event for 
IL-1- and TLR-family signalling (Ordureau et al, 2008). 
The eigth and unconventional ubiquitin linkage type does not rely on one of the seven lysine 
residues within ubiquitin but uses instead the N-terminal methionine (M1) for elongating 
ubiquitin chains. Linear ubiquitin chains exist in cells per se as ubiquitin is encoded by 
several genes that generate polypeptides of multiple ubiquitin moieties that are linearly linked. 
However the multi-ubiquitin proteins are processed to single molecules post-translationally. 
Interestingly, in 2006 Iwai and colleagues described the generation of this chain type as a 
post-translational modification (Kirisako et al, 2006). They identified a large complex 
comprising the haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1 (HOIL-1) and 
HOIL-1-interacting protein (HOIP), and showed that the purified complex is able to form 
ubiquitin chains in vitro with lysine-null variants of ubiquitin. Due to this activity, the 
complex consisting of HOIL-1 and HOIP was named linear ubiquitin chain assembly complex 
(LUBAC). Three years later, the same group demonstrated a role for linear ubiquitin in TNF-
induced NF-κB activation (Tokunaga et al, 2009). They showed that the IKK complex 
component NEMO is targeted by LUBAC and modified with linear ubiquitin chains after 
overexpression of LUBAC components. In line with this finding, binding of NEMO to linear 
ubiquitin was shown to be important for NF-κB activation (Rahighi et al, 2009). In the same 
year, Walczak and colleagues showed the recruitment of LUBAC to the TNF-RSC is 
stimulation-dependent, and that LUBAC and its linear-ubiquitin chain forming activity are 
required for TNF-RSC stability, integrity and functionality (Haas et al, 2009). 
Three recently published studies, including work from this thesis, expand the function of 
LUBAC in two important aspects: first, another component of LUBAC was identified, 
namely SHARPIN (SHANK-associated RH-domain-interacting protein), and second, linear 
ubiquitin chains were shown to play a role in signalling pathways other than TNF signalling. 
SHARPIN was first identified in the rat brain in association with SHANK in the post-synaptic 
density of excitatory neurotransmitters (Lim et al, 2001). However, its mutation causes the 
Chapter 1: Introduction 
45 
 
chronic proliferative dermatitis (cpdm) phenotype in mice which is characterised by severe 
inflammation, eosinophilic dermatitis and defects in secondary lymphoid organ development 
(Seymour et al, 2007). In addition, a role for LUBAC was demonstrated in signalling induced 
by IL-1β, TLRs and CD40 (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). 
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1.5 Aims of the project 
CD40 belongs to the TNF-Receptor superfamily and is an important signal mediator for the 
humoral immune response. CD40L expressed on T-helper cells is required for stimulation of 
CD40 on B cells resulting in the formation of a multi-protein complex, the CD40 receptor 
signalling complex (CD40-RSC). Signals emanating from the CD40-RSC activate various 
cellular signalling pathways. Elucidation of the biochemical composition of the CD40-RSC, 
as well as the functional interplay of the different constituents therein, is therefore crucial for 
the understanding of CD40 signal initiation, and consequently CD40 biology.  
 
To unravel the composition and function of the CD40-RSC, 
1. a method should be established to purify the CD40-RSC, and 
2. the purified CD40-RSC should be analysed by Western blotting and mass 
spectrometry to identify unknown components of this signalling complex. 
 
These analyses revealed three novel components of the CD40-RSC, namely SHARPIN, HOIP 
and HOIL which together constitute the linear ubiquitin chain assembly complex (LUBAC). 
In subsequent experiments their role in CD40 signalling should be analysed in the following 
aspects: 
3. the manner in which these novel components are recruited to the CD40-RSC, 
4. the signalling pathways in which they are involved upon CD40 stimulation, and 
5. the immunological consequences when one of the components is missing. 
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Chapter 2. Material and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
All chemicals and biological reagents were purchased from Roth, Sigma/Aldrich (Fluka), 
Merck (Calbiochem), Invitrogen (Gibco; Molecular Probes), AppliChem, Pierce, Honeywell 
(Riedel-de Häen) or Amersham Biosciences. All chemicals were purchased in pA quality 
unless indicated otherwise. 
2.1.2 Specific inhibitors 
Table 2.1: List of inhibitors used in this thesis. 
Inhibitor Source 
Complete Protease Inhibitor 
Cocktail 
Roche 
Phosphatase Inhibitor 
Cocktail 
Sigma 
 
2.1.3 Buffers and solutions 
Blocking buffer (Western blotting)   1 x PBS 
       5% milk powder (w/v) 
       0.05% Tween-20 (v/v) 
 
Citrate buffer      0.025 M citric acid (pH = 4.5) 
 
ELISA assay buffer     1 x PBS 
       0.5% BSA (w/v) 
       0.05% Tween-20 (v/v)  
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FACS buffer      1 x PBS 
       5% FCS (v/v) 
       0.05% NaN3 (w/v) 
Freezing medium     90% FCS (v/v) 
       10% DMSO (v/v) 
 
2 x HBS (pH = 7.0)     50 mM HEPES 
       280 mM NaCl 
       1.5 mM Na2HPO4 x 2 H2O 
 
IP-lysis buffer      30 mM Trizma Base (pH 7.4) 
       120 mM NaCl 
       2 mM EDTA 
       2 mM KCl 
       10% Glycerol (v/v) 
       (1% Triton X-100 (v/v) or 
1% NP-40 (v/v)) 
       (+ Complete Protease Inhibitor cocktail) 
       (+ Phosphatase Inhibitor) 
 
Luciferase assay buffer A (pH = 7.8)  20 mM HEPES 
       33.3 mM DTT 
       8.0 mM MgCl2 
       130 µM EDTA 
       530 µM ATP 
       470 µM Luciferin 
       270 µM Coenzyme A 
 
Luciferase assay buffer B (pH = 5.0)  15 mM Na4P2O7 
       7.5 mM NaOAc 
       400 mM Na2SO4 
       10 mM CDTA 
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       25 µM APMBT 
       1% Methanol (v/v) 
       2 µM Benzyl-Coelenterazin 
 
MACS buffer      1 x PBS 
       2 mM EDTA 
       0.5% BSA (w/v) 
 
Maintenance buffer     50 mM Trizma Base 
       100 mM NaCl 
       0.02% Tween 20 (v/v) 
       2 mM DTT 
       (0.5 M L-Arginine) 
 
MOPS running buffer (pH = 7.7)   50 mM MOPS 
       50 mM Trizma Base 
       3.5 mM SDS 
       1 mM EDTA 
 
Nicoletti buffer      0.1% Sodium citrate (w/v) 
       0.1% Triton X-100 (v/v) 
       50 µg/ml Propidium iodide 
 
PBS (pH = 7.4)     137 mM NaCl 
       8.1 mM Na2HPO4 
       2.7 mM KCl 
       1.5 mM KH2PO4 
 
Pull-down buffer     150 mM NaCl 
       50 mM Trizma Base  (pH 7.5) 
       5 mM DTT 
       0.1% NP-40 (v/v) 
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Stripping buffer (pH = 2.3)    50 mM Glycine 
 
TAE buffer (10x)     400 mM Tris/HCl 
       200 mM Acetic Acid 
       10 mM EDTA 
 
TB buffer      10 mM Pipes 
       55 mM MnCl2 
       15 mM CaCl2 
       250 mM KCl 
 
Transfer buffer     192 mM Glycine 
       25 mM Trizma Base 
       0.01% EDTA (w/v) 
       20% Methanol (v/v) 
 
Wash buffer (Western blotting)   1 x PBS 
       0.05% Tween-20 (v/v) 
 
 
2.1.4 Biological reagents 
Table 2.2: Commercial Biological Agents. 
Antibody Source 
murine IL-4 R&D systems 
murine CD40L R&D systems 
human CD40-Fc Abcam 
human CD40L R&D systems 
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2.1.5 Antibodies 
Table 2.3: List of unconjugated antibodies used in this thesis. 
(WB: Western blotting; IP: immunoprecipitation; FACS: fluorescence activated cell sorting) 
Antibody Isotype Source Application 
anti-Actin (A5441) mIgG1 Sigma WB 
anti-CD16/32 (93) ratIgG2a eBioscience FACS 
anti-CD40 (EA-5) mouse Bioscourse FACS 
anti-CD40 (H-120) rabbit Santa Cruz WB 
anti-cIAP Pan (MAB3400) mIgG2a R&D Systems WB 
anti-cIAP1 rat John Silke WB 
anti-cIAP-2 rat John Silke WB 
anti-FLAG (M2) mIgG1 Sigma WB, IP 
anti-HOIL-1 mIgG2a Tobias Haas WB 
anti-HOIP rabbit Eurogentec WB 
anti-IκBα (C-15) mIgG1 Santa Cruz WB 
anti-JNK (56G8) rabbit Cell Signalling WB 
anti-p-IkBα (5A5) mIgG1 Cell Signaling WB 
anti-p-JNK (G9) mIgG1 Cell Signalling WB 
anti-RIP mIgG2a BD WB 
anti-SHARPIN mIgG1 Tobias Haas WB 
anti-TRAF2 (C-20) rabbit Santa Cruz WB 
anti-TRAF3 (H-122) rabbit Santa Cruz WB 
anti-V5 (V5-10) mIgG1 Sigma WB, IP 
 
Table 2.4: List of conjugated antibodies used in this thesis. 
Antibody Source Application 
Goat-anti-mIgG1-HRP Southern Biotech WB 
Goat-anti-mIgG2a-HRP Southern Biotech WB 
Goat-anti-mIgG2b-HRP Southern Biotech WB 
Goat-anti-mIgM-HRP Southern Biotech WB 
Goat-anti-rabbit-IgG-HRP Southern Biotech WB 
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Goat-anti-rat-HRP Southern Biotech WB 
Rabbit-anti-goat-IgG-HRP Santa Cruz WB 
anti-IgG1 FITC BD FACS 
anti-IgM PE BD FACS 
anti-B220 APC BD FACS 
2.1.6 Beads for protein precipitation 
Table 2.5: List of beads for protein precipitation. 
Kit Source 
anti-FLAG M2 Affinity Gel Sigma-Aldrich 
anti-V5 AGAROSE (clone V5-10) Sigma-Aldrich 
Protein G Sepharose 4 Fast Flow GE Healthcare 
2.1.7 Commercial detection and isolation systems (kits) 
Table 2.6: List of commercial detection and isolation systems. 
Kit Source 
BCA Protein Assay Pierce 
Chemoluminescent Substrate 
SuperSignal West Dura 
Pierce 
Chemoluminescent Substrate 
SuperSignal West FEMTO 
Pierce 
ECL Western Blotting Detection GE Healthcare 
ECL Western Blotting Detection Plus GE Healthcare 
IL-6 ELISA (CytoSet) BioSource 
NE-PER Nuclear and Cytoplasmic 
Extraction Reagents 
Thermo Fisher 
QIAprep Maxi Kit Qiagen 
QIAprep Spin Mini Kit Qiagen 
QIAquick Gel Extraction kit Qiagen 
RevertAid
TM
 H Minus first strand cDNA 
synthesis kit 
Fermentas 
SilverQuest
TM
 Silver Staining Kit Invitrogen 
CellTrace
TM
 Violet Proliferation Kit Invitrogen 
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2.1.8 Instruments 
Table 2.7: List of instruments required during the thesis. 
Instrument Source 
ÄKTAprimeTM GE Healthcare 
Biofuge Stratos Heraeus 
Blotting equipment X cell IITM Novex 
Electrophoresis chamber Biorad 
Flow Cytometer FACSCalibur Becton Dickinson 
GelSystem Flexi 4040 Biostep 
Hyper Processor X-Ray film Developer Amersham Bioscience 
Incubator Stericult 200 Forma Scientific 
Microscope Axiovant 25 Zeiss 
Mithras Luminometer LB 940 Berthold Technologies 
Multifuge 3S-R Heraeus 
Multiskan Ascent Thermo Labsystems 
Multitron Incubator Shaker Appropriate Technical Resources 
NanoDrop Spectrophotometer ND-1000 NanoDrop Technologies 
Photometer Ultrospec 3100 pro Amersham Bioscience 
Sonifier Branson Ultrasonics Corporation 
XCell SureLock™ Mini-Cell Invitrogen 
 
 
2.1.9 Bacteria strains 
Table 2.8: List of bacteria strains. 
Strain Genotype Application 
Top10F’ 
F'[lacIq Tn10(tetR)] mcrA ∆(mrr-hsdRMS-
mcrBC) φ80lacZ∆M15 ∆lacX74 deoR nupG 
recA1 araD139 ∆(araleu) 7697 galU galK 
rpsL(StrR) endA1 λ- 
plasmid amplification 
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2.1.10 Additional materials 
Table 2.9: Additional materials used in the thesis. 
Material Source 
Dialysis Membrane 
12,000-14,000 MWCO 
KMF 
Hybond ECL Nitrocellulose Membrane Amersham Bioscience 
NuPAGE SDS-Gels Invitrogen 
RBC lysis buffer eBiosciences 
SDS-Sample buffer Invitrogen 
SeeBlueTM Plus2 Pre-Stained Standards Novex 
SmartLadder DNA Standards Eurogentec 
Sterile filter (0.22 µm and 0.45 µm pore 
size) 
Millipore 
Tissue culture equipment TPP 
X-Ray film HyperfilmTM ECL Amersham Bioscience 
ZOOM® Carrier Ampholytes Invitrogen 
ZOOM® Gels for 2D Electrophoresis Invitrogen 
ZOOM® strips Invitrogen 
 
2.2 Cell biology 
2.2.1 Cell lines 
2.2.1.1 HEK293T 
HEK293T cells were generated by transformation of human embryonic kidney (HEK) cell 
cultures with sheared adenovirus 5 DNA (Graham et al, 1977). HEK293T cells are highly 
transfectable due to expression of the SV40 large T-antigen, and support the extra 
chromosomal replication of plasmids bearing the SV40 origin of replication. 
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2.2.1.2 HeLa 
The HeLa cell line was isolated from an adenocarcinoma of the cervix in 1952 and was the 
first human epithelial cancer cell line established in long-term cell culture (Scherer et al, 
1953). The cells have a hypertriploid chromosome number (3n+), 20 clonally abnormal 
chromosomes and contain multiple copies of HPV type 18 (HPV18), integrated at specific 
sites (Chen, 1988; Popescu et al, 1987). 
2.2.1.3 MCF-7 
The human breast carcinoma cell line MCF-7 was first described in 1973 by Brooks and 
colleagues (Brooks et al, 1973). 
2.2.1.4 BJAB 
The human lymphoma cell line BJAB was established from an exceptional case of African 
Burkitt’s lymphoma; both the tumour and the BJAB cell line are negative for EBV (Epstein-
Barr virus) DNA and do not express the EBV-specified nuclear antigen EBNA (Menezes et 
al, 1975). 
2.2.1.5 Raji 
Raji cells are a human lymphoblast-like cell line which was established by R.J.V Pulvertaft in 
1963 from a Burkitt’s lymphoma of the left maxilla of an 11-year-old black male (Pulvertaft, 
1964). 
2.2.1.6 SKW6.4 
This Epstein-Barr virus nuclear antigen (EBNA) negative cell line was originally established 
in vitro from a patient with diffuse histiocytic lymphoma (Nilsson et al, 1983). 
2.2.1.7 U937 
The human hematopoietic cell line U937 was derived from a patient with generalised 
histiocytic lymphoma and first described in 1976 by Sundstrom and Nilsson (Sundstrom & 
Nilsson, 1976). 
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2.2.1.8 HL-60 
This cell line was derived from a 36-year-old woman with acute promyelocytic leukaemia at 
the National Cancer Institute (Gallagher et al, 1979). 
2.2.1.9 Ramos 
Ramos cells are an in vitro cell line derived from an American Burkitt lymphoma. The cells 
have B-lymphocyte characteristics with surface associated µ and κ chains (Klein et al, 1975). 
2.2.1.10 BHK CD40L 
This cell line was derived from baby hamster kidney and is stably transfected with CD40L. It 
was a gift from Michael Conzelmann (Rodionova et al, 2007). 
2.2.1.11 THP-1 
The human cell line THP-1 is a leukaemia cell line with distinct monocytic markers and was 
established by Tsuchiya and colleagues in 1980 (Tsuchiya et al, 1980). 
2.2.2 Cell culturing conditions 
All adherent cell lines were cultured in a 10% CO2 humidified atmosphere at 37°C. HeLa and 
HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal bovine serum. MCF-7 cells were cultured in DMEM 
containing 10% foetal bovine serum, 1% pyruvate and 0.1% human insulin. These adherent 
cells were split using a 1 x Trypsin/EDTA solution.  
All suspension cell lines were maintained in RPMI supplemented with 10% FBS at 5% CO2 
(37°C). Cell density was determined with a Neubauer chamber slide. Cells were centrifuged 
(Heraeus Multifuge 3 S-R) for pelleting at 300 x g for 4 min. 
2.2.3 Freezing and thawing of eukaryotic cells 
Cells were harvested and resuspended in freezing medium. The cell density was adjusted to 1-
1.5 x 106 cells/ml. The cells were slowly cooled down to -80°C in an isopropanol box. Cells 
were kept for long-term storage in liquid nitrogen at -196°C. 
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Cells were thawed rapidly to 37°C and immediately transferred into prewarmed cell culture 
medium. Adherent cells were directly placed in cell culture flask; after cell attachment the 
medium was replaced by prewarmed fresh medium. Suspension cells were spun down in 
prewarmed medium after thawing out and the cell pellet resuspended in growth medium.  
2.2.4 Transfection of adherent cells 
MCF-7 and HeLa cells were transfected with FuGene 6 (Roche Applied Science) according to 
the manufacturer’s protocol. 
HEK293T cells were transfected by the calcium phosphate method. For that purpose, 40 µg 
plasmid DNA and 50 µl CaCl2 (2M) were added to 450 µl H2O for the transfection of 75 cm² 
plates with 70-80% confluency. While 500 µl HBS (2x) were gently mixed, the DNA/CaCl2 
solution was slowly added. After 30 min incubation at room temperature, the transfection 
mixture was added drop wise to the cell medium. 14-16 hours later, the cells were scraped off 
the cell culture dish and lysed in 1 ml IP-lysis buffer if lysates were prepared. If proteins of 
interest were secreted into the supernatant (e.g. MoTAP CD40L), the medium was changed 
and then collected after 48 and 96 hours. If necessary, the volumes for the transfection were 
scaled up or down according to the surface area on which the cells grew.  
2.2.5 Lentiviral infection of eukaryotic cells 
2.2.5.1  Production of recombinant viruses 
HEK293T cells were used for the production of recombinant, lentiviral particles. These 
viruses were then used for the stable transduction of Raji cells. HEK293T cells were split to 
about 50-60% confluency prior to calcium phosphate transfection in a 150 cm² plate. The 
transfection mixture containing 28 µg pCMV-dR8.91 (HIV_Gag, HIV_Rev, packaging 
vector), 12 µg pMD2G (VSVG) and 40 µg pLKO.1 (shRNA-constructs) was added drop wise 
to the cells. After 48 hs incubation at 37°C, the lentivirus containing cell supernatant was 
collected. 
2.2.5.2 Generation of stable HOIL-1 knockdown cells 
To generate Raji and BJAB cells in which the HOIL-1 expression level was stably reduced, 
pLKO.1 vectors encoding different HOIL-1-specific shRNAs were obtained from the RNAi 
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consortium (TRC). In this study, the vectors TRCN0000007599 (HOIL-1 shRNA, 5'-
CCACAACACTCATCTGTCAAA-3´) and RHS4080 (ctr shRNA) were used. Lentiviral 
particles were produced as described before (section 2.2.5.1). Cells were centrifuged with 
viral particle in the presence of 5 µg/ml polybrene (2000 x g for 4 hs at RT) and selected with 
puromycin (2.5 µg/ml) for 5 days. Knockdown efficiency was controlled by qPCR and 
Western blotting. 
2.2.6 Treatment with SMAC mimetics  
SMAC mimetics are small chemicals with biological activity. They are able to activate the 
ubiquitin ligase function of cIAP1 and cIAP2, thereby leading to the autoubiquitination and 
degradation. SMAC 59 (SM-164) was synthesised and kindly provided by Pierfausto Seneci 
and Leonardo Manzoni (Cossu et al, 2009). Before CD40L stimulation, cells were pre-treated 
with SMAC 59 (100 nM in cell culture medium) for 1 hs at 37°C. 
2.2.7 Quantification of apoptotic cells (Nicoletti staining) 
A method specific for propidium iodide staining of genomic DNA, established by Nicoletti 
and colleagues (Nicoletti et al, 1991), was used to discriminate between apoptotic and living 
cells. 2 x 105 cells were lysed in the dark in 100 µL Nicoletti buffer at 4°C for 12 h to obtain 
nuclei. The portion of cells showing a subdiploid DNA-fraction (< 2n) was detected by flow 
cytometry. This subdiploid DNA peak is a characteristic feature for the nuclei of cells 
undergoing apoptosis, due to DNA-fragmentation after caspase-activation, whereas living 
cells show a diploid (2n) or a tetraploid (4n) DNA content. The PI-content in nuclei was 
measured with a FACS Calibur (BD) and the FlowJo software used for analysing the data. It 
was gated on all nuclei in the FSC- and SSC-dot blot for the histogram.  
2.2.8 FACS analysis of surface protein expression 
The analysis of surface protein expression was done with 2-10 x 105 cells. Cells were blocked 
in 50 µl of FACS buffer with Fc-Receptor blocking antibody. After 5 min incubation on ice, 
50 µl of primary antibody solution was added and incubated on ice for 30 min. Staining was 
stopped by the addition of 1 ml ice cold FACS buffer; cells were centrifuged and washed 
again with 1 ml FACS buffer. Next, cells were incubated in 100 µl of secondary antibody 
solution at 4°C for 30 min. The cells were washed twice in FACS buffer and if necessary the 
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last antibody added for 30 min in the dark. Cells were washed twice with 1 ml FACS buffer, 
resuspended in 100 µl FACS buffer and subjected to FACS analysis. 2 x 104 cells of each 
sample were acquired. 
2.2.9 Magnetic cell sorting of CD43 negative splenocytes 
Magnetic cell sorting (MACS) was carried out according to the manufacture’s protocol 
(Miltenyi) and cells were used for further applications (Miltenyi et al, 1990). Briefly, this 
method relies on the fact that most leukocytes, other than resting B cells, express CD43. 
Expression of CD43 was demonstrated on immature B cells, plasma cells, and some mature 
B1 cells, in addition to granulocytes, monocytes, macrophages, platelets, natural killer (NK) 
cells, thymocytes, and peripheral CD8+ and most CD4+ T cells (Borche et al, 1987; Ostberg et 
al, 1998; Rosenstein et al, 1999; Wells et al, 1994; Yedidia et al, 1998). Single cell spleen 
suspensions were washed and incubated with magnetic microbeads coupled to an anti-CD43 
monoclonal antibody for 15 min on ice. Cells were washed twice and applied to LS column in 
a magnet. Column was washed three times with 3 ml of MACS buffer and the flow through 
containing the B cells was collected. The B cells were washed once and respuspended to 106 
cells/100µL for direct used in different assays. 
2.2.10 Staining cells for determination of cell proliferation 
Cells were stained with CellTraceTM Violet Cell Proliferation Kit (Invitrogen). Briefly, 106 
isolated splenocytes were incubated in 1 ml PBS supplemented with CellTraceTM Violet to a 
final concentration of 5 µM. This cell suspension was incubated for 20 min at 37°C in the 
dark. Subsequently, 5 ml of culture medium was added and cells incubated for 5 min. Cells 
were pelleted and washed one more time in medium before they were applied for stimulation. 
After 3 to 4 days of incubation, cells were monitored by FACS analysis. 
2.3 Molecular Biology 
2.3.1 DNA digestion and restriction analysis 
For the sequence-specific cleavage of DNA molecules the samples were incubated with 
restriction endonucleases (Fermentas FastDigest®) for 1 hour at 37°C.  
 Chapter 2: Material and Methods 
60 
 
2.3.2 Agarose gel electrophoresis of nucleic acids 
For the analysis of Plasmid DNA or DNA fragments, DNA molecules were resolved by 
agarose gel electrophoresis. Gels were prepared by dissolving 0.8 - 2% agarose (w/v) in TAE 
buffer, concentration was chosen according to the expected fragment size. Electrophoresis 
was performed in a gel chamber filled with TAE buffer at 10 Volts per cm of electrodal 
distance. After electrophoretic separation the gel was incubated for at least 15 min in TAE 
buffer + ethidium bromide (0.5 µg/ml) and DNA fragments were visualised by UV light (λ = 
254 nm). 
2.3.3 Gel extraction of DNA fragments 
Isolation of DNA fragments from agarose gels was achieved using the QIAquick Gel 
Extraction kit (Qiagen) according to manufacturer’s instructions. DNA was eluted with an 
appropriate volume of ddH2O or 10 mM Tris/HCl, pH 8.0 and used in further applications. 
2.3.4 Ligation of DNA fragments 
T4 DNA ligase (NEB) was used for ligation of linearised vectors and DNA fragments 
encoding proteins (inserts). For ligations of cohesive ends a molar ratio of 1:3 (vector : insert 
DNA) and for ligations of blunt ends a molar ratio of 1:5 was chosen. The ligation reaction 
was carried out in 10 µl total volume containing 1 µl T4 DNA ligase and 1 µl 10 x Ligase 
buffer (NEB). The reaction volume was brought up to 10 µl with ddH2O. Ligation reactions 
were incubated at room temperature for 2 h and used directly for the transformation of 
competent bacteria. 
2.3.5 Generation of competent E. coli bacteria 
To generate E. coli that are chemically competent for transformation of ligation reactions or 
plasmids, E. coli Top10F´ bacteria (Invitrogen) were grown in 5 ml Lysogeny Broth (LB) 
medium overnight at 37°C and then used to inoculate 250 ml of LB medium. This culture was 
grown until an OD600 value of 0.5 was reached. The bacterial suspension was incubated on ice 
for 10 min and then harvested by centrifugation at 3000 rpm at 4°C for 10 min. The 
supernatant was removed and the bacteria were resuspended in 80 ml ice-cold TB buffer. 
After 10 min incubation on ice, the bacteria were centrifuged and resuspended in 10 ml ice-
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cold TB buffer. DMSO was added to a final concentration of 7%. The competent bacteria 
were flash frozen in liquid nitrogen and stored at -80°C. 
2.3.6 Transformation of competent E. coli bacteria 
Competent bacteria were thawed out on ice and an appropriate amount of plasmid DNA or 
5 µl of a ligation reaction were added to the bacteria followed by incubation on ice for 30 min. 
Afterwards, a heat-shock step was performed at 42°C for 60 sec and the bacteria were 
subsequently cooled on ice for 3 min. 300 µl SOC medium was added and the bacterial 
suspension was incubated at 37°C for 60 min. Afterwards, bacteria were spread onto LB 
plates containing the respective antibiotic selection and incubated overnight at 37°C.  
2.3.7 Isolation of Plasmid-DNA 
For analytical plasmid isolation 5 ml LB medium (containing antibiotic) was inoculated with 
a single bacterial colony and incubated overnight at 37°C. Plasmid DNA was isolated using 
the QIAprep Spin Mini Kit (Qiagen) according to the manufacturer’s instructions. For the 
production of larger amounts of plasmid DNA, 400-500 ml LB medium, supplemented with 
the appropriate antibiotic, were inoculated and the culture was grown at 37°C in a shaker 
(200 rpm) overnight. The preparation of plasmid DNA was carried out with the QIAprep Spin 
Maxi Kit (Qiagen) according to the manufacturer’s protocol. 
2.3.8 Polymerase Chain Reaction (PCR) 
All PCRs were done in a volume of 50 µl, containing 1-50 ng plasmid- or cDNA as template. 
The synthetic oligonucleotides were designed with 40-60% GC content, no internal structure 
or complementarity at the 3’-ends. The final primer concentration was 0.4 µM. Annealing 
temperatures were chosen ~5-10°C lower than the melting temperature Tm. The final 
concentration of each dNTP was 200 µM. All DNA polymerases were used with supplied 
buffers.  
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2.3.9 Quantitative PCR 
2.3.9.1 RNA purification 
Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s 
instructions. Trizol was removed by addition of 0.2 ml chloroform followed by isopropanol 
precipitation. The concentration and purity of RNA was determined with a ND-1000 
Spectrophotometer (NanoDrop). 
2.3.9.2 cDNA preparation 
A reverse transcription was performed on 0.5 - 5 µg total RNA for 1 h at 42°C using the 
RevertAidTM H Minus first strand cDNA synthesis kit (Fermentas) according to the 
manufacturer’s instructions. 
2.3.9.3 Quantitative Real-time PCR 
Quantitative Real-time PCR was performed with the ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems) using the ABsoluteTM QPCR ROX Mix (ABgene). 
The ProbeFinder software (Roche) was used to design the optimal assay, comprising the 
respective labelled probe of the Universal ProbeLibrary (Roche) and gene-specific primers. 
For the RT-PCR reaction, cDNA (section 2.3.9.2) was diluted 1:3 to 1:10 depending on the 
amount of RNA which was used. Amplification was carried out in stages of incubation at 
95°C for 15 min following 40 cycles of 95°C for 15 s and 60°C for 60 s. The mRNA levels 
were measured as double determinations and normalised with reference to the amount of 
housekeeping gene transcripts (GAPDH or HPRT1).  
The following gene-specific primers were used: ctgtgcatttacaccgacaac and 
cactaccagttcccactccag (CyclinD2), cccacgctacctctgctc and gatggatacctgagcatcacc (ICAM-1), 
gctcaactggtgtcgtgaag and aatgaggcagtttccatcacc (A20), acgagcaaatggtgaaggag and 
atgattgccaagtgcagga (IκBα), aaattcaacggcacagtcaa and gtagcccaagatgcccttc (GAPDH), 
tgatagatccattcctatgactgtaga and aagacattctttccagttaaagttgag (HPTR1). 
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2.4 Biochemistry 
2.4.1 Expression and purification of human TAP-CD40L  
MoTAP-CD40L was purified with a HiTrapTM rProtein AFF column from GE Healthcare. 
The ÄktaPrime was washed with PBS first without the column for 10 min (10 ml/s) and 
afterwards washed for 20 min with a flow of 1 ml/s. The supernatant containing the moTAP-
CD40L was filtered (0.45 µm) and then applied to the column with a flow of 0.5 ml/min over 
night. On the next day the column was washed with PBS and the first washing steps collected 
(700 - 900 µl). The flow through was collected until it became clear and the column was then 
washed again with 30 ml PBS. The MoTAP-CD40L was eluted with a glycine solution (10 
mM, pH 2) and the eluted samples were collected. The elution fraction was transferred 
directly into tubes which contained 100 µl of Tris buffered solution (100mM, pH 8) to 
neutralise the low pH of the glycine solution. 
After analyzing the samples by SDS-PAGE and Western blotting the fractions E1 to E3 were 
pooled and dialysed in Maintenance Buffer (1.5 l) overnight. The next day the buffer was 
changed to fresh Maintenance Buffer with 0.5 M L-Arginine and the protein was again 
dialysed over night. The protein concentration was measured with a ND-1000 
Spectrophotometer (NanoDrop). 
2.4.2 Determination of protein content 
To determine the protein concentration of cell lysates, the bicinchoninic acid (BCA)-
containing protein assay was applied according to the manufacture’s protocol (Pierce). 3 µl of 
the lysate were incubated in 200 µl BCA solution at 60°C for 15 min, followed by measuring 
light absorption at 562 nm in a Multiskan Ascent (Thermo Labsystems). 
2.4.3 CD40-RSC precipitation 
CD40-RSC was precipitated by either single or tandem step protocols. 
2.4.3.1 Protocol for single step precipitation 
A single step precipitation protocol was used for the analytical CD40-RSC analysis without 
mass spectrometry. 
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5 x 106 cells were stimulated with moTAP-CD40L-containing supernatant for different time 
periods. The cells were washed with ice-cold PBS and lysed in 0.125 ml IP-lysis buffer/106 
cells with 0.5% NP-40 at 4°C for 30 min. The detergent-insoluble fraction was pelleted 
(30 min; 13000 rpm) and the cell lysate was incubated with 10 µl M2 beads (Sigma, SIGMA, 
Schnelldorf, Germany) for 16 hs. Beads were washed four times with 1 ml IP-lysis buffer and 
the buffer was completely removed. 25 to 45 µl of 2 x LDS buffer was applied and the 
samples incubated for 10 min at 75°C. 
2.4.3.2 Protocol for Tandem-Affinity-Purification 
For the preparative CD40-RSC isolation, 3.5x109 Raji cells were stimulated with 50 ml 
moTAP-CD40L-containing supernatant (approx. 50 µg/ml) at 37°C for 10 min. Cells were 
washed twice with ice-cold PBS and lysed in 1.2 ml IP-lysis buffer/108 cells with detergent 
(see section 3.3) at 4°C for 30 min. The detergent-insoluble fraction was pelleted (30 min; 
13000 rpm) and the cell lysate was incubated with 4 µl M2 beads/108 cells (SIGMA, 
Schnelldorf, Germany) for 8 h. Beads were washed four times with 1 ml IP-lysis buffer and 
subsequently incubated in 1 ml lysis buffer containing 5 U/ml PreScission (GE Healthcare 
Life Sciences, Amersham, UK) and 250 µg/ml FLAG-peptide (SIGMA, Schnelldorf, 
Germany) for 12 h. Protein complexes were eluted from the beads, and the beads were rinsed 
once with 500 µl IP-lysis buffer. The second precipitation step was carried out using 25 µl 
Protein G-coupled beads (GE Healthcare Life Sciences, Amersham, UK) at 4°C for 6 h. The 
beads were washed four times and proteins were directly eluted with 2 x LDS buffer. The 
purified CD40-RSC was loaded on a NuPAGE gel. The gel was silver stained using a mass-
spectrometry compatible protocol (Invitrogen, Carlsbad, CA, USA) and photo-documented 
before the lane containing the CD40-RSC was cut into 24 pieces of equal size. The gel pieces 
were then subjected to tryptic digest as described (Haas et al, 2009) and used for mass 
spectrometric analysis. 
2.4.4 Chemical precipitation of proteins 
The chemical precipitation of proteins was done with 100% Trichloroacetic acid (TCA). 
1 volume of TCA was added to 4 volumes of protein sample and incubated at 4°C for 10 min. 
The solution was centrifuged at 4°C (13,000 rpm; 10 min) to precipitate the proteins. The 
pellet was immediately washed with 200 µl acetone (-20°C) and centrifuged again 
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(13000 rpm; 5 min). The acetone wash was repeated once. The pellet was then dried at 95°C 
for 5 - 10 min and dissolved in SDS loading buffer. 
2.4.5 Protein interaction studies 
For in vivo interaction studies, 7.5 x 106 HEK293T cells were transfected with 5 µg of the 
respective DNAs by standard calcium phosphate transfection. Cells were harvested 24 h post 
transfection and lysed in 1 ml IP-lysis buffer supplemented with 1% Triton X-100 for 30 min 
at 4°C. Subsequently, lysates were centrifuged at 15,000 x g for 30 min. 
Immunoprecipitations were performed at 4°C for 16 h. Anti-V5-agarose resin (SIGMA) was 
used for precipitations of V5-tagged proteins. The beads were washed four times with IP-lysis 
buffer and the proteins were eluted in 30 µl LDS sample buffer. Precipitated proteins were 
analysed by Western blotting.  
2.4.6 Ubiquitin pull-down assay 
10 µg of purified GST, GST-HOIL-1 or GST-HOIP N-term were incubated with glutathione-
sepharose resin in 600 µl Pull-down buffer (PDB) at 4°C for 6 h. Beads were washed three 
times with PDB, split into two aliquots and incubated at 4°C overnight with 2 µg ctr or 
ubiquitin beads in 450 µl PDB. The beads were washed five times with PDB. The bound 
proteins were eluted using 2 x LDS sample buffer and subsequently subjected to SDS-PAGE 
and Western blotting using ubiquitin specific antibodies. 
2.4.7 Isoelectric focusing for 2D gel electrophoresis 
Isoelectric focusing of proteins was done using a system from Invitrogen and performed 
according to the manufacture’s protocol. Briefly, after immunoprecipitation the last washing 
step of the beads was done with distilled water and 50 µl of loading buffer added for the 
isoelectric focusing. The prepared ZOOMstrip was loaded into the appropriate chamber and 
the buffered protein solution added. After focusing the sample the strip was loaded on a 4 -
 12% Bis-Tris-NuPAGE gel with appropriate wells for the strip and separated as described in 
section 2.4.8. 
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2.4.8 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed based on the method by Laemmli (Laemmli, 1970) 
using 4 - 12% Bis-Tris-NuPAGE gels from Invitrogen. Samples were mixed with SDS-
Sample buffer and heated for 10 min at 75°C. The SeeBlueTM Plus2 Pre-Stained marker 
(Novex) was used as a molecular weight standard. The electrophoretic separation was carried 
out at a constant voltage of 120 V for 10 min and subsequently 185 V for 55 min. For 
separation of proteins with a molecular weight above or below 40 kDa, MOPS buffer or MES 
buffer was used for the SDS-PAGE, respectively.  
2.4.9 Western blotting 
Western blotting was performed using the NOVEX gel-system based on the method of 
Towbin (Towbin et al, 1979). Proteins from SDS-PAGE gels were transferred onto 
nitrocellulose membranes (Amersham Pharmacia) by application of a current of maximum 
160 mA (30 V) per gel for 2 h. Afterwards, membranes were incubated for at least 15 min 
with blocking buffer at room temperature to occupy non-specific protein binding sites. 
Subsequently, membranes were subjected to immunoprobing with primary antibodies and 
secondary horseradish-peroxidase (HRP)-conjugated antibodies. Proteins were visualised 
using different ECL® detection systems (Amersham Biosciences). 
2.4.10 Stripping of Western blot membranes 
Nitrocellulose membranes containing transferred proteins were incubated with alternative 
antibodies if necessary. For that purpose, the already bound immunoglobulins were removed 
by incubating the nitrocellulose membranes with stripping buffer at RT for 15 min. The acidic 
pH of the stripping solution leads to denaturation of the bound antibodies. Subsequently, the 
membranes were washed 4 - 6 times with PBST, followed by incubation in blocking solution 
and probing as described in 2.4.9. 
2.4.11 Silver Stain of Polyacrylamide Gels 
The silver staining was performed using the Silver Quest Silver Staining Kit (Invitrogen) 
according to the manual. Briefly, the gel was washed in ddH2O for 10 min and then incubated 
in fixative solution for 20 min. The gel was washed with 30% ethanol for 10 min. After this 
washing step the gel was incubated for 10 min with the sensitizer solution and then washed 
 twice, first with 30% ethanol and second with ddH
was left on the gel for 15 min, followed by a short washing 
was left to develop until bands were visible.
solution for 10 min. Finally the gel was washed for 10
2.4.12 Enzyme-Linked Immuno Sorbent Assay (ELISA)
The IL-6 ELISA was performed using the Human IL
well plates were coated in a 1:1000 
100 µl/well of this coating solution was
washed once and blocked with 300
washing twice, 100 µl of samples and standards (recombinant human IL
into the designated wells in duplic
detection antibody (biotinylated anti
incubated for 2 h at room temperature with continual shaking. Subsequently the plate 
washed five times and 100 µl 
10 ml of Assay buffer) were transferred into each well. After incubation 
temperature, the plate was washed 7
Phenylene-diaminedihydrochloride (OPD) + 12
added. To stop the enzymatic reaction, 50
absorbance was measured at a wavelength of 450
2.4.13 NF-κB Luciferase assay
HeLa and MCF-7 cells (20,000 cells/well) were seeded into 96
to 12 h in DMEM + 10% FCS before transfection. 
NF- B-luciferase reporter plasmid DNA (Stratagene) and with 5
plasmid (Stratagene) using FuGENE 6 (Roche). 16 to 24
stimulated with MoTAP-CD40L
cells were lysed with 1 x Passive lysis buffer (Promega) and the luminescence was measured. 
Firefly luciferase data were normalised
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step with ddH2O for
 This process was stopped by adding the stopping
 min in ddH2O. 
 
-6 CytoSetTM kit from Biosource. 96
dilution of antibody (anti-human IL-6
 added and incubated for 12 h at 4°
 µl/well Assay buffer for 1 h at room temperat
-
ates. Following this step, 50 µl of PBS, containing the 
-human IL-6; 0.05 mg/ml) were added into 
of the streptavidin-HRP solution (1.7 µL of streptavidin
 times and 100 µl/well of the substrate solution (10
 µl H2O2 (30%) in 10 ml 
 µl of stop solution (3 N H2SO4) was added and the 
 nm. 
 
-well plates and cultured for 10 
Cells were cotransfected with 45
 ng/well of the pCMV
 h after transfection, cells were 
 or BHK-CD40L for different time periods
 to Renilla luciferase activity. 
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C. The plate was 
ure. After 
6) were transferred 
each well and 
was 
-HRP in 
for 1 hour at room 
 mg o-
Citrate buffer) was 
 ng of 
-RLuc 
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2.5 Animal models 
2.5.1 Chronic proliferative dermatitis mice 
Mice with a mutation in the SHARPIN gene were obtained from the Jackson Laboratory and 
kept under conventional conditions. Mutation of the SHARPIN gene causes a chronic 
proliferative dermatitis (cpdm) phenotype which was described by HogenEsch et al. 
(HogenEsch et al, 1993). 
2.5.2 Isolation of lymphocytes from spleen 
Mice were killed by CO2 asphyxiation and death ensured by dislocation of the neck. Spleens 
were dissected out into 10 ml DMEM. A single cell suspension was made by homogenising 
the spleen with a syringe plunger. The cell suspension was filtered through a 40 µm cell 
strainer and centrifuged (1,400 rpm for 4 min). The cell pellet was dissolved in 2 ml red blood 
cell (RBC) lysis buffer (eBioscience) per spleen for 5 min. For neutralisation, 8 ml DMEM 
was added and cells were counted. Cells were pelleted (1,500rpm; 5 min) was resuspended in 
MACS buffer. 
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Figure 3.1: Schematic representation of moTAP-
CD40L.  
The extracellular domain of the CD40L is fused to two 
different tags (2 x FLAG and Fc-tag), a protease cleavage 
site (PS) and a signal sequence for extracellular 
expression (signal). 
PS Fc-tag CD40L [116 - 261]2xFLAGNH2-
274 aa 146 aa
signal
55 aa
Chapter 3.  Anaysis of the CD40-RSC for mass spectrometry 
The signalling process of members of the TNF-RSC includes the recruitment of several 
adaptor molecules to the intracellular part of the receptor. To gain a better understanding of 
these receptor proximal signalling events a method was established to purify the CD40-RSC 
for subsequent mass spectrometric analysis. This unbiased assay allows the identification of 
so far unknown components of this complex and can provide new insights into early signal 
transduction events. Briefly, two different tags separated by a PreScission cleavage site 
(Figure 3.1) were fused to the extracellular domain of CD40L to precipitate the native CD40-
RSC and to allow a “modified 
tandem-affinity purification” 
(moTAP) resulting in a higher 
purity of the receptor signalling 
complex. This double tagged 
CD40L will be referred to as 
moTAP-CD40L. The following 
chapter describes the 
establishment of this method 
and the results of the mass 
spectrometric analysis. 
3.1 Production of moTAP-CD40L 
CD40L is expressed on T cells and activates APC via CD40, for which a higher order cross-
linking of the ligand is needed to stimulate its receptor effectively. In vivo this is achieved via 
a clustering of the ligand in the membrane of the activating cell. Different options are 
available to achieve this in vitro, e.g. with an isoleucine zipper motif or an Fc-portion of an 
antibody. Holler et al showed that Fc portions of antibodies are able to crosslink recombinant 
ligands in higher order (Holler et al, 2003) which was the reason why the Fc-motif was 
chosen for the moTAP-CD40L. Since the Fc-portion binds ProteinG effectively, it is possible 
to precipitate the ligand via the Fc-tag. This motif serves both the oligomerisation and the 
precipitation, thereby comprising dual function in the precipitation protocol. A double FLAG 
tag was chosen as a second tag because it can be eluted from the beads with commercially 
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Figure 3.2: The moTAP-CD40L was purified with a ProteinG column. 
a, Coomassie gel and b, Western blot of the different fractions during the purification 
process. W: washing fraction, E: elution fraction. 
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available FLAG-peptide. The two tags are separated by a protease cleavage site which is 
specific for the protease PreScission. This protease is a genetically engineered fusion protein 
consisting of human rhinovirus 3C protease and GST (Walker et al, 1994). PreScission 
protease specifically cleaves between the glutamine and glycine residues of the recognition 
sequence of LeuGluValLeuPheGln/GlyPro (Cordingley et al, 1990). Its catalytic activity is 
optimal at 5°C and, therefore, it is possible to perform all steps of the IP at low temperatures. 
Theoretically it is possible to elute the ligand from the beads only with PreScission, however, 
set-up experiments revealed that addition of FLAG peptide strongly increased effectiveness of 
the elution process (data not shown). 
The moTAP-CD40L was overexpressed in HEK293T cells by calcium phosphate transfection. 
In addition, a plasmid expressing GFP was transfected as an efficiency control for the 
transfection and to obtain control supernatant. 300 ml of the supernatant containing moTAP-
CD40L were collected and the recombinant ligand was subsequently purified from this 
supernatant by ProteinG affinity chromatography. 
Figure 3.2 shows the amount of recombinant moTAP-CD40L obtained at different 
purification steps as determined by Coomassie staining and Western blotting respectively 
(Figure 3.2a or b). The prominent signal in the first lane at 64 kDa on the Coomassie stained 
gel (Figure 3.2a) is most likely serum albumin which is present in the growth medium of 
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Figure 3.3: Quantification of moTAP-CD40L in the supernatant from HEK293T cells. 
Different concentrations of purified moTAP-CD40L and different volumes of conditioned 
medium were analysed by Western blotting. No reducing agent was used to show 
oligomerised forms. The Western blot was developed with an anti-FLAG antibody. 
100   50   25   10   5    1      10     5   2.5     1
Purified moTAP-
CD40L [ng/lane]
Supernatant with 
moTAP-CD40L [µl]
191
Oligomerised form
Reduced formM
W
 [
k
D
a
]
39
51
64
97
HEK293T cells. This protein is still visible in the filtrate which was transferred to the column 
and in the first washing fraction (W1). However, this unspecific protein is lost during 
subsequent washing steps (W27 and W33). The column was washed with 30 ml of PBS after 
sample W33 was taken therefore this band is not visible in the elution steps E1-E6.  
A protein with a molecular weight of 55 kDa could be detected in fraction E2 on the 
Coomassie gel. Since the calculated weight of the moTAP-CD40L is approximately 55 kDa, 
this band is most likely the ligand and the purity quite high since no other proteins were 
visible in this lane.  
The presence of moTAP-CD40L was confirmed by Western blot analysis which specifically 
detected the protein via its FLAG-tag (Figure 3.2b). A faint band is already visible in the 
supernatant but cannot be seen in the lanes with the filtrate and samples during the washing, 
therefore the ligand must have bound to the column. The elution samples show a strong band 
for moTAP-CD40L which means that the protein is concentrated in these samples. The 
elution fractions E1 to E3 were pooled and the resulting solution had a protein concentration 
of 240 µg/ml. Since these three fractions had a volume of 1.5 ml, the total amount of ligand 
from 300 ml supernatant was 360 µg.  
Alternatively, cells can also be stimulated directly with conditioned supernatant from 
HEK293T cells. To estimate the amount of moTAP-CD40L in the supernatant different 
dilutions of the supernatant were loaded and run on the same gel with different concentrations 
of purified ligand (Figure 3.3). The Western blot shows the purified ligand in different 
concentrations from 1 ng/lane to 100 ng/lane and 4 different dilutions of the supernatant. A 
comparison reveals that the concentration of moTAP-CD40L in the supernatant is 
approximately 25 µg/ml.   
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Figure 3.4: moTAP-CD40L induces NF-κB activity and IL-6 production in CD40 
overexpressing cells. 
a, HeLa and MCF-7 cells expressing CD40 were stimulated with moTAP-CD40L or 
irradiated BHK-CD40L cells after transient transfection with NF-κB-Luciferase reporter. 
Cells were lysed and activation of luciferase was measured. b, CD40 overexpressing 
HeLa cells were incubated with indicated stimulus for 24 hours and IL-6 concentration in 
the supernatant measured by ELISA. 
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3.2 Characterisation of the moTAP-CD40L 
The recombinantly produced CD40 ligand was meant to be used for precipitating the 
CD40-RSC. To do so it was important to determine binding properties and the  biological 
activity of the moTAP-CD40L. To test the ability of the ligand to activate signalling events, 
cells stably expressing CD40 were stimulated with irradiated BHK-CD40L cells or moTAP-
CD40L containing supernatant. HeLa cells and MCF-7 cells were stably transfected with 
CD40 and transiently with an NF-κB reporter. These cells were known to induce NF-κB 
signalling by TNF and by the membrane bound ligand of BHK-CD40L cells (data not shown). 
The luciferase assay revealed that stimulation with moTAP-CD40L also results in NF-κB 
activity (Figure 3.4 a, b). However, the stimulation with the CD40L transfected BHK cell line 
was slightly better when compared to the stimulation with moTAP-CD40L. Although it was 
not possible to compare the real quantity of the CD40L between the different stimuli it is 
likely that the ligand in its natural membrane environment is slightly more effective. The 
same observation was made analysing IL-6 production of CD40-expressing HeLa cells after 
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Figure 3.5: CD40 is expressed on different cell lines. 
Indicated B cell lines were stained with control antibody or anti-CD40 antibody and CD40 
expression levels examined by flow cytometry. Black line: Isotype; Grey line: CD40. 
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stimulation for 24 hours (Figure 3.4c). These results show that the produced ligand was active 
and can be used to stimulate CD40. 
The artificial system in HeLa and MCF-7 to investigate CD40 signalling is advantageous 
because these cell lines were easy to transfect and the activation of the NF-κB reporter could 
be investigated. Yet, these cell lines are derived from organs which usually do not need CD40 
signalling and therefore do not guarantee that all components are expressed which are part of 
the signalling cascade. To investigate CD40 signalling in detail it is important to use cell lines 
in which CD40 signalling naturally occurs, e.g. B cell lines. Different B cell lines and 
monocytic cell lines were screened for CD40 expression, assuming that cells expressing high 
CD40 levels are better suited for the analysis of the CD40-RSC because of a higher 
abundance. For this purpose different cell lines were stained with either a control antibody or 
an anti-CD40 antibody and analysed by flow cytometry. Figure 3.5 shows the different CD40 
expression levels whereas the B cell lines BJAB, Raji and SKW showed the highest surface 
expression. Also the monocytic cell lines U937 and THP-1 show a considerable expression of 
CD40 in contrast to the myeloid cell line HL-60.  
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Figure 3.6: moTAP-CD40L binds to Raji cells. 
One million Raji cells were first stained with either purified moTAP-CD40L (left panel) or 
conditioned supernatant containing moTAP-CD40L (right panel). In a second staining 
step a mouse anti-FLAG antibody was used, and thirdly a mouse anti-IgG1-PE coupled 
antibody. Cells were analysed by flow cytometry. 
CD40
c
o
u
n
ts
100 101 102 103 104 100 101 102 103 104
control
0.01 µg/µl
0.1 µg/µl
1 µg/µl
control
TAP-CD40L 
250 250
Raji cells showed the highest level of CD40 expression, and were therefore used to test the 
binding efficiency of different concentrations of moTAP-CD40L. Cells were incubated with 
different concentrations of moTAP-CD40L and cytometrically analysed for CD40L binding 
(Figure 3.6 left panel). A concentration of 0.1 µg/µl moTAP-CD40L was sufficient to stain 
cells effectively as staining with 1 µg/µl moTAP-CD40L caused only a minor additional shift 
compared to 0.1 µg/µl. This suggests that most receptors on the surface are already saturated 
with ligand at this concentration. Since the cells in the subsequent experiments were 
stimulated with moTAP-CD40L from unpurified supernatant, the staining efficiency of the 
supernatant had to be tested as well. Therefore, cells were incubated with 50 µl control and 
moTAP-CD40L-containing supernatant. A similar shift was observed for the supernatant as 
for the staining with 0.1 µg/µl purified moTAP-CD40L although the supernatant had an 
estimated concentration of 25 ng/µl. This shows that 1.25 µg of unpurified moTAP-CD40L 
achieved a similar effect as the concentration of 0.1 µg/µl which is equivalent to 5 µg protein. 
In summary, one million cells were effectively stained in a volume of 50 µl containing 
1.25 µg moTAP-CD40L. In the follow-up experiments, one million cells were stimulated with 
the amount of unpurified supernatant containing approximately 1.5 µg TAP-CD40L. 
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Figure 3.7: Stimulation of different B cell lines with moTAP-CD40L. 
Indicated B cell lines were left unstimulated or stimulated for either 20 min or 60 min and 
lysates were adjusted and investigated by Western blotting with the indicated antibodies. 
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To test the ability of the ligand to activate the CD40 signalling cascade in B cell lines which 
were used for the subsequent identification of proteins within the native CD40-RSC, different 
CD40-responsive cell lines were stimulated and the activation of two different signalling 
pathways investigated. The B cell lines Raji, Ramos, SKW and BJAB, and the monocytic cell 
line U937, were stimulated for 20 min and 60 min with supernatant containing moTAP-
CD40L and the lysates were analysed for the phosphorylation of JNK and IκBα and the 
degradation of IκBα (Figure 3.7). All investigated cell lines were stimulated with the 
supernatant to different extents: phosphorylation of JNK was only observed in Ramos and 
BJAB cells and phosphorylation of IκBα was detected in all cells except BJAB cells. 
Interestingly, cIAP2 showed additional modifications in CD40-stimulated cells, especially in 
Ramos cells. Together, this shows that the ligand exhibits a biological activity and identifies 
the tested cell lines as suitable for investigation of the CD40-RSC.  
The observation that some cell lines did not show a phosphorylation of JNK does not 
necessarily mean that this cell line is not able to activate this signalling pathway, for two 
reasons: first, this experiment compares the amount of phosphorylated proteins directly 
between cell lines and one cell line might have less phoshporylated protein than the other, 
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Figure 3.8: Blockade of CD40L stimulated Raji cells with CD40-Fc. 
Raji cells were stimulated for 10 min with moTAP-CD40L or commercially available 
CD40L (100 ng/ml). Additionally, different concentrations of CD40-Fc were incubated with 
the ligands 10 min prior the stimulation. Western blots were probed with pIκBα and Actin. 
GFPsn is supernatant of GFP-transfected HEK293T cells. 
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therefore resulting in no detection of pJNK at the conditions used. Second, the kinetics of the 
phosphorylation can vary between cell lines and phosphorylation of JNK could for example 
be much faster in Raji cells and therefore no longer detectable after 20 min. 
The stimulation in Figure 3.7 was done with moTAP-CD40L contained in supernatant of 
HEK293T cells. To test whether the stimulation was indeed due to the moTAP-CD40L and 
not due to another stimulating agent which was produced by HEK293T cells after 
transfection, recombinant CD40-Fc was used to block moTAP-CD40L. To do this, Raji cells 
were stimulated with control supernatant, moTAP-CD40L containing supernatant and with 
recombinant CD40L and both stimulations with CD40L were blocked by recombinant CD40-
Fc which binds to free CD40L in solution (Figure 3.8). Lanes 2 and 6 in Figure 3.8 show 
phoshphorylated IκBα in cells after stimulation with both ligands although the signal is more 
prominent after stimulation with moTAP-CD40L compared to untagged CD40L. The addition 
of recombinant CD40-Fc partially inhibits the phosphorylation of IκBα at a concentration of 
0.1 µg/µl and completely blocks it at a concentration of 2.5 µg/µl. This experiment shows that 
the stimulating effect of the moTAP-CD40L containing supernatant is indeed due to the 
biological effects of CD40L. 
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Figure 3.9: TRAF2 is associated with the CD40-RSC in different cell lines in a 
stimulation dependent manner.  
The indicated cell lines were left unstimulated or stimulated for 10 min with moTAP-
CD40L and the RSC precipitated with M2 Agarose. “m”: mock control, cells were left 
unstimulated and lysates incubated with M2 beads; “-“: unstimulated control, cells were 
left unstimulated and lysates incubated with moTAP-CD40L pre-coupled to M2 beads; 
“+”: stimulation, cells were stimulated for 10 min and lysates incubated with M2 beads. 
m   - +  m  - +     m   - +  m    - + m    - +
Raji          BJAB      SKW 6.4  THP-1    U937
TRAF2
TAP-CD40L
51
64
51
64M
W
 [
k
D
a
]
m   - +   m   - +   m   - + m    - + m    - +
3.3 Optimisation of the Tandem-Affinity-Purification Protocol for CD40-RSC 
isolation 
For a better understanding of the formation of the native CD40-RSC, cell lines with high 
expression of CD40 were used for a one-step purification protocol (Figure 3.9). A similar 
experiment was done by Kuhné et al. who pulled down the CD40-RSC from DND39 B cells 
with an anti-CD40 antibody after stimulation with CD40L (Kuhne et al, 1997). This group 
showed for the first time that TRAF2 and TRAF3 are recruited to the native CD40-RSC. This 
was confirmed by several studies using different oligomerised forms of CD40 in an 
overexpression system in HEK293 cells (Werneburg et al, 2001) and B cells from mouse 
spleens (Matsuzawa et al, 2008). To test whether moTAP-CD40L can also be used to pull 
down components of the CD40-RSC, different CD40 expressing cell lines were left 
unstimulated or stimulated with the ligand. Figure 3.9 shows TRAF2-precipitation after cells 
were stimulated with moTAP-CD40L. Both controls, “beads only” (mock) and beads pre-
incubated with moTAP-CD40L, did not reveal any precipitation of TRAF2, suggesting that 
the interaction must be stimulation-dependent and specific.  
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Figure 3.10: TRAF2 and TRAF3 are recruited to the CD40-RSC in both Raji and 
BJAB cells but cIAP2 only in Raji cells.  
BJAB and Raji cells were stimulated with moTAP-CD40L for the indicated time points and
a single step IP was performed. Precipitate and lysates were analysed by Western 
blotting with the indicated antibodies. “m”: mock control, unstimulated lysates incubated 
with beads only, “-“: unstimulated control, unstimulated lysates incubated with moTAP-
CD40L pre-coupled beads. 
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The two cell lines with the most significant recruitment of TRAF2, Raji and BJAB, were 
stimulated again for different times and analysed for TRAF3, cIAP2 and RIP1 recruitment 
(Figure 3.10). TRAF3 was the first protein found to interact with CD40 in a yeast-to-hybrid 
system (Hu et al, 1994) and the stimulation-dependent recruitment to the CD40-RSC was also 
confirmed in B cells generated from spleens (Matsuzawa et al, 2008). This interaction could 
also be shown after stimulation of Raji and BJAB cells with moTAP-CD40L (Figure 3.10). 
Werneburg et al. found in overexpression experiments that cIAP1 binds to the cytoplasmic 
domain of a trimeric CD40 in HEK293 cells. Interestingly, they did not observe an interaction 
with cIAP2. However, in this thesis a strong stimulation-dependent binding of cIAP2 to CD40 
was observed in Raji cells. It is not recruited in BJAB cells because these cells do not express 
cIAP2 (Figure 3.7 and Figure 3.10). Importantly, cIAP2 is highly modified after CD40 
stimulation. An interaction between TRAF2 and RIP1 was shown in an overexpression 
system (Takeuchi et al, 1996) and the recruitment of RIP to the TNF-RSC is well established 
(Haas et al, 2009; Hsu et al, 1996). However, recruitment of RIP1 to the CD40-RSC was not 
observed in any of the cell lines used in this thesis. 
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Figure 3.11: TRAF2 is lost during the tandem CD40-RSC IP. 
Raji cells were stimulated with moTAP-CD40L and RSC purified with M2 beads (lane1-3), 
then eluted from the beads with PreScission and FLAG-peptide (lane 4-6) and then 
precipitated again with ProteinG beads (lane7-9). The Western blot was incubated with 
anti-TRAF-2 and anti-human Fc antibody. “m”: mock control, cells were left unstimulated 
and lysates incubated with M2 beads; “-“: unstimulated control, cells were left 
unstimulated and lystes incubated with moTAP-CD40L pre-coupled M2 beads; “+”: 
stimulation, cells were stimulated and lysates incubated with M2 beads. 
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The established protocol for the one-step precipitation was brought forward to the two-step 
precipitation with anti-FLAG IP first, then the elution from the beads and the final 
precipitation with ProteinG Sepharose. For this protocol cells were stimulated as before for 10 
min. The anti-FLAG precipitation was performed for 8 hours and the anti-FLAG beads were 
washed. One third of the ant-FLAG beads were kept for analysis by Western blotting and two 
thirds were subsequently incubated with lysis buffer which was supplemented with FLAG-
peptide and PreScission for elution of the complex. Half of the eluted supernatant (one third 
of the starting solution) was used for chemical protein precipitation and the other half for 
precipitation with ProteinG beads (Figure 3.11). It was observed that the moTAP-CD40L was 
found in all three purification steps. It was also possible to detect the decrease in molecular 
weight of the ligand following the proteolytic cleavage of the FLAG-tag by the PreScission 
protease.  
Notably, TRAF2 was present in the anti-FLAG-IP as shown in previous experiments (Figure 
3.10), but its abundance decreased in the elution fraction and it was completely absent in the 
ProteinG-IP (Figure 3.11). Since it was possible to detect moTAP-CD40L throughout the 
experiment one explanation is that the interaction of TRAF2 with the receptor, or the 
interaction between the receptor and the ligand, is lost. One possibility for the decreased 
abundance of TRAF2 is an unstable CD40-RSC. The protein-protein interactions might not be 
robust enough to withstand the purification conditions in contrast to the TNF-RSC, which 
seems to be stable under these conditions (Haas et al, 2009).  
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Figure 3.12: NP-40 and 0.5% Triton X-100 give the best recovery of TRAF2 in the 
CD40-RSC IP. 
Raji cells were left unstimulated or stimulated with moTAP-CD40L and cells were then 
lysed with different detergents in lysis buffer. Single IP was performed under the same 
conditions as the lysis. Asterix indicates unspecific band. 
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So far, Triton X-100 was used as a detergent to solubilise cells. However, this non-ionic 
detergent with its critical micelle concentration (CMC) of 0.2-0.9 mM is harsher then NP-40 
(CMC of 0.05- 0.3 mM) or Brij58 (CMC of 0.092 mM) (Sigma-Aldrich, 2010). Therefore, 
different detergents were next compared to gain a better understanding of the stability of the 
CD40-RSC under different conditions. Raji cells were left unstimulated or stimulated with 
moTAP-CD40L and subsequently lysed in parallel with different concentrations of Triton X-
100, NP-40 or Brij58. Indeed, at a concentration of 1% Triton X-100, less TRAF2 was 
precipitated compared to 0.5% Triton X-100 or NP-40 (Figure 3.12). Interestingly, there was 
also less TRAF2 precipitated when the cells were lysed with Brij58.  
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Figure 3.13: TRAF2 binding to the CD40-RSC is stabilised with 1% NP-40 during 
tandem purification. 
Raji cells were stimulated with moTAP-CD40L and RSC purified with M2 beads (lanes 1-
3), eluted from the beads with PreScission and FLAG-peptide (lanes 4-6) and then 
precipitated with ProteinG beads (lanes 7-9). The Western blot was incubated with anti-
TRAF2 and anti-human Fc antibody. “m”: mock control, cells were left unstimulated and 
lysates incubated with M2 beads; “-“: unstimulated control, cells were left unstimulated 
and lystes incubated with moTAP-CD40L pre-coupled M2 beads; “+”: stimulation, cells 
were stimulated and lysates incubated with M2 beads. 
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The optimised buffer conditions with NP-40 as detergent were used for a two-step 
precipitation protocol (Figure 3.13). In this experiment it was again possible to detect the 
moTAP-CD40L decreased in size following PreScission treatment indicating efficient 
cleavage and elution following the final step of the IP. Furthermore, TRAF2 could also be 
detected in the stimulated cells throughout this experiment. Although there seemed to be 
slightly less TRAF2 present following ProteinG-IP than after the anti-FLAG-IP, the 
experiment worked considerably better with the optimised conditions. Therefore 1% NP-40 
was used in all further experiments for the purification of the CD40-RSC.  
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Figure 3.14: Tandem precipitation of CD40-RSC for mass spectrometric analysis. 
9 x 10
9
 Raji cells were stimulated with moTAP-CD40L and tandem purified. 5% of the 
precipitate was analysed beside the controle (4,5 x 10
8
 cells) on a PAG with silver stain. 
95 % of the sample were run in a searate lane and cut into 23 pieces as indicated. 
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3.4 Mass spectrometric analysis of the CD40-RSC 
Since the discovery of CD40 several studies investigated the recruitment of proteins, mainly 
TRAF proteins, to the intracellular domain in biased assays (Kuhne et al, 1997; Matsuzawa et 
al, 2008). In these studies the stimulated CD40 receptor was precipitated and analysed by 
Western blotting. Thereby it was possible to identify several interaction partners. Only 
recently, Hostager et al. used an approach in which cells were stimulated with an anti-CD40 
antibody and the precipitated proteins were analysed by mass spectrometry (Hostager et al, 
2010). This approach used only a single precipitation protocol but it compared an 
overexpressed wild type receptor with truncated receptor for the intracellular domain, thereby 
revealing three new interaction partners of the receptor. 
The advantage of the tandem CD40-RSC purification with subsequent analysis by mass 
spectrometry is the higher purity of the native CD40-RSC and the identification of proteins in 
an unbiased approach. Therefore, the established tandem affinity purification protocol was 
used for the purification of signalling complexes from 9 x 109 Raji cells. 5% of the stimulated 
sample was run on a separate lane in a SDS-PAGE which was subsequently used for silver 
staining whereas the lane with the main part of precipitated protein was cut in 23 slices and 
analysed by mass spectrometry (Figure 3.14).  
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The mass spectrometric analysis revealed several known constituents of the CD40-RSC, such 
as CD40L, CD40, TRAF2, TRAF1, cIAP1, cIAP2 and ubiquitin (Table 3.1), but also 
contained proteins which must be contaminations. The complete list of proteins found in the 
mass spectrometric analysis can be found in the appendix (Table 7.1). Interestingly, three 
proteins were found which were also described to be recruited to the TNF-RSC and shown to 
be important for TNF-R1 mediated signalling (Haas, 2008). These proteins, HOIL-1, HOIP 
and SHARPIN, were additionally described to form a complex that generates linear ubiquitin 
chains, termed the linear ubiquitin chain assembly complex (LUBAC) (Gerlach et al, 2011; 
Ikeda et al, 2011; Tokunaga et al, 2011). HOIL-1, HOIP and SHARPIN were also found in 
the CD40-RSC (Table 3.1) thereby suggesting a role for LUBAC in this receptor complex. 
Surprisingly, it was not possible to detect other proteins known to form part of the CD40-
RSC, including TRAF3, TRAF6 and the IKKα/IKKβ/NEMO and TAK1/TAB2/TAB3 
complexes (Matsuzawa et al, 2008). However, it was possible to detect TRAF3 by Western 
blotting following a single-step precipitation of the CD40-RSC (Figure 3.11 and 4.2).  
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Table 3.1: Selected proteins of mass spectrometric analysis.  
If proteins were found in different gel slices, it was reduced to only one entry, however, all gel slices in which the respective protein was found, are provided in 
this table.  
Dark grey fields with white writing: proteins which were known to be recruited to the CD40-RSC; medium grey fields with black writing: proteins investigated in 
this thesis. White fields proteins discussed in Chapter 6. Information about proteins was taken from: www.uniprot.org. 
Acc. No. Name alternative Names Lane (Proteinscore/ 
No. of peptides) 
Properties Uniprot-
Ref No. 
gi|14994115 E3 ubiquitin-protein 
ligase TRIM21 
52 kDa Ro protein/RNF81/Ro(SS-A)/Sjoegren 
syndrome type A antigen 
6(311/8), 7(61/2), 
12(415/10), 13(898/28), 
14(1174/44), 15(101/2) 
Function: ubiquitin ligase complex with E2 UBE2D2; 
monoubiquitinates IKBKB and thereby negatively 
regulates Tax-induced NFkB signalling; several other 
functions described 
P19474 
gi|4507581 Tumor necrosis factor 
receptor superfamily 
member 5 
B-cell surface antigen CD40/Bp50/CD40L 
receptor/CDw40/CD_antigen=CD40 
in almost all gel slices 
with peak in slice 16 
Function: Receptor expressed mainly on B cells; 
important for immune response 
P25942 
gi|22027612 TNF receptor-associated 
factor 2 /TNFT2AF3 
E3 ubiquitin-protein ligase TRAF2/Tumor necrosis 
factor type 2 receptor-associated protein 3 
6(52/11), 11(167/5), 
12(561/13) 13(679/19), 
Function: E3 ubiquitin ligase; regulates activation of 
NFkB and JNK 
Q12933 
gi|109150431 Ring finger protein 31  HOIL-1-interacting protein (HOIP) /Zinc in-between-
RING-finger ubiquitin-associated domain 
protein(ZIBRA 
5(665/13) Function: component of LUBAC; can form linear 
ubiquitin chains 
Q96EP0 
gi|3978244 Inhibitor of apoptosis 
protein-1 
Baculoviral IAP repeat-containing protein 3/Apoptosis 
inhibitor 2/RING finger protein 49/TNFR2-TRAF-
signalling complex protein 1 
6(95/2), 7(144/4), 
8(413/11)9(112/2), 
10(424/9), 11(499/12) 
Function: Apoptotic suppressor. Heteromeric 
complexes with TRAF-2 
Q13489 
gi|4502141 Inhibitor of apoptosis 
protein 2 
Baculoviral IAP repeat-containing protein 2/RING 
finger protein 48/TNFR2-TRAF-signalling complex 
protein 2 
8(139/4), 11(480/11) Function: Apoptotic suppressor. Heteromeric 
complexes with TRAF-2 
Q13490 
gi|264672 CD40 ligand T-cell antigen Gp39/TNF-related activation 
protein/Tumor necrosis factor ligand superfamily 
member 5/CD154 
in almost all gel slices 
with peak in slice 15 
Function: B cell proliferation; Induces Isotype switch 
on B cells 
P29965 
gi|10999057 Receptor-type tyrosine-
protein phosphatase C 
Leukocyte common antigen/T200/CD45 3(313/7) Function: Protein tyrosine-protein phosphatase 
required for T-cell activation. Upon T-cell activation, 
recruits and dephosphorylates SKAP1 and FYN. 
P08575 
gi|34189561 RanBP-type and 
C3HC4-type zinc finger 
containing 1  
HBV-associated factor 4/Heme-oxidized IRP2 
ubiquitin ligase 1 (HOIL-1) /Hepatitis B virus X-
associated protein 4/RING finger protein 54/ubiquitin-
conjugating enzyme 7-interacting protein 3 
12(295/7) Function: Component of E3 ubiquitin-protein ligase 
complex which forms linear ubiquitin chains. 
Q9BYM8 
gi|229532 ubiquitin    2-12, 16, 23     
gi|5032193 TNF receptor-associated 
factor 1 
Epstein-Barr virus-induced protein 6 12(157/3) regulation of cell survival and apoptosis. ubiquitin 
ligase complex with TRAF2. 
Q13077 
gi|19264112 
 
SHARPIN protein Shank-associated RH domain-interacting protein/ 
Shank-interacting protein-like 1 (SIPL-1) 
16(95/2) Function: Component of the LUBAC complex. Forms 
linear Ubiquitin chains. 
Q9H0F6 
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Figure 3.15: 2D-separation of tandem purified CD40-RSC used for mass 
spectrometry. 
Raji cells were stimulated for 10 min with moTAP-CD40L and the RSC was tandem 
purified and analysed on a 2D gel with a silver staining protocol. The circled protein 
spots were picked and analysed by mass spectrometry. Table 3.2 shows selected 
proteins whereas the complete analysis can be found in the appendix (Table 7.2). 
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In a second approach, the components of the tandem purified CD40-RSC were separated on a 
two dimensional (2D) gel and after silver staining selected spots were picked for analysis by 
mass spectrometry (Figure 3.16). The complete list of proteins can be seen in Table 7.2 in the 
Appendix and the list of proteins which were not considered to be contaminants is in 
Table 3.2 (except spot 13 which only revealed contaminants). In this analysis it was possible 
to detect several known components of the CD40-RSC, e.g. CD40L (spot 1 and spot 2), 
cIAP1 (spot 11 and spot 12) and cIAP2 (spot 12). In spot 7 SHARPIN was detected which 
was also found to be recruited to the TNF-RSC (Haas, 2008).  
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Table 3.2: CD40-RSC components found in 2D gel by mass spectrometry.  
Spots from 2D gel in Figure 3.16 were picked by hand and analysed by mass spectrometry. This list shows the proteins after reduction of contaminants. The 
prominent spot 13 revealed only contaminants. Complete list of proteins for each spot can be found in table 7.2 in the appendix. 
Dark grey fields with white writing: proteins which were known to be recruited to the CD40-RSC; medium grey fields with black writing: proteins investigated in 
this thesis; light grey fields: proteins found in Mitochondria. Information about proteins was taken from: www.uniprot.org. 
 Acc. Nr. Name alternative Names Protein 
score 
No. of hits Properties Uniprot- 
Ref No. 
Spot 1 gi|264672 Tumor necrosis factor receptor 
superfamily member 5 
B-cell surface antigen CD40/Bp50/CD40L 
receptor/CDw40/CD_antigen=CD40 
115 4  Receptor expressed mainly on B cells; important for 
immune response 
P25942 
Spot 2 gi|264672 Tumor necrosis factor receptor 
superfamily member 5 
B-cell surface antigen CD40/Bp50/CD40L 
receptor/CDw40/CD_antigen=CD40 
210 4  Receptor expressed mainly on B cells; important for 
immune response 
P25942 
Spot 3 gi|14278227 Chain B, Nmr Structure Of 
Dff40 And Dff45 N-Terminal 
Domain Complex 
Inhibitor of CAD/DNA fragmentation factor subunit 
alpha 
217 3 Inhibitor of the caspase-activated DNase (DFF40). O00273 
Spot 4 gi|7019477 HtrA serine peptidase 2 
isoform 1 preproprotein 
High temperature requirement protein A2/Omi stress-
regulated endoprotease 
342 10 Serine protease with proteolytic activity. Binds 
cIAPs. Cleaves THAP5. 
O43464 
Spot 5 gi|7019477 HtrA serine peptidase 2 
isoform 1 preproprotein  
High temperature requirement protein A2/Omi stress-
regulated endoprotease 
196 5 see above O43464 
Spot 6 gi|62122917 Filaggrin-2 Intermediate filament-associated and psoriasis-
susceptibility protein 
56 1  Q5D862 
Spot 7  gi|22761713 SHARPIN Shank-associated RH domain-interacting protein/Shank-
interacting protein-like 1(SIPL) 
137 5 Role in signaltransduction in the immunesystem Q9H0F6 
Spot 8 gi|9845297 Diablo homolog, mitochondrial Direct IAP-binding protein with low pI/Second 
mitochondria-derived activator of caspase 
46 1 Promotes apoptosis by activating caspases in the 
cytochrome c/Apaf-1/caspase-9 pathway.  
Q9NR28 
Spot 9 gi|62122917 Filaggrin-2 Intermediate filament-associated and psoriasis-
susceptibility protein 
74 1  Q5D862 
Spot 10 gi|762885 Junction plakoglobin Catenin gamma/Desmoplakin III 189 4 Central role in the structure and function of 
submembranous plaques.  
P14923 
Spot 11 gi|3978244 inhibitor of apoptosis protein-1 Baculoviral IAP repeat-containing protein 3/Apoptosis 
inhibitor 2/RING finger protein 49/TNFR2-TRAF-
signalling complex protein 1 
264 7 Apoptotic suppressor. Heteromeric complexes with 
TRAF-2 
Q13489 
gi|4502141 Inhibitor of apoptosis protein 2 Baculoviral IAP repeat-containing protein 2/RING 
finger protein 48/TNFR2-TRAF-signalling complex 
protein 2 
31 1 Apoptotic suppressor. Heteromeric complexes with 
TRAF-2 
Q13490 
Spot 12 gi|3978244 inhibitor of apoptosis protein-1 Baculoviral IAP repeat-containing protein 3/Apoptosis 
inhibitor 2/RING finger protein 49/TNFR2-TRAF-
signalling complex protein 1 
315 7 Apoptotic suppressor. Heteromeric complexes with 
TRAF-2 
Q13489 
Spot 13 gi|11935049 Keratin, type II cytoskeletal 1 67 kDa cytokeratin/Cytokeratin-1/Hair alpha 
protein/Keratin-1/Type-II keratin Kb1 
2085 68 Structural Protein/May regulate the activity of 
kinases such as PKC and SRC 
P04264 
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3.5 Summary 
The identification of proteins within RSCs is an important step in understanding the signal 
transduction from the extracellular environment into cells. This chapter described the 
purification of the CD40-RSC complex and subsequent analysis by mass spectrometry. The 
CD40L was tagged with a tandem tag and the fusion protein was produced in HEK293T cells. 
Its biological activity was tested under different conditions and the precipitation protocol 
optimised by varying several parameters. It was possible to purify the CD40-RSC from B cell 
lines and get a stable RSC throughout the tandem purification procedure which was shown by 
Western blotting. Finally, the tandem purified CD40-RSC was analysed by mass spectrometry 
which revealed potential proteins of interest for further analysis. Especially, HOIL-1, HOIP 
and SHARPIN, which are constituents of a linear ubiquitin chain assembly complex, might 
play a role in CD40 signalling. This idea is supported by the fact that they are required for 
TNF-induced NF-κB and MAPK signalling, which are common signalling pathways between 
TNF and CD40 but also of other members of the TNF-RSF. Therefore, the role of these three 
proteins in CD40 signalling is analysed in the following two chapters.  
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Figure 4.1: Summary of mass spectrometric analysis of CD40-RSC. 
The gel shows the tandem affinity purified CD40-RSC which was cut into pieces for the 
analysis by mass spectrometry. The table shows the number of peptides which were 
found for the indicated proteins according to the gel piece. 
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Chapter 4. Characterisation of SHARPIN, HOIL-1 and HOIP in 
CD40 signalling 
The mass spectrometric analysis of the CD40-RSC identified SHARPIN, HOIL-1 and HOIP 
as proteins associated with this complex. In fact, these three proteins had previously been 
identified by our laborator as consitutents of the TNF-RSC in a similar approach (Haas, 
2008). For these reasons, the subsequent analysis in this thesis focussed on the role of those 
proteins in CD40 signalling. Figure 4.1 shows the distribution in the gel and the number of 
peptides found for each of these three proteins. This figure also shows other proteins already 
described to form part of the CD40-RSC, and the position within the gel at which each of 
them was identified. It can be observed that cIAP1/2 and TRAF2 were present in several gel 
slices starting from their expected molecular weight. This strongly supports the idea that they 
must be modified, most likely by ubiquitination, to run at a higher molecular weight. This 
notion is supported by the fact that peptides for ubiquitin were also identified in gel slices of 
higher molecular weight. This is in line with Figure 3.11 in which a laddering for cIAP2 was 
observed upon CD40-RSC precipitation.  
Surprisingly, it was not possible to detect other proteins known to form part of the CD40-
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Figure 4.2: SHARPIN, HOIL-1 and HOIP are recruited to the CD40-RSC in a 
stimulation-dependent manner. 
Single step precipitation of the CD40-RSC from Raji cells (a) and human peripheral 
blood mononuclear cells (b) with anti-FLAG beads. 
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RSC, including TRAF3, TRAF6 and the IKKα/IKKβ/NEMO and TAK1/TAB2/TAB3 
complexes (Matsuzawa et al, 2008). However, it was possible to detect TRAF3 by Western 
blotting following a single-step precipitation of the CD40-RSC (Figure 3.11 and 4.2).  
4.1 SHARPIN, HOIP and HOIL-1 form part of the CD40-RSC 
The identification of SHARPIN, HOIP and HOIL-1 as components of the CD40-RSC by 
mass spectrometry needs further analysis because the interaction can be non-specific or 
stimulation-independent. To test both of these possibilities, stimulation kinetics were 
performed with Raji cells (Figure 4.2a) and the recruitment of different constituents was 
analysed. It was observed that SHARPIN, HOIP and HOIL-1 were recruited in a stimulation-
dependent manner to the CD40-RSC as none of these proteins could be detected in the 
unstimulated sample. The same is true for cIAP1, cIAP2, TRAF2 and TRAF3. As Raji cells 
have been established in cell culture since 1964 (Pulvertaft, 1964), these cells might have 
adapted to culture conditions and no longer represent physiological conditions. Therefore, the 
stimulation was performed with human peripheral blood mononuclear cells (PBMCs, 
Figure 4.2b). The observations in these primary cells were in line with results obtained with 
Raji cells. In both experiments cIAP2 was strongly modified, an observation not previously 
described. Matsuzawa and colleagues only described cIAP2 recruitment to the CD40-RSC but 
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Figure 4.3: HOIL-1 is recruited to the CD40-RSC in primary mouse B cells. 
a, B cells were purified with CD43 negative isolation kit from Miltanyi and stained 
before and after isolation with a B220-PE antibody. b, Single step precipitation of the 
CD40-RSC from B cells purified from mice. 1.5 x 10
7
 cells were used per stimulation.  
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did not observe any modifications (Matsuzawa et al, 2008).  
All experiments until this point were done in cells representing the human system; however, it 
is also of great interest to establish this technique in a murine system as knockout mice for 
these components are available for SHARPIN and will become available for HOIL-1 and 
HOIP. Since the human CD40L does not bind to the murine receptor (Bossen et al, 2006), a 
murine moTAP-CD40L was cloned so that the CD40-RSC could also be analysed in murine 
cells. The same TAP-tag was used as for the human ligand since it did not interfere with the 
biological activity of the CD40L (Figure 3.7).  
The murine moTAP-CD40L was expressed in HEK293T cells and the concentration was 
estimated by the same Western blotting procedure employed for human moTAP-CD40L. The 
concentration was approximately 20 µg/ml and therefore it was used in a same manner as the 
recombinant human ligand (data not shown). 
Since CD40 is expressed on B cells, these cells are often used to investigate CD40 signalling 
because they are easily accessible and many cells can be purified from a single spleen. 
Therefore, a CD43 negative-selection procedure developed by Miltenyi and colleagues 
(Miltenyi et al, 1990) was chosen for purification of splenic B cells and a purity of 95% could 
be achieved (Figure 4.3a). 
The isolated B cells were stimulated with murine moTAP-CD40L and receptor complexes 
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from cell lysates were analysed by Western blotting (Figure 4.3b). A stimulation dependent 
recruitment of HOIL-1 to the CD40-RSC was observed in primary mouse B cells. 
Recruitment of SHARPIN and HOIP could not be analysed in the mouse system because the 
antibodies against these proteins were raised against human peptides and do not cross-react 
with the murine proteins. 
It was shown before that HOIL and HOIP form a higher order protein complex in the cytosol 
which is stimulation-independent and able to generate the formation of linear ubiquitin chains 
(Kirisako et al, 2006). Later, it was shown that SHARPIN also forms part of this complex 
(Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). Therefore, and considering the 
results obtained with human B cells, it can be assumed that SHARPIN and HOIP are also 
recruited to the murine CD40-RSC as part of a preformed multi-protein complex but 
techniqual limitations prevented detection of such a complex in the context of this thesis.  
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Figure 4.4: HOIP and HOIL-1 are not recruited to CD40-RSC in BJAB cells. 
BJAB and Raji cells were stimulated with moTAP-CD40L for different time points and 
the RSC precipitated. The precipitate was analysed by Western blotting with the 
indicated antibodies. 
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4.2 HOIL-1, HOIP and SHARPIN are recruited in a cIAP1/2 dependent 
manner 
The observation that SHARPIN, HOIP and HOIL-1 are recruited to the CD40-RSC begged 
the question via which components they are recruited to the complex. While investigating the 
recruitment of HOIL-1, HOIP and SHARPIN to the CD40-RSC in various cell lines, it 
became clear that they were recruited to the CD40-RSC in Raji cells but not in BJAB cells 
(Figure 4.2 and Figure 4.4). Interestingly, this is not due to differences in expression of 
HOIL-1 or HOIP protein or mRNA level (Figure 4.4 and Figure 4.5). This suggested that a 
different component expressed in Raji cells but not in BJAB cells must be essential for the 
recruitment of HOIL-1 and HOIP to the CD40-RSC. One candidate was cIAP2 which was 
readily detectable in Raji cells but not in BJAB cells.   
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Figure 4.5: BJAB cells do not express cIAP1 and cIAP2 mRNA. 
mRNA expression of indicated genes in Raji, BJAB and Ramos cells were quantified 
by qPCR. For each gene the mRNA expression of BJAB and Ramos cells was related 
to the expression in Raji cells. 
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To test wether that cIAP2 is indeed absent from BJAB cells, and to exclude that protein levels 
were not only below the detection limit of Western blotting, mRNA levels were determined 
by quantitative PCR. The results confirmed that BJAB cells do not express cIAP1 and cIAP2 
mRNA (Figure 4.5). These data therefore strongly support a recruitment of LUBAC to the 
CD40-RSC via cIAP2 and possibly cIAP1. 
 
One way to further confirm these results is by ablation of cIAP1 and cIAP2 by SMAC 
mimetics in Raji cells. SMAC mimetics are small chemical compounds mimicking the natural 
antagonist of IAPs, SMAC/DIABLO. SMAC/DIABLO is released from the mitochondria to 
block the anti-apoptotic capacity of IAPs, thereby favouring induction of apoptosis 
(Falschlehner et al, 2007). SMAC mimetics were found to be effective in sensitising cells to 
apoptosis and lead to a degradation of cIAPs (Varfolomeev et al, 2007; Vince et al, 2007). 
Degradation of cIAPs by SMAC mimetics is achieved by activating the E3 ubiquitin ligase 
activity of cIAP1 and cIAP2, resulting in their autoubiquitination and degradation by the 
proteasome. However, since induction of apoptosis by SMAC mimetics was reported in some 
cell lines, different SMAC mimetics were tested in this thesis for their application in CD40-
RSC pulldown studies. 
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Figure 4.6: Degradation of cIAP2 by SMAC mimetics in B cell lines. 
a, Raji cells were treated with three different SMAC mimetics at different 
concentrations. b, Three different B cell lines were treated with different SMAC 
mimetics. c, Kinetics were performed with SMAC mimetics on different B cell lines. In 
each case the lysates were analysed by Western blotting with the indicated antibodies. 
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For the following analysis, SMAC55, SMAC59 and SMAC66 were used. Whereas SMAC55 
and SMAC66 are monovalent mimetics, SMAC59 is a bivalent mimetic [personal 
communication by D. Lecis and (Cossu et al, 2010)]. These three SMAC mimetics were first 
tested on Raji cells at different concentrations (Figure 4.6a). The cells were incubated with the 
different compounds for one hour, and lysates were subsequently prepared and analysed for 
cIAP2 levels by Western blotting. Whereas SMAC59 reduced cIAP2 levels in the cells at 1 
nM and a complete loss of cIAP2 at 10 nM was observed, SMAC55 and SMAC66 were less 
effective at these concentrations. In fact, even at a concentration of 1 µM an alteration of 
cIAP2 levels was barely detectable. The effectiveness of SMAC mimetics on other cell lines 
was also tested (Figure 4.6b). SMAC59 was used at a concentration of 10 nM and induced 
complete loss of cIAP2 in all tested cell lines. Interestingly, SMAC55 and SMAC66 were 
more effective in SKW6.4 and Ramos cells in degrading cIAP2. As the protein levels within 
the different cell lines were almost the same, it might be possible that post-translational 
modifications occurred or that the protein environment was different.  
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Figure 4.7: SMAC treatment does not lead to DNA fragmentation in Raji cells. 
Raji cells were either left untreated or treated for 16 hours with DMSO (left panel) or 
SMAC mimetic (right panel). Cells were lysed and stained with PI to investigate DNA 
fragmentation in nuclei. All nuclei from FSC/SSC-dot blot were analysed in this 
histogram. Green: unstimulated, red: 16 hours stimulation. 
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To test whether the pre-incubation period of one hour is optimal, a kinetic was performed 
with Raji, SKW6.4 and Ramos cells. SMAC59 was used for Raji and Ramos cells and 
SMAC66 was used for SKW6.4 cell line because it was quite effective in this cell line (Figure 
4.6b). The degradation of cIAP2 in Raji cells and Ramos cells was very efficient after 
stimulating for only one hour (Figure 4.6c). It was observed that post-translational 
modifications of cIAP2 take place after 20 min and the protein shifts to a higher molecular 
weight. This is due to the addition of ubiquitin chains to the proteins, leading to proteasomal 
degradation.  
These experiments showed that the optimal concentration of 10 nM of SMAC59 and an 
incubation period of at least one hour effectively depletes cIAP2. Therefore, this treatment 
could be used to investigate the composition of CD40-RSC in the absence of cIAPs. 
However, it was observed that SMAC mimetic treatment can result in apoptosis of cells by 
the activation of non-canonical NF-κB which induces autocrine production of TNF 
(Varfolomeev et al, 2007; Vince et al, 2007). Based on this result, SMAC mimetic treated 
Raji cells were investigated for induction of apoptosis. After 16 hours of treatment it was not 
possible to detect any fragmentation of the DNA in Raji cells by quantitative DNA staining of 
lysed cells (Figure 4.7). Since no apoptosis was observed and the cells were not kept in 
SMAC-containing medium for more than 3 hours when CD40-RSC composition was 
evaluated, dead or dying cells could not influence the experimental results obtained in this 
thesis.  
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Figure 4.8: SHARPIN, HOIP and HOIL-1 need cIAPs for the recruitment to the 
CD40-RSC. 
Raji cells were pre-treated with DMSO or SMAC mimetic for two hours and the CD40-
RSC precipitated with a single step precipitation protocol. The Western blot was 
probed with the indicated antibodies.  
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Finally, the experiment was scaled up to 5 x 107 cells and the CD40-RSC precipitated from 
DMSO or SMAC mimetic-treated cells. TRAF2 and TRAF3 were observed to be recruited to 
the CD40-RSC in the absence of cIAP2, although in slightly reduced amounts. In contrast, 
recruitment of SHARPIN, HOIP and HOIL-1 to the CD40-RSC could not be detected when 
cIAP2 was excluded from the stimulation (Figure 4.8).  
Together these results strongly suggest an important role for cIAP2 in the recruitment of 
SHARPIN, HOIP and HOIL-1 to the CD40-RSC.  
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Figure 4.9: CD40 expression is not influenced by SMAC mimetics. 
a, Raji cells were treated either with DMSO or with SMAC mimetic and stained with an 
isotype control or with an anti-CD40 antibody. b, Raji cells were stimulated with DMSO 
or SMAC mimetic for various times and lysates analysed by Western blotting with the 
indicated antibodies. 
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Since there was a decrease in TRAF2 and TRAF3 recruitment, and also less CD40 
precipitated in SMAC mimetic-treated cells, the question arose whether there was less CD40 
expressed in these cells after SMAC mimetic treatment. Therefore Raji cells were treated with 
DMSO or SMAC mimetics and the cell surface analysed for CD40 expression (Figure 4.9a). 
No obvious differences in the CD40 surface expression between DMSO and SMAC mimetic-
treated cells could be observed. In addition, Western blot analysis confirmed equal expression 
levels of CD40 protein with and without SMAC mimetic treatment (Figure 4.9b).  
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Figure 4.10: LUBAC
HL+HP
 is coprecipitated with cIAP2. 
HOIL-1 and HOIP were coexpressed in HEK293T cells with either wt cIAP2 or delta 
RING mutant cIAP2. HOIL-1 and HOIP were precipitated via the V5 tag and analysed 
by Western blotting using the indicated antibodies. 
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4.3 HOIL-1 and HOIP bind to cIAP2 via ubiquitin chains 
It has been shown that HOIL-1 and HOIP are recruited to the TNF-RSC and that they are able 
to form a functional unit, LUBACHL+HP, which is able to form linear ubiquitin chains 
(Kirisako et al, 2006). The essential components for the recruitment to the TNF-RSC are 
TRADD, TRAF2 and cIAPs (Haas et al, 2009). However, this study also shows a binding to 
poly-ubiquitin chains. It was shown here that cIAP2 is essential for the recruitment of HOIL-1 
and HOIP to the CD40-RSC and it was observed that cIAP2 is highly modified within the 
CD40-RSC, most likely with ubiquitin. Taken together, these findings suggest a recruitment 
of HOIL-1 and HOIP via ubiquitin chains of cIAP2. 
This hypothesis was addressed in an overexpression experiment in HEK293T cells. 
LUBACHL+HP was either expressed alone, with wt cIAP2, or a ligase-inactive cIAP2 mutant 
(cIAP2 deltaRING). In contrast to wt cIAP2, the ligase-inactive mutant was not able to 
autoubiquitinate when overexpressed. In this overexpression experiment HOIL-1 and HOIP 
were pulled down and co-precipitation of cIAP2 was analysed by Western blotting. Both 
variants were also overexpressed without LUBACHL+HP to observe non-specific binding of 
cIAP2 to the beads (Figure 4.10). Indeed, the unmodified wt cIAP2 was already precipitated 
without LUBACHL+HP due to unspecific binding to the beads. However, overexpression of 
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Figure 4.11: LUBAC
HL+HP
 bind to Ubiquitin. 
HOIL-1 and HOIP were overexpressed in HEK293T cells and a ubiquitin-pulldown 
performed from the lysates. The Western blots were incubated with the indicated 
antibodies. V: empty vector control, TCL: total cell lysate. 
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LUBACHL+HP with wt cIAP2 revealed a specific precipitation of modified cIAP2 with these 
two proteins. The deltaRING mutant of cIAP2 showed no difference in the IP with or without 
concomitant overexpression of LUBACHL+HP, thereby further supporting a role for the 
interaction of LUBACHL+HP with the ubiquitin chains on cIAP2. 
 
The ability of LUBACHL+HP to bind to ubiquitin chains on cIAP2 should also allow the 
binding to ubiquitin itself. Therefore, HOIL-1 and HOIP were overexpressed either separately 
or together and a pulldown assay was performed from lysates with ubiquitin-coupled beads 
(Figure 4.11). HOIL-1 and HOIP were able to bind to ubiquitin beads when overexpressed 
alone but the binding was more efficient when they were overexpressed together.  
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Figure 4.12: HOIL-1 is not needed for recruiting HOIP and SHARPIN to the CD40-
RSC. 
Raji cells stably transfected with either ctr or HOIL-1 shRNA were stimulated with 
moTAP-CD40L, and the CD40-RSC was precipitated. Western blotting was analysed 
with indicated antibodies. IP: immune precipitation, TCL: total cell lysate  
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4.4 HOIL-1 is not essential for recruiting HOIP and SHARPIN to the CD40-
RSC 
SHARPIN, HOIP and HOIL-1 are recruited to the CD40-RSC in a cIAP2-dependent manner. 
Furthermore it was shown that these three proteins are found in the same high molecular 
weight fraction in gel filtration analyses, thereby supporting the hypothesis of a tripartite 
complex. This complex forms stimulation-independently as it can be detected as a preformed 
complex in the cytoplasm (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). To 
study CD40-RSC formation in the absence of HOIL-1, the CD40-RSC was compared 
between Raji cells with control shRNA and shRNA directed against HOIL-1 (Figure 4.12). 
The lysates of cells in which HOIL-1 expression was suppressed also showed a strong 
reduction of SHARPIN and HOIP expression indicating that most of the cellular protein of 
the three factors is contained in tripartite complexes. The CD40-RSC in HOIL-1 knockdown 
cells showed almost no HOIL-1 recruitment whereas SHARPIN and HOIP could readily be 
detected; although their abundance appeared to be slightly decreased. There was no effect on 
the recruitment of TRAF2, TRAF3 and cIAP2 when HOIL-1 expression was reduced. 
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Figure 4.13: HOIL-1 is needed for complete NF-κB activation in CD40 signalling. 
Raji cells stably transfected with either ctr or HOIL-1 shRNA were stimulated with 
moTAP-CD40L and lysates analysed by Western blotting with the indicated antibodies. 
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4.5 HOIL-1 is needed in B cells for the activation of NF-κB and MAPK 
So far the analysis of the different LUBAC components was restricted to their molecular 
interaction. Next, their functional role in CD40 signalling was addressed. To investigate 
whether these proteins play a role in CD40-mediated signal transduction, stable HOIL-1 
knockdown cells were generated by viral shRNA transfection (Figure 4.13). These cells were 
stimulated with moTAP-CD40L and lysates were Western blotted with an antibody detecting 
phosphorylated IκBα. Indeed, cells with silenced HOIL-1 expression showed considerably 
less phosphorylation of IκBα than cells transfected with a control shRNA construct 
(Figure 4.13).  
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Figure 4.14: HOIL-1 is needed for full p38 and JNK activation upon CD40 
stimulation. 
Raji cells stable transfected with either control (ctr) or HOIL-1 shRNA were stimulated 
with moTAP-CD40L and lysates were analysed by Western blotting with the indicated 
antibodies.  
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CD40 signalling also activates several MAPK like p38 and JNK which are able to activate the 
AP-1 transcription factors (Karin & Gallagher, 2009). To investigate whether HOIL-1 plays a 
role in p38 and JNK activation after CD40 stimulation, Raji cells transfected with control or 
HOIL-1 shRNA were stimulated with moTAP-CD40L; and lysates analysed for the 
phosphoralytion of p38 and JNK (Figure 4.14). In the absence of HOIL-1, phosphorylation of 
p38 is significantly reduced following CD40 stimulation whilst the phosphorylation of JNK 
seems to be only marginally affected.  
Taken together, HOIL-1 is needed for CD40-induced activation of NF-κB and the p38 
pathway. 
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4.6 Summary 
In this chapter it was shown that SHARPIN, HOIP and HOIL-1 are recruited to the 
CD40-RSC in a stimulation-dependent manner. Their recruitment depends on cIAP2, and 
most likely cIAP1, and ubiquitin chains on cIAP2 are important for the interaction between 
cIAP2 and LUBAC. Furthermore, HOIL-1 has a positive effect on the activation of NF-κB 
and MAPK signalling because loss of this protein results in a decreased activation of these 
signalling pathways.  
Consequently, these results indicate that a role for LUBAC is expanded to another member of 
the TNF-RSF beside TNF-R1.  
 
 Chapter 5: CD40 signalling in cpdm mice 
104 
 
Chapter 5. Analysis of CD40 signalling in cpdm mice  
 
In 1993 a spontaneous chronic proliferative dermatitis (cpdm) mouse phenotype was 
described in C57BL/K mice which was characterised by the development of skin lesions at 5 
to 6 weeks of age. The lesions were defined by epidermal hyperplasia, and hyper- and 
parakeratosis (HogenEsch et al, 1993). The same group also investigated the immunological 
aspects of the phenotype and found severe abnormalities in lymphoid tissue architecture, 
including poorly defined follicles and no germinal centres, the complete lack of marginal 
zones in the spleen, and lower serum concentrations of IgG, IgA and IgE (HogenEsch et al, 
1999). Eight years later it was discovered that the phenotype is caused by point mutations in 
the SHARPIN gene leading to a frame shift with an early stop codon (Seymour et al, 2007).  
The finding that these mice show a defect in isotype switching, together with the finding that 
SHARPIN is recruited the CD40-RSC as part of a protein complex that generates linear 
ubiquitin chains, suggests that SHARPIN and linear ubiquitination play a physiologically 
important role in CD40 signalling. 
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Figure 5.1: cpdm mice show a skin phenotype and abnormal spleen architecture. 
a cpdm mice show skin lesions in contrast to wt mice. b and c, the spleens of cpdm
mice are enlarged. d, Spleen architecture of cpdm is disrupted. Haematoxylin and 
Eosin (H&E) stains and immunofluorescence staining against CD3 (red), B220 (green) 
and nuclei (blue). Scale bars, (from left to right) 500 µm, 200 µm, 50 µm and 50 µm. 
(Figure 5.1c & d provided by J. Silke lab, LaTrobe University, Melbourne) 
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5.1 cpdm mice show abnormal spleen architecture 
The following studies on cpdm mice were performed in collaboration with the laboratory of 
Prof. John Silke (LaTrobe University, Melbourne). Cpdm mice started developing skin lesions 
on their back (Figure 5.1a) and were killed before further expansion of the lesions. Spleens 
from cpdm mice were enlarged to almost three times the size of spleens in wt mice (Figure 
5.1b). The enlargement of spleens was significant throughout different experiments (Figure 
5.1c, provided by Prof. Silke lab, LaTrobe University, Melbourne). Microscopic analysis of 
hematoxylin and eosin stained spleen sections revealed a disruption of the spleen structure. In 
wt mice the white and red pulp could be observed whereas no structure could be observed in 
cpdm mice (Figure 5.1d, provided by J. Silke lab, LaTrobe University, Melbourne). In 
addition, the development of a T cell zone and germinal centres could not be observed in 
spleens from cpdm mice compared with spleens of wt mice. These results are in line with 
previously obtained data (HogenEsch et al, 1999).  
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Figure 5.2: cpdm mice show abnormal follicular and marginal zone B cell 
numbers. 
Splenocytes from wt and cpdm mice were stained for B220, CD23 and CD21/35. B220 
positive cells are shown for their expression of CD23 and CD21/35 respectively.  
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A detailed analysis of B cells from the spleen of wt mice and cpdm mice revealed decreased 
numbers of follicular B cells and increased numbers of marginal zone B cells (Figure 5.2). 
The B cell population of CD23high and CD21/CD35medium characterising follicular B cells was 
decreased from 53.7% in wt cells to 42.2% in cpdm spleens. In contrast, the CD23 
intermediate and CD21/CD35 high population in the B cell subset is increased from 7.4% in 
wt spleens to 10.8% in cpdm spleens. HogenEsch et al. showed in flouresence stained spleen 
sections from cpdm mice a loose organisation of follicles with B cell markers and follicular 
dendritic cell markers. A staining against marginal zone macrophages showed a well 
organised marginal zone in wt spleens and a few scattered cells in cpdm mice showing that 
cells of the marginal zone exist but are not organised in their common structure (HogenEsch 
et al, 1999). 
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Figure 5.3: B cells from cpdm mice show a defect in isotype switching and 
proliferation after CD40 stimulation. 
a and b, CD43
-
 sorted splenocytes were stained with celltrace violet and incubated 
with CD40L + IL-4 for four days. Cells were then stained either for IgM (a) or IgG1 (b). 
c, the number of cells in each division cycle of wt and cpdm mice is indicated. d,
number of IgG1 positive cells of indicated division cycle. 
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5.2 B cells from cpdm mice show a defect in isotype switching 
HogenEsch et al. described low levels of IgG, IgA and IgE in the serum of cpdm mice but 
similar IgM levels as compared to wt mice (HogenEsch et al, 1999). This observation is in 
line with early reports of CD40-deficient lymphocytes in mice (Castigli et al, 1994) or CD40L 
knock out mice (Renshaw et al, 1994). These mouse strains also show a defect in isotype 
switching and have decreased IgG levels. In addition, the hyper IgM syndrome in humans is, 
in most cases, based on a mutation in the CD40L gene (Aruffo et al, 1993).  
B cells from wt and cpdm mice were isolated from the spleen and sorted with a CD43-
isolation kit from Miltenyi. The isolated B cells were then incubated for four days in the 
presence of CD40L and IL-4. The cells were stained for the expression of IgM and IgG1 
(Figure 5.3). 77% of B cells from cpdm mice showed expression of IgM on the surface. In 
contrast, only 63% of B cells from wt mice still express IgM (Figure 5.3a). The opposite was 
observed for the IgG1 expression: with 33% representation, IgG1-positive B cells were more 
abundant in B cells obtained from wt mice than in B cells obtained from cpdm mice as only 
21% of these cells expressed IgG1 (Figure 5.3b). A direct comparison of IgG1-positive cells 
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Figure 5.4: B cells from cpdm mice show a decreased number of the lymphocyte 
population after incubation in cell cultures. 
Gating of B cells in the forward and side scatter from Figure 5.3a. Gating in the left 
panel for single cells whereas gating in the right panel is for the lymphocyte population. 
B cells derived from cpdm mice show a decrease of the lymphocyte population 
compared with wt B cells.  
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between wt and cpdm mice showed how the IgG1-positive cells emerge after the second 
division in cells derived from both mice. However, after the fifth division the percentage of 
IgG1-expressing cells from cpdm mice was 2.5 times less than in B cells obtained from wt 
mice (Figure 5.3d).  
The cell number of each division cycle in cells derived from wt mice was higher in division 
cycles 3 to 6 compared to cpdm derived cells, whereas cells from cpdm mice were more 
abundant in the early division cycles from 0 to 2 (Figure 5.3c). This suggests that B cells from 
cpdm mice did not proliferate as proficially as B cells from wt mice following CD40 
stimulation, especially in the later division cycles. In line, it is observed that the populations 
of the different division cycles from cpdm derived B cells cannot be distinguished as well as 
the populations in wt mice (Figure 5.3a, b), again pointing towards an additional defect of 
cpdm derived cells in cell proliferation and cell survival or an increased susceptibility for cell 
death. This observation is also reflected on the dot blot of these cells with the forward vs. side 
scatter. The B cell population is decreased in cells derived from cpdm mice after cell culture 
for four days compared with B cells from wt mice (Figure 5.4).  
In summary, these observations also support a role for SHARPIN in cell survival, but 
additional experiments will be needed to address the defect of these cells to proliferate and 
survive under cell culture conditions.  
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Figure 5.5: SHARPIN is needed for complete NF-κB and JNK activation after 
CD40 stimulation in B cells. 
B cells from wt and cpdm mice were stimulated for the indicated times and lysates 
were analysed by Western blotting for presence of the indicated proteins. 
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5.3 B cells from cpdm mice have defects in CD40-induced NF-κB and JNK 
activation 
A variant of the human hyper IgM syndrome which is a result of a mutation in the NEMO 
gene provides evidence that isotype switching relies on NF-κB signalling (Jain et al, 2001). 
The defect in isotype switching is therefore likely to be mirrored in a defect in signal 
transduction. To study the activation of NF-κB upon CD40 signalling in SHARPIN-deficient 
B cells, this cell type was isolated from wt and cpdm mice and stimulated with moTAP-
CD40L for different times. The lysates were analysed by Western blotting for different 
signalling events known to occur following CD40 stimulation. Less phosphorylation of IκBα 
in cpdm versus wt cells could be detected, and the degradation of this molecule was strongly 
inhibited when SHARPIN was absent. Furthermore, it was also observed that phosphorylation 
of JNK was strongly inhibited in cpdm-derived B cells (Figure 5.4). These results indicate that 
CD40 signal transduction is defective on the level of canonical NF-κB signalling and JNK 
activation in SHARPIN-deficient cells. 
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Figure 5.6: SHARPIN is needed for complete NF-κB activation after CD40 
stimulation in B cells. 
B cells from wt and cpdm mice were stimulated with moTAP-CD40L. The nucleus was 
separated from the cytoplasma and both fractions analysed by Western blotting.  
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A defect in NF-κB signalling following CD40 stimulation was also shown by diminished 
translocation of p65 into the nucleus. B cells from wt and cpdm mice were stimulated with 
moTAP-CD40L and following lysis the nuclei were separated from the cytoplasm. Both 
cellular compartments were then analysed by Western blotting for the presence of p65. In the 
wt cells p65 was detected after 10 min in the nucleus but the signal increased after 30 min and 
60 min. In cpdm cells p65 was also observed to translocate, however, the intensity of the 
bands was much lower compared to that of wt B cells (Figure 5.5). Therefore it was possible 
to confirm with another readout that NF-κB activation after CD40 stimulation is defective in 
cells lacking SHARPIN.  
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Figure 5.7: Non-canonical NF-κB signalling is not affected by loss of SHARPIN. 
a, B cells from wt and cpdm mice were stimulated with moTAP-CD40L and lysates 
analysed by Western blotting. b, Quantification of p100 bands from three independent 
experiments. Quantification was done using ImageJ software.  
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It was reported that CD40 is also able to activate the non-canonical NF-κB pathway by 
processing p100 to p52 (Coope et al, 2002). Later it was shown by two independent groups 
that this processing is controlled by constitutive degradation of NIK; accomplished by a 
complex of cIAP1/2, TRAF2 and TRAF3. Upon cellular stimulation, the cIAP-TRAF-
complex is inhibited from degrading NIK, which is then stable enough to activate the IKK 
complex; this in turn leads to p100 processing to p52 and translocation of a p52/RelB hetero-
dimer to the nucleus (Vallabhapurapu et al, 2008; Zarnegar et al, 2008). In this context it was 
interesting to investigate whether NIK stabilisation and p100 degradation was also altered in 
cells derived from cpdm mice compared to wt mice. Figure 5.6a shows that stabilisation of 
NIK was not significantly altered between wt and cpdm B cells. The same was true for p100 
degradation, although the expression level of p100 was reduced in cpdm cells when compared 
with wt cells. To compare the p100 levels in cpdm and wt B cells, it was necessary to quantify 
the p100 signals for each time point (Figure 5.6b). A degradation of p100 was observed after 
4 hours of stimulation and there was no significant difference visible between the two cell 
types. These experiments lead to the conclusion that, in contrast to canonical NF-κB 
activation following CD40 stimulation, non-canonical CD40-induced NF-κB signalling is not 
significantly influenced by absence of SHARPIN. 
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Figure 5.8: SHARPIN is needed for CD40 induced gene induction in B cells. 
B cells from wt (black line) and cpdm (grey line) mice were stimulated for the indicated 
times and mRNA expression quantified by qPCR. All samples are related to 
unstimulated cells from wt mice. 
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5.4 Gene induction is decreased in B cells from cpdm mice 
It was shown that CD40 signal transduction is negatively affected in B cells from cpdm mice. 
Therefore it was interesting to test whether this resulted in a diminished gene expression of 
CD40 target genes like A20, ICAM1 and IκBα after CD40 stimulation of these cells 
(Schonbeck & Libby, 2001). To investigate the effect of SHARPIN-deficiency on gene 
induction by CD40 stimulation, wt and cpdm-derived B cells were stimulated with moTAP-
CD40L in a timecourse up to four hours and mRNA levels for the two different cell types 
were compared (Figure 5.7). Indeed, upregulation of the A20, ICAM1 and IκBα genes was 
almost completely inhibited in SHARPIN-deficient cells. Besides these typical NF-κB target 
genes, the expression of CyclinD, which is important for CD40-induced proliferation 
(Gallagher et al, 2007), was also decreased.  
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5.5 Summary 
In the early 1990’s the cpdm phenotype was discovered in C57BL/K mice and the mutation 
was mapped to the SHARPIN gene (HogenEsch et al, 1993; Seymour et al, 2007). Several 
immunological phenotypes were observed in these mice (HogenEsch et al, 1999) and one of 
them, the defect in isotype switching, was investigated in this chapter. It is demonstrated in 
this thesis that SHARPIN-deficient B cells show a defect in isotype switching and have a 
decreased proliferation rate. Furthermore, B cells derived from cpdm mice show a defect in 
CD40-induced canonical NF-κB and JNK activation, whereas non-canonical NF-κB 
activation does not seem to be significantly affected. SHARPIN deficiency also results in a 
defect of CD40-induced gene transcription as shown by qPCR.  
Together, it is shown that SHARPIN, and consequently LUBAC, are crucial mediators of 
CD40 signalling in B cells. 
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Chapter 6. Discussion 
Members of the TNF-SF are important modulators within the immune system. Their binding 
to the cognate receptors activates a complex signalling cascade. As receptors of the TNF-RSF 
do not display enzymatic activity in their cytoplasmic domains, initiation of signal 
transduction is achieved by recruiting adapter proteins and establishing receptor proximal 
protein complexes which initiate signal transduction (Aggarwal, 2003). Many proteins within 
RSCs show enzymatic activity whereas others serve as adapter proteins for the recruitment of 
these additional proteins to the complexes. Despite many studies investigating these 
complexes, the events leading to their formation and the mechanism mediating their function 
are far from understood. In this thesis, the native CD40-RSC was purified and its composition 
was analysed by mass spectrometry. To better understand the function of this signalling 
complex in vivo, the roles of HOIL-1, HOIP and SHARPIN, which were shown to be novel 
components of the CD40-RSC, were studied in detail. 
6.1 Tandem-Affinity-Purification of CD40-RSC and mass spectrometry 
The classical TAP technology was established using an overexpression vector to analyse 
protein complexes in yeast cells (Rigaut et al, 1999). In this thesis a modified approach for the 
purification of the CD40-RSC was devised. Most importantly, this modified approach does 
not rely on the overexpression of proteins within cells to perform a precipitation assay. 
Instead, the moTAP-tagged ligand can be purified in a separate cellular system, either 
eukaryotic or bacterial, and subsequently be used to stimulate different kinds of cells 
expressing the cognate receptor. The stimulated cells form a native RSC, which was also 
shown for several other members of the TNF-RSF, such as TNF, TRAIL and CD95 (Haas, 
2008) and the moTAP-tagged ligand allows the purification of the attached protein 
complexes. The tandem purification of the complex results in higher RSC purity because 
proteins binding non-specifically to beads during the first IP are eliminated after elution from 
the beads with FLAG peptide and PreScission protease. Use of this protease is another 
significant improvement of the modified tandem affinity purification as the low temperature 
optimum of the protease allows the elution to take place at 4°C, thereby favouring complex 
stability. Following a second IP step, purified RSC components can then be analysed by 
Western blotting or mass spectrometry, therefore allowing the identification of previously 
unrecognized components of these protein complexes. 
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6.1.1 Analysis of the CD40-RSC 
The CD40-RSC was initially purified under the same conditions established for the TNF-RSC 
precipitation (Haas et al, 2009). By first performing a single IP, TRAF-2, TRAF-3 and cIAP-2 
were successfully precipitated in a stimulation-dependent manner (Figure 3.10 and 3.11). 
However, using the tandem two step purification protocol, it was observed that certain 
signalling proteins dissociate from the CD40-RSC during the purification process whereas the 
ligand was present in all purification fractions (Figure 3.12). This observation supports the 
hypothesis that the CD40-RSC is not as stable as the TNF-RSC. In line with this thought, 
studies analysing TNF-R1 and TNF-R2 show that soluble TNF has a higher affinity to TNF-
R1 than to TNF-R2 and forms a more stable complex with TNF-R1 (Grell et al, 1998). In 
contrast to TNF-R1, TNF-R2 has no DD and is therefore similar to CD40 in its structure and 
signalling initiation. TNF-R2 and CD40 recruit TRAF proteins directly to specific TRAF-
binding sites within their intracellular domain. Interestingly, crystal structure analysis 
revealed that these direct interactions of TRAF2 and intracellular domains of TNF-RSF 
members are weaker than that between TRAF2 and TRADD as it occurs in the context of the 
TNF-R1 signalling complex. Although a similar surface of TRAF2 mediates the interaction 
with TRADD as well as with TRAF-binding-sites of receptors, the actual molecular surface 
enabling these interactions are entirely different (Park et al, 2000). It is therefore likely that 
stability of different RSCs differ substantially between members of the TNF-RSF, especially 
when comparing receptors with a DD to receptors without such a domain. 
Because of the potentially lower affinity of the protein-protein-interactions in the CD40-RSC, 
milder lysis conditions were chosen for the purification protocol. Indeed, the CD40-RSC was 
more stable with a milder detergent (NP-40 instead of Triton X-100) because the detected 
CD40-RSC components stayed within the complex during the purification protocol (Figure 
3.14). This modified purification protocol was used to purify the CD40-RSC from 1010 Raji 
cells and the resulting complex was analysed by mass spectrometry. This analysis revealed 
the recruitment of the known constituents of the CD40-RSC, namely CD40L, CD40, TRAF1, 
TRAF2, cIAP1, cIAP2 and ubiquitin. These proteins were found among 451 proteins, 
however, most of them can be considered as contaminants and are detected due to the high 
sensitivity of the mass spectrometric analysis. Table 7.1 in the appendix lists all proteins 
found in this analysis. Mentionable is also the finding of TRAF1 because this protein was 
described to form a constitutive complex with TRAF2 (Zheng et al, 2010) and shown to 
interact with the intracellular part of CD40 (Pullen et al, 1998) but never described in the 
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native CD40-RSC. The identification of the LUBAC components HOIL-1, HOIP and 
SHARPIN as components of the CD40-RSC and their influence on signalling events are 
experimentally discussed in this thesis. However, some other proteins found in this analysis 
might also play a role in CD40 signalling and it would be interesting to study their role in 
detail. For example, it was already described for TRIM21 to play a role in NF-κB signalling 
after Tax stimulation (Wada et al, 2009) and it might be possible that TRIM21 also plays a 
role in CD40 induced NF-kB activation. In chapter 6.1.2 a potential role for TRIM21 and 
CD45 will be discussed for CD40 signalling. 
One important player in CD40 signalling, TRAF3, was not found in the mass spectrometric 
analysis following the 2-step purification procedure. However, it could be readily detected by 
Western blot analysis after a single IP. Additional experiments are therefore needed to gain a 
more in-depth understanding of the role of TRAF3 in the formation of the CD40-RSC. A 
direct interaction of TRAF3 with CD40 was shown in vitro (Pullen et al, 1998), but surface 
plasmon resonance studies revealed a weaker interaction of TRAF3 than TRAF2 with CD40, 
possibly explaining the dissociation of TRAF3 (Pullen et al, 1999b). In contrast, Matsuzawa 
et al. suggested a central role for TRAF3 in CD40 signalling (Matsuzawa et al, 2008). This 
work describes a role for TRAF3 as a brake for the signal transduction in which TRAF3 is 
recruited to the CD40-RSC and subsequently degraded to release part of the complex into the 
cytosol. The authors of this study claim that this cytosolic complex is needed to activate 
further signal transduction such as phosphorylation of early signalling proteins.  
Interestingly, in the context of this thesis it was not possible to detect a significant release of 
proteins from CD40 or a prominent degradation of TRAF3 over time (Figure 4.2). The major 
difference between the experiments performed by Matsuzawa et al. and the ones in this thesis 
is the stimulating agent. In this thesis the biological ligand was used for the stimulation 
whereas Matsuzawa et al. used an antibody to stimulate cells. Thus, the signalling outcome 
might be qualitatively different. A possible explanation could be that upon antibody 
stimulation the intracellular RSC is released from the intracellular part of the receptor due to 
an atypical conformational change induced by the antibody. In this case, the observation by 
Matsuzawa et al. would be due to characteristics of antibody stimulation and the observation 
would not be of physiological relevance. However, another possibility is that the complex is 
released from the membrane into the cytosol but the ligand used in this thesis immediately 
induces the formation of a new RSC and the transition state of the “empty” receptor is 
therefore too short to be detected. A comparison of this thesis with the article by Matsuzawa 
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shows some differences especially in respect to the role of TRAF3 and future analysis should 
focus on the mechanism by which the early signalling molecules are recruited to the CD40-
RSC and on their contribution to complex formation and signal initiation. 
As already mentioned, TRAF3 could not be detected in the tandem purificiation with 
subsequent mass spectrometric analysis although it is present in the CD40-RSC following 
single-step purification. Therefore, it is quite likely that this also applies to other proteins 
which are recruited via low affinity interactions, e.g. the TAK/TAB-complex and the IKK-
complex, which were also not identified by mass spectrometry. In this respect, it may be 
interesting to further develop the purification method and combine it with other techniques, 
e.g. a cross-linking step before the purification protocol. The chemical fixation of the complex 
at the beginning of the stimulation may conserve its formation and protein interactions to 
allow the detection of loosely attached proteins. However, it has to be considered that the 
cross-linker may interfere with the moTAP-procedure as it may prohibit the release by 
protease cleavage and thereby impair realease of the complex after the first 
immunoprecipitation. 
6.1.2 Components of potential interest from the mass spectrometric analysis 
The mass spectrometric analysis of the CD40-RSC revealed a variety of possible new RSC 
components beside the contaminants, such as keratin or mitochondrial proteins which are not 
present in the cytosol of healthy cells. Proteins with a potential role in CD40 signalling are 
such which were already described to play a role in signal activation of receptors with 
overlapping signal pathways compared to CD40. TRIM21 and CD45 were picked of the list 
of proteins not considered to be contaminants and discussed in detail. 
The E3 ubiquitin-protein ligase TRIM21 (also refered to Ro52) belongs to the TRIM 
superfamily which consists of over 60 proteins. Members of this family play functional roles 
in anti-bacterial and anti-viral immune responses. TRIM proteins were shown to regulate IRF 
and NF-κB pathways and this might be a connection to CD40 signalling. TRIM25’s ability to 
ubiquitinate and subsequently activate the CARD domain in RIG-I activates NF-κB and 
induces IFN type I production (Gack et al, 2007). The degradation of TAB2 and TAB3 by 
TRIM30, on the other hand, inhibits TRAF6 and inactivates NF-κB (Shi et al, 2008). 
TRIM21 was shown to interact with Calreticulin as well as the chaperone Grp78 (Cheng et al, 
1996; Purcell et al, 2003). An explanation for the importance of the discovered interaction, 
however, is still missing. In 2006, Waba and Katamani found a ubiquitin ligase activity for 
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TRIM21 based in its RING domain. Cellular overexpression of TRIM21 led to 
autoubiquitination but treatment with the proteasome inhibitor MG132 did not stabilise the 
protein (Wada & Kamitani, 2006). A yeast two hybrid screen revealed an interaction with 
IgG1 and a role for TRIM21 was proposed for quality control during production of 
immunoglobulins via the ERAD system, but the study lacks any data for this hypothesis under 
physiological conditions (Takahata et al, 2008). Later on, it was described that TRIM21 is a 
negative regulator of IKKβ (Wada et al, 2009). This observation is further supported by the 
study of a TRIM21 knockout mouse which demonstrated a role as an important negative 
regulator for proinflammatory cytokine production (Espinosa et al, 2009). In this respect it 
would be interesting to investigate the effect of TRIM21 ablation on CD40 induced NF-κB 
signalling and cytokine production.  
Another protein with a potential role in CD40L-meditated signalling events is the receptor-
type tyrosine protein phosphatase (CD45) which is a leukocyte specific glycoprotein that was 
first identified in the late 1960s and 1970s using antisera and monoclonal antibodies 
(Saunders & Johnson, 2009). It was found that the large cytoplasmic domain has similarities 
with a phosphatase domain (Charbonneau et al, 1988) and subsequently a role was established 
as a receptor-like protein tyrosine phosphatase (Tonks et al, 1988). It was also shown to be 
required for antigen-induced T cell proliferation (Pingel & Thomas, 1989). Soon afterwards, 
the Src family kinases Lck and Lyn were identified as substrates for CD45 in T cells and 
B cells respectively (Katagiri et al, 1995; Mustelin et al, 1989; Ostergaard et al, 1989). Studies 
in CD45-deficient mice established the importance of CD45 in TCR and BCR signalling in 
vivo and identified a role for CD45 in T and B cell development (Alexander, 2000; 
Huntington & Tarlinton, 2004). The Janus kinases (JAKs) were identified as potential CD45 
substrates (Irie-Sasaki et al, 2001) and CD45 was also shown to be involved in cytokine 
signalling as well as NK receptor and TLR signalling. 
A group of researchers led by Rajiv S. Geha observed a role for the protein tyrosine kinase 
Lyn in CD40 signal transduction (Ren et al, 1994). Studies from the same group three years 
later showed a direct activation of JAK3 by CD40 and a stimulation-independent interaction 
between the two molecules (Hanissian & Geha, 1997). These results indicate that a protein 
tyrosine phosphatase may also play a role in CD40L-induced signalling pathways to regulate 
the signalling outcome. The fact that CD45 knockout mice do not show any defects in class 
switching (Kong et al, 1995) could be due to the fact that phosphotyrosine signalling upon 
CD40 stimulation is important for other biological outcomes such as expression of surface 
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molecules or cytokines. This was not investigated in more detail in the study published by 
Kong and colleagues. One way to address this question would be to stimulate B cells from 
CD45-deficient mice with CD40L and check for alterations in JAK3 phosphorylation and 
expression of surface molecules. Prolonged phosphorylation of JAK3 and enhanced 
expression of surface molecules would suggest a role for CD45 as a negative regulator in 
these signalling events.  
6.2 LUBAC recruitment to the CD40-RSC 
The CD40-RSC forms within minutes following binding of CD40L to its receptor. This 
membrane-spanning protein complex consists of a variety of proteins. Among these, TRAF 
proteins were shown to play a predominant role for CD40-induced NF-κB and JNK 
activation. However, the events leading to the activation of signal transduction after binding 
of the ligand are not completely understood. Using recombinant proteins, it was shown that 
TRAF proteins can bind directly to the intracellular domain of CD40 (Pullen et al, 1998). It is 
therefore likely that TRAF proteins comprise the first layer of proteins recruited to the CD40 
signalling complex. Until recently, there was no further proof of another layer of proteins 
binding to TRAF proteins. However, Matsuzawa et al. and data from this thesis showed that 
cIAPs are recruited to the native CD40-RSC (Matsuzawa et al, 2008). Interestingly, it was 
also shown in overexpression studies that TRAF2 and cIAPs can directly interact with each 
other (Vince et al, 2009). Vince et al. also observed that cIAPs are not recruited to the TNF-
RSC when TRAF2 is missing. This is confirmed in this thesis as TRAF proteins are still 
recruited to the CD40-RSC in the absence of cIAPs. This supports a model for the CD40-RSC 
in which cIAPs are recruited as a second layer after direct binding of TRAF proteins to CD40 
(Figure 6.1). After cIAP molecules are recruited to the CD40-RSC, they become highly 
ubiquitinated, which can be best observed for cIAP2 (Figure 4.8). Although it was shown 
already by Gallagher et al. and Matsuzawa et al. that ubiquitinated proteins exist within the 
CD40-RSC both studies do not clarify which proteins are modified (Gallagher et al, 2007; 
Matsuzawa et al, 2008). Therefore, the results presented here are the first evidence for highly 
modified cIAP2 within the CD40-RSC.  
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Figure 6.1: Schematic model of CD40 signalling. 
After CD40 crosslinking by CD40L TRAF molecules are recruited to the intracellular 
part of the receptor. This results in further recruitment of cIAPs which can directly bind 
to TRAF2. cIAP molecules autoubiquitinate [1] and ubiquitinate other RSC components 
including TRAF molecules, thereby providing a ubiquitin network which can be used as 
a recruiting platform for protein complexes, e.g. LUBAC and the IKK complex. 
Recruitment of LUBAC probably facilitates linear ubiquitination of proteins like NEMO 
[2] and ubiquitin chains already attached to proteins. Thereby it activates downstream 
signalling like NF-κB and MAPK signalling [3-5]. 
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Besides cIAP1/2, TRAF2 is also suggested to be ubiquitinated as shown by a pulldown of 
TRAF2 after CD40 stimulation (Matsuzawa et al, 2008). However, these data did not exclude 
that additional proteins binding to TRAF2 were responsible for the signal obtained by the 
ubiquitin antibody on Western blot level and actually not TRAF2. In this specific case the 
authors must control that no other proteins are attached to TRAF2 during the 
immunoprecipitation to claim that TRAF2 is modified with ubiquitin chains. However, 
Western blot analyses in this thesis showed a modification for TRAF2 (Figure 4.2 and 4.8) 
with a TRAF2-specific antibody, although it is not as prominent as for cIAP2. Additionally, 
TRAF2 peptides were found by mass spectrometry in samples of higher molecular weights 
than would be expected for TRAF2, thereby supporting that TRAF2 is indeed modified. 
Taken together, the currently available results support the notion that TRAF2 resides as a 
ubiquitiniated protein in the CD40-RSC.  
So far it remains elusive which ubiquitin ligase generates the ubiquitin chains present in the 
CD40-RSC and it is not known of which linkage type they are. However, Vince et al. showed 
for the TNF-RSC that the ubiquitin ligase function of TRAF2 is not necessary for the 
activation of TNF-induced signalling events. In fact, a recent crystal structure analysis 
provided evidence that TRAF2 is in fact unable to act as an E3 ubiquitin ligase because 
TRAF2 cannot interact with Ubc13 and related E2s (Yin et al, 2009). However, a study by 
Alvarez et al. suggested that TRAF2 would need sphingosine-1-phosphate (S1P) as a cofactor 
for its function as a ubiquitin ligase (Alvarez et al, 2010). This observation is in contrast to 
results obtained by Yin et al. who did not consider S1P. S1P is supposed to induce a 
conformational change within TRAF2 making an interaction with an E2 possible. However, 
the interaction was not convincingly shown as point mutations in TRAF2 that should abrogate 
S1P interaction were not made. Since Ubc13 was described to be recruited to the CD40-RSC 
(Matsuzawa et al, 2008), this E2 is therefore likely to interact with one of the E3s and 
responsible for ubiquitination. However, future studies have to clarify which ubiquitin ligase 
is responsible for the modification of different target proteins in the CD40-RSC.  
 
The composition of the ubiquitination pattern within the CD40-RSC is of great interest 
because the ubiquitin chains of TRAF2 and cIAPs are most likely an important binding 
platform for several other proteins. By using a K63-specific antibody, Matsuzawa et al. 
showed that this chain type is present in a complex containing TRAF2. However, it is still 
unclear which protein is modified with this chain type. In this thesis it was shown that 
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SHARPIN, HOIL-1 and HOIP bind to the CD40-RSC in a cIAP-dependent manner. 
Furthermore, HOIL-1 and HOIP could only be precipitated with cIAP2 when cIAP’s ubiquitin 
ligase-domain was functional. Disruption of cIAP2 ligase activity by a point mutation in its 
RING domain abrogated autoubiquitination and as a result interaction with HOIL-1 and 
HOIP. The interaction of HOIL-1 and HOIP with ubiquitin was also shown in a ubiquitin 
pulldown experiment. Additionally, it was shown that SHARPIN, HOIP and HOIL-1 are able 
to bind recombinant ubiquitin chains, preferentially K63- and M1-linked over K48-linked 
ubiquitin chains (Gerlach et al, 2011; Haas et al, 2009). However, we and others have also 
shown that K11 chains can be found in the TNF-RSC (Dynek et al, 2010; Gerlach et al, 2011) 
and this chain type can probably also be found in the CD40-RSC. Furthermore, it cannot be 
excluded that other ubiquitin chain types play an important role in CD40 signalling as well. 
Since LUBAC binding to these other chain types was not investigated yet, it remains elusive 
which chain type is required for LUBAC recruitment to the CD40-RSC. In summary, this set 
of data leads to the assumption that LUBAC is recruited via ubiquitin chains to the CD40-
RSC which are generated by cIAPs and most likely also attached to these proteins.  
SHARPIN, HOIP and HOIL-1 form a stimulation-independent cytosolic complex as they are 
co-eluted from a Sepharose column at higher molecular orders using whole cell lysates 
(Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 2011). This supports a role for a 
tripartite complex and it is most likely that all LUBAC components are recruited together as a 
single unit. Interestingly, when HOIL-1 is absent, HOIP and SHARPIN are still recruited to 
the CD40-RSC (Figure 4.12) and to the TNF-RSC (Gerlach et al, 2011). Therefore, HOIL-1 is 
not the decisive component recruiting the trimeric complex. Consistently, HOIP knockdown 
led to a strong decrease in recruitment of SHARPIN and HOIL-1, whereas in the absence of 
SHARPIN, HOIL-1 and HOIP are still recruited to the TNF-RSC (Gerlach et al, 2011). The 
same recruiting mechanism can be proposed for the CD40-RSC since this is a receptor-distal 
event and the intracellular domains of TNF-R1 or CD40 are not directly involved in the 
LUBAC recruitment process.  
6.3 Role of LUBAC in CD40 signalling 
The combinations of SHARPIN/HOIP (LUBACSH+HP), HOIL-1/HOIP (LUBACHL+HP) and 
SHARPIN/HOIP/HOIL-1 (LUBACSH+HP+HL) form different LUBAC complexes and are all 
able to produce M1-linked ubiquitin chains (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga 
et al, 2011). By knockdown or ablation of HOIL-1 or SHARPIN respectively, it was possible 
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to show that these complexes play a role in CD40 signalling. HOIL-1 knockdown 
experiments showed a decrease in canonical NF-κB activation in human B lymphoma cell 
lines. Additionally, MAPK signalling was also diminished in these cells as shown by 
decreased phosphorylation of JNK and p38. Although HOIL-1 was described to act as an E3 
on its own (Yamanaka et al, 2003), it has become clear that the enzymatic activity of LUBAC 
resides in HOIP. These observations described above therefore suggest a role for 
LUBACHL+HP and LUBACSH+HP+HL respectively in CD40 signalling. In addition, primary B 
cells derived from cpdm mice showed reduced activation of NF-κB and MAPK signalling 
upon CD40 stimulation. Cpdm B cells also showed decreased induction of CD40-induced 
genes, reduced proliferation and isotype switching to IgG1 in vitro. Hereby, it was shown that 
loss of SHARPIN has an effect on signalling activation and this is again most likely due to a 
dysfunctional LUBACSH+HP or LUBACSH+HP+HL.  
In contrast to an effect on signalling of canonical NF-κB and MAPK pathways, cpdm B cells 
did not show a significant alteration on non-canonical NF-κB signalling as demonstrated in 
this thesis. This was surprising considering that mice with defects in non-canonical signalling 
show similar phenotypes to cpdm mice. The IKKα, NFκB2 and LTβ knockout mice for 
example all show a lack of Peyer’s patches, defects in B cell maturation and failure to form 
germinal centres (Futterer et al, 1998; Paxian et al, 2002; Senftleben et al, 2001). Western blot 
analysis of p100 levels in cpdm cells showed a decreased expression of p100 in unstimulated 
cells whereas p52 levels seem to be similar to those observed in control cells (Figure 5.3). 
Interestingly, p100 degradation upon CD40L stimulation seems to be similar in wt and cpdm 
derived B cells in spite of different basal levels. This points towards a minor role for LUBAC 
in the non-canonical NF-κB pathway, at least when triggered by CD40 stimulation. The p100 
gene is a target of the canonical NF-κB pathway and the difference in expression levels might 
be due to decreased basal levels of canonical NF-κB signalling. This change of basic p100 
expression levels might also be a reason for the immunological phenotype: the cytoplasmic 
pool of p100 is decreased in cpdm-derived cells and therefore less protein is available for 
signalling events. Therefore, the overall non-canonical NF-κB signalling outcome in cpdm 
cells cannot reach the same level as in wt cells, although the activation itself is not altered by 
loss of LUBAC components. Therefore, cpdm mice cannot initiate as much non-canonical 
NF-κB signalling as they would need for developing a normal immunological phenotype but 
exhibit a phenotype similar to the one of mice with direct defects in non-canonical NF-κB 
signalling.  
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The different LUBAC complexes are to date the only known E3 ligase described with the 
specific activity of forming M1-linked ubiquitin chains. Tokunaga and colleagues showed that 
NEMO binds to and is ubiquitinated by LUBACHL+HP in vitro (Tokunaga et al, 2009). We and 
others were able to show that NEMO is linearly ubiquitinated by all three different 
combinations of LUBAC in vitro (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al, 
2011). Additionally, we analysed the tandem-purified and fluorescently labeled components 
of the TNF-RSC on 2D gels with subsequent fluorescence-guided robotic spot picking and 
tryptic digestion followed by multiple reaction monitoring (MRM) mass spectrometry. This 
highly sensitive technique revealed that not only NEMO, but also RIP1, is modified with M1-
linked ubiquitin. This finding represents the first in-vivo proof for linear ubiquitin chains 
being involved in ligand-induced signal transduction events. 
The peptides for NEMO and M1-linked ubiquitin in the MRM mass spectrometry were found 
in a spot with a molecular size corresponding to one NEMO molecule and two ubiquitin 
molecules suggesting that a linearly linked diubiquitin is attached directly to NEMO (Gerlach 
et al, 2011). NEMO has been implicated in CD40 signalling (Jain et al, 2004) and it has been 
described to be recruited to the CD40-RSC (Matsuzawa et al, 2008). Thus, it seems quite 
likely that NEMO is also linearly ubiquitinated by LUBAC during CD40 signalling. 
Additionally, humans with mutations in NEMO have defective isotype switching, an 
observation that is also reported in mice with defective SHARPIN (HogenEsch et al, 1999). 
Taken together, these findings support a role for linear ubiquitination of NEMO in CD40 
signalling. This reduced modification of NEMO could quite likely result in the observed 
reduction of NF-κB activation in HOIL-1 knockdown cells and cpdm-derived B cells. 
However, the MRM-approach combined with moTAP for the CD40-RSC will be necessary to 
investigate and get a better understanding of the ubiquitin network in the CD40-RSC. 
RIP1 and ubiquitin peptides with four different linkage types were found in a 2D gel spot with 
high molecular weights upon TNF-RSC precipitation, indicating that RIP1 is modified with 
several ubiquitin molecules. From this set of data it is not possible to determine whether RIP1 
is a direct target of LUBAC or whether LUBAC targeted preexisting ubiquitin chains. This is 
a possibility since the different LUBAC versions are able to form linear ubiquitin chains 
independently of any target protein by using mono-ubiquitin as a substrate, at least in vitro 
(Gerlach et al, 2011). RIP1 does not form part of the CD40-RSC as shown in this thesis 
(Figure 3.10). However, a strong modification of cIAP2 was observed. Therefore, cIAP2 
might be modified with linear ubiquitin chains in the CD40-RSC, similar to RIP1 in the TNF-
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RSC. However, an in-vitro ubiquitination assay suggests that, at least in vitro, cIAP2 is not a 
direct target of LUBAC (Gerlach et al, 2011). However, it is possible that LUBAC attaches 
M1-linked ubiquitin only to pre-existing ubiquitin molecules on certain proteins meaning that 
a target protein must be modified with other ubiquitin molecules, or indeed non-linear 
ubiquitin chains, before LUBAC can attach M1-linked ubiquitin chains. Alternatively, the 
composition and activation status of different components of the CD40-RSC may not be 
adequately represented in an in-vitro assay that addresses LUBAC activity on cIAPs. 
Therefore, further experiments are needed to clarify whether cIAPs are LUBAC targets. 
A possible choronology of events after binding of CD40L to CD40 could be the recruitment 
of TRAF proteins which are subsequently able to recruit cIAPs (Figure 6.1). cIAPs become 
autoubiquitinated thereby facilitating a recruitment of LUBAC and most likely the IKK and 
TAB/TAK complexes. LUBAC is activated and modifies NEMO with linear ubiquitin chains. 
Since NEMO was shown to specifically bind to linear ubiquitin chains, its modification with 
linear ubiquitin chains might result in enhanced recruitment and activation of the IKK 
complex. This enables canonical NF-κB signalling. Probably, LUBAC activity also directly or 
indirectly affects recruitment and activity of other proteins, such as TAB/TAK-complex and 
MEKK1, resulting in activation of MAPK signalling pathways.  
Beside the function of recruiting signalling components, linear ubiquitin chains probably also 
stabilise the CD40-RSC as it was already shown for the TNF-RSC (Haas et al, 2009). The 
linear ubiquitin chain might protect the ubiquitin network from degradation by DUBs. In this 
respect it is also interesting to determine which factors are responsible for the disassembly of 
the different ubiquitin chains. So far, two DUBs were described to play a role in CD40 
signalling, A20 and CYLD. Both proteins were shown to be important negative regulators of 
canonical NF-κB signalling upon CD40L stimulation (Chen, 2005). It will be interesting to 
determine whether these are the only two negative regulators for CD40 signalling or whether 
other DUBs may also play a role in signalling events triggered by CD40L. CYLD is of special 
interest because it is the only known DUB which prefers to cleave linear ubiquitin chains over 
K48- and K63-linked ubiquitin chain types (Komander et al, 2009b). A role for CYLD was 
described in CD40 signalling in an overexpression system (Trompouki et al, 2003). CYLD 
ablation led to increased NF-κB activation after CD40 overexpression in HEK293 cells. These 
results are in line with a signal-promoting role of linear ubiquitin for CD40 signalling as 
shown in this thesis for NF-κB and MAPK signalling. 
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6.4 Outlook to study the role of LUBAC in CD40 signalling 
This thesis presented new aspects of CD40 signalling as it provides evidence for the 
recruitment and functional importance of the E3 ubiquitin ligase LUBAC for in CD40 
signalling. However, more work will be needed to unravel all aspects of this signalling 
pathway, beginning from the composition of the CD40-RSC and the attachment of ubiquitin 
molecules in general but also especially concerning the enzymatic function of LUBAC and 
M1-linked ubiquitin chains in this protein complex. 
So far, direct proof for the existence of linearly linked ubiquitin chains in the CD40-RSC is 
missing. To investigate this, the established moTAP-2D-MRM approach should be applied to 
the CD40-RSC. As for the TNF-RSC, different spots on the 2D gel could be analysed and 
traced for M1-linked and other ubiquitin chain types. Once established, follow-up 
experiments should compare the ubiquitin pattern in different B cells deficient for LUBAC 
components. Since HOIP is the functionally important component in all three different 
LUBAC combinations (Gerlach et al, 2011), cells with HOIP ablation might be the best 
system to identify a difference in the linear ubiquitination pattern. These cells should also 
have the greatest decrease in signal transduction efficiency since the active component of 
LUBAC is missing. Cells with SHARPIN ablation still contain LUBACHL+HP which might be 
able to produce enough linear ubiquitin chains to trigger certain signalling events. This can 
actually be seen in cpdm B cells and in HOIL-1 knock down B cell lines which still show 
partial signalling events. This might be due to the residual LUBAC, i.e. LUBACSH+HP in 
HOIL-1 knockdown cells and LUBACHL+HP in cpdm B cells respectively. However, it is also 
possible that signalling events occur without linear ubiquitin chains but cannot reach full 
activation levels compared with wt cells. 
Cpdm mice played an important role in these investigations so far, as they have abnormalities 
in the development and architecture of lymphoid organs, where members of the TNF-RSF 
were shown to play a key role (HogenEsch et al, 1999). However, in these mice it is not 
possible to trace which cells and which signals are responsible for the defect in organ 
development. Therefore, cell- and tissue- specific knockout mice for different LUBAC 
components are needed to answer these questions. Conditional knockouts in T cells, B cells, 
macrophages and DCs seem to be good candidates to determine in which cells LUBAC 
components are important for the development of a functional immune system and response. 
T cells for example provide essential help for B cells in GC formation (Elgueta et al, 2009), a 
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process for which the importance of CD40-CD40L interaction was established more than a 
decade ago (Han et al, 1995).  
As mentioned above, it will also be important to investigate the ubiquitination pattern in 
signalling complexes and the role of different ubiquitin chain types. Ubiquitin chains attached 
to components of the signalling complex play an important role for the recruitment of proteins 
and it is now clear that different binding affinities for the different chain types exist. However, 
we are only beginning to understand how this complex network functions since it is not yet 
known whether other ubiquitin chains are also involved in signalling or other processes within 
cells. Future studies should focus on the biochemistry of these ubiquitin chain-protein 
interactions and on the identification of affinity constants for different chain types and 
proteins. The challenge will be to describe a biological role for these different ubiquitin chains 
in vivo and to show their specific effects on immune responses. In detail, a mouse strain with 
ablated ubiquitin in B cells and expressing mutated ubiquitin, e.g. K63 mutated to R63, would 
make it possible to investigate the exact role of this chain type for B cell biology in vivo. To 
create such a system, all four ubiquitin genes would have to be ablated and a variant of 
ubiquitin re-expressed. However, it was already shown that solely deficiency in the Ubc gene 
is lethal and knockout of the Ubb gene causes adult-onset obesity (Ryu et al, 2007; Ryu et al, 
2008). Thus, mice must be crossed to get an inducible knockout system in all four ubiquitin 
genes. However, these mice must be transgenic for ubiquitin variants and still express the 
ribosomal subunits which are fused to the ubiquitin genes. Hence, this would be a complex 
and challenging undertaking but it would allow valuable insights. 
Once the knockout mice for LUBAC components are generated and investigated for their 
phenotype, it will be invaluable to apply these mice to disease models involving CD40 
signalling to determine the role of LUBAC disease progression. Two such models are 
collagen-induced arthritis (CIA) and pneumonia. 
CIA is a well established model for the human disease rheumatoid arthritis. Although the 
primary cause of the human disease initiation is not known yet, it was shown that disease 
onset involves a wide variety of immune cells, such as T cells and B cells but also 
macrophages (Bugatti et al, 2007; Fournier, 2005). It was shown that deletion of B cells and 
anti-TNF treatment had positive effects on rheumatoid arthritis patients. Progression of CIA 
could be blocked by administration of IL-1- and TNF-blockers, and also by anti-CD40L 
antibodies (Durie et al, 1993). This observation proves that these cytokines play crucial roles 
in disease progression, although their functions involve different cell types. As we recently 
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established a role for LUBAC in these three pathways, these findings suggest a role for linear 
ubiquitin during CIA development. It will therefore be interesting to study the role for 
LUBAC components in this system. The disease progression can be investigated from 
different angles by using mice lacking LUBAC components in different cell types, like B cells 
and T cells. This would allow for dissecting the individual role of LUBAC in different cell 
types and thereby also discriminating the importance in innate and adaptive immunity. Since 
CD40 is mainly expressed on B cells, a knockout in B cells should result in slower disease 
progression than in wt mice, assuming that these mice do not show a strong phenotype 
without any immune stimulation per se. The immune response of the different mouse strains 
can be evaluated by swelling of the paws, production of specific antibodies and by T cell 
responses (Rosloniec et al, 2001).  
CD40- and CD40L-deficiency was also correlated with a higher susceptibility to several 
pathogens in mice, including Pneumocystis, Trypanosoma, Leishmania and Listeria 
(Schonbeck & Libby, 2001; Wiley & Harmsen, 1995). Additionally, patients suffering from 
the HIGM syndrome are more prone to the fungal pathogen Pneumocystis jirovecii which 
causes pneumocystic pneumonia (Grewal et al, 1997; Milledge et al, 2003). This observation 
suggests that the higher susceptibility of these patients to the infection is due to limited high 
affinity antibody production. SCID mice reinjected with lymphocytes were no longer 
sensitive to Pneumocystis carinii pneumonia, however it was possible to restore disease 
progression by application of anti-CD40L antibodies. However, if SCID mice were supplied 
only with CD4+ T cells, they were protected against infection but could still be sensitised with 
anti-CD40L antibodies. These data supported an important role for CD40 on cells of the 
native immune system which are stimulated by the help from the CD4+ T cells. The cells 
stimulated with CD40L are probably DCs. If this model is applied to mice deficient in various 
LUBAC components, LUBAC-deficiency in B cells would lead to a milder disease 
progression as ablation in DC. Hence, CD40 seems to have a more pronounced role in DCs 
for the protection against this disease.  
In summary these disease models may prove to be useful in gaining a better understanding of 
the role of LUBAC in different aspects of immunity. Thereby, these models may help in 
unravelling this aspect of the biology and physiological importance of LUBAC and its 
product, linearly linked ubiquitin chains. 
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6.5 Summary 
Activation of signal transduction by TNF-RSF members often involves multiple protein 
signalling cascades resulting in activation of different transcription factors. In this thesis a 
modified tandem-affinity purification protocol was applied to the CD40-RSC isolated from B 
cells. The mass spectrometric analysis identified HOIL-1, HOIP and SHARPIN as novel 
components of the CD40-RSC. These three proteins form the LUBAC complex which is able 
to synthesise linear ubiquitin chains. The mechanism for the recruitment to the CD40-RSC is 
discussed and occurs via ubiquitin chains attached to cIAPs. Furthermore, a signalling 
promoting role for LUBAC is shown in HOIL-1 knockdown and SHARPIN deficient cells as 
CD40-induced activation of canonical NF-κB and MAPK signalling is decreased. 
Interestingly, a different signalling pathway not so commonly activated by TNF-RSF 
members, non-canonical NF-κB signalling, is not significantly influenced by this protein 
complex. The impact of LUBAC and linear ubiquitin chains on CD40 signalling is discussed 
in detail. It is suggested that linear ubiquitination within the CD40-RSC is needed for receptor 
complex stability and recruitment of signalling proteins, such as the IKK/NEMO complex. To 
further investigate the role of LUBAC on the immune system, different knockout, knockin 
and experimental disease models are described. 
In summary, this thesis adds important details to the current knowledge of CD40 signalling 
but also raises interesting questions, such as the identity of the targets of LUBAC in the 
CD40-RSC, the ubiquitin chain types that are important for CD40 signalling and the specific 
roles of both the ubiquitin chain types and LUBAC in signalling and regulation of the immune 
response. 
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Chapter 7. Appendix 
7.1 Mass spectrometric analysis of the CD40-RSC 
Table 7.1: Complete list of proteins found in the mass spectrometric analysis. 
Proteins from different slices were combined and reduced to one entry although it was found in 
different slices. Highest proteinscore of the different entries was used for the order of the table.  
Light grey fields: proteins which were most likely contaminants; dark Grey fields: proteins which were 
known to be constituents of the CD40-RSC or discussed in this thesis. 
 Acc. Nr. Protein Description Protein 
score 
Protein 
Mass 
matches 
1 gi|31621305 leucine-rich PPR motif-containing protein 
precursor [Homo sapiens] 
3848 159003 85 
2 gi|11935049 keratin 1 [Homo sapiens] 3062 66198 131 
3 gi|339880 tripeptidyl peptidase II [Homo sapiens] 2787 139844 71 
4 gi|114644568 PREDICTED: keratin 6A [Pan troglodytes] 2593 60266 80 
5 gi|4557701 keratin 17 [Homo sapiens] 2427 48361 91 
6 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 2421 66110 60 
7 gi|47132620 keratin 2 [Homo sapiens] 2230 65678 61 
8 gi|21961605 Keratin 10 [Homo sapiens] 2123 59020 67 
9 gi|862457 enoyl-CoA hydratase/3-hydroxyacyl-CoA 
dehydrogenase alpha-subunit of trifunctional 
protein [Homo sapiens] 
1904 83648 75 
10 gi|1195531 type I keratin 16 [Homo sapiens] 1830 51548 55 
11 gi|119617035 keratin 6E, isoform CRA_b [Homo sapiens] 1653 60144 47 
12 gi|1147813 desmoplakin I [Homo sapiens] 1492 334023 41 
13 gi|16507237 heat shock 70kDa protein 5 [Homo sapiens] 1475 72402 37 
14 gi|14670350 general transcription factor IIi isoform 1 [Homo 
sapiens] 
1378 112859 32 
15 gi|12667788 myosin, heavy polypeptide 9, non-muscle [Homo 
sapiens] 
1304 227646 21 
16 gi|119581149 keratin 14 (epidermolysis bullosa simplex, 
Dowling-Meara, Koebner), isoform CRA_a 
[Homo sapiens] 
1295 30075 47 
17 gi|32567786 keratin 6L [Homo sapiens] 1291 58085 34 
18 gi|435476 cytokeratin 9 [Homo sapiens] 1280 62320 30 
19 gi|31542947 chaperonin [Homo sapiens] 1279 61187 27 
20 gi|14994115 SSA1 [Homo sapiens] 1174 55261 44 
21 gi|307086 keratin-10 [Homo sapiens] 1152 46473 40 
22 gi|862457 enoyl-CoA hydratase/3-hydroxyacyl-CoA 
dehydrogenase alpha-subunit of trifunctional 
protein [Homo sapiens] 
1137 83648 25 
23 gi|1903220 type II intermediate filament of hair keratin 
[Homo sapiens] 
1135 54756 27 
24 gi|20127551 transient receptor potential cation channel, 
subfamily V, member 2 [Homo sapiens] 
1095 86838 24 
25 gi|84040267 Keratin 6C [Homo sapiens] 1082 60245 24 
26 gi|239552 squamous cell carcinoma antigen [Homo 
sapiens] 
1074 44564 31 
27 gi|33317676 SCCA2/SCCA1 fusion protein isoform 1 [Homo 
sapiens] 
1052 44677 27 
28 gi|2146957 Ig heavy chain V region precursor - human 1019 42327 310 
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29 gi|254574800 Chain A, Human 1gg1 Fc Fragment, 2.5 
Angstrom Structure 
1003 24189 278 
30 gi|28592 serum albumin [Homo sapiens] 1000 71316 23 
31 gi|4504935 keratin 85 [Homo sapiens] 959 57306 24 
32 gi|229601 Ig G1 H Nie 957 49801 288 
33 gi|1870688 Bruton~s tyrosine kinase-associated protein-135 
[Homo sapiens] 
949 108325 23 
34 gi|48762932 chaperonin containing TCP1, subunit 8 (theta) 
[Homo sapiens] 
947 60153 17 
35 gi|862457 enoyl-CoA hydratase/3-hydroxyacyl-CoA 
dehydrogenase alpha-subunit of trifunctional 
protein [Homo sapiens] 
924 83648 19 
36 gi|292059 MTHSP75 [Homo sapiens] 909 74019 18 
37 gi|4504811 junction plakoglobin [Homo sapiens] 898 82434 21 
38 gi|19717684 immunoglobulin gamma-1 heavy chain constant 
region [Homo sapiens] 
892 24609 257 
39 gi|5453603 chaperonin containing TCP1, subunit 2 [Homo 
sapiens] 
880 57794 21 
40 gi|146387531 Chain A, Crystal Structure Of An Autoimmune 
Complex Between A Human Igm Rheumatoid 
Factor And Igg1 Fc Reveals A Novel Fc Epitope 
And Evidence For Affinity Maturation 
864 26489 227 
41 gi|5729877 heat shock 70kDa protein 8 isoform 1 [Homo 
sapiens] 
827 71082 20 
42 gi|254574798 Chain A, Enzyme Deglycosylated Human Igg1 
Fc Fragment 
796 24190 120 
43 gi|166007160 Chain C, Solution Structure Of Human 
Immunoglobulin M 
795 57294 30 
44 gi|55956899 keratin 9 [Homo sapiens] 789 62255 19 
45 gi|15825647 Chain H, Crystal Structure Of The Intact Human 
Igg B12 With Broad And Potent Activity Against 
Primary Hiv-1 Isolates: A Template For Hiv 
Vaccine Design 
758 51012 29 
46 gi|220702506 Chain A, TapasinERP57 HETERODIMER 749 54541 15 
47 gi|4504327 mitochondrial trifunctional protein, beta subunit 
precursor [Homo sapiens] 
746 51547 17 
48 gi|4501885 beta actin [Homo sapiens] 742 42052 21 
49 gi|10334611 immunoglobulin heavy chain [Homo sapiens] 713 40580 160 
50 gi|272982598 anti-HIV-1 gp120 immunoglobulin heavy chain 
[Homo sapiens] 
706 52459 104 
51 gi|2950208 hair keratin acidic 3-II [Homo sapiens] 698 42453 16 
52 gi|4507581 CD40 antigen isoform 1 precursor [Homo 
sapiens] 
686 31910 40 
53 gi|22027612 TNF receptor-associated factor 2 [Homo 
sapiens] 
679 57590 19 
54 gi|908801 keratin type II [Homo sapiens] 678 60448 15 
55 gi|38455427 chaperonin containing TCP1, subunit 4 (delta) 
[Homo sapiens] 
674 58401 17 
56 gi|119581133 keratin, hair, acidic, 4 [Homo sapiens] 670 50837 14 
57 gi|230581 Chain H, Dir Primaerstruktur Des 
Kristallisierbaren Monoklonalen 
Immunoglobulins Igg1 Kol. Ii. 
Aminosaeuresequenz Der L- Kette, Lambda-
Typ, Subgruppe I (German) 
667 50444 41 
58 gi|109150431 ring finger protein 31 [Homo sapiens] 665 122654 13 
59 gi|2950168 type I keratin [Homo sapiens] 665 48628 16 
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60 gi|229905 Chain A, Crystallographic Refinement And 
Atomic Models Of A Human Fc Fragment And 
Its Complex With Fragment B Of Protein A From 
Staphylococcus Aureus At 2.9-And 2.8-
Angstroms Resolution 
632 25532 52 
61 gi|115270970 Mid-1-related chloride channel 1 isoform 1 
[Homo sapiens] 
615 62667 15 
62 gi|20070220 protein arginine methyltransferase 5 isoform a 
[Homo sapiens] 
611 73322 18 
63 gi|55743096 collagen, type XIV, alpha 1 precursor [Homo 
sapiens] 
601 194478 13 
64 gi|1160963 transmembrane protein [Homo sapiens] 599 84015 14 
65 gi|75677353 AAA-ATPase  TOB3 [Homo sapiens] 596 73098 17 
66 gi|4502643 chaperonin containing TCP1, subunit 6A isoform 
a [Homo sapiens] 
591 58444 13 
67 gi|4506773 S100 calcium-binding protein A9 [Homo 
sapiens] 
578 13291 21 
68 gi|386834 involucrin [Homo sapiens] 577 68541 12 
69 gi|5031875 lamin A/C isoform 2 [Homo sapiens] 577 65153 11 
70 gi|67464043 Chain O, Crsytal Structure Of Human Liver 
Gapdh 
574 36483 10 
71 gi|36796 t-complex polypeptide 1 [Homo sapiens] 571 60869 14 
72 gi|5453607 chaperonin containing TCP1, subunit 7 isoform 
a [Homo sapiens] 
565 59842 12 
73 gi|975273 tumor necrosis factor type 2 receptor associated 
protein 3 [Homo sapiens] 
561 57696 13 
74 gi|18999435 Keratin 5 [Homo sapiens] 556 62568 15 
75 gi|35360 PDC-E2 precursor (AA -54 to 561) [Homo 
sapiens] 
554 65806 13 
76 gi|119617032 keratin 6B, isoform CRA_a [Homo sapiens] 543 60159 19 
77 gi|4505775 solute carrier family 25 member 3 isoform b 
precursor [Homo sapiens] 
541 40389 19 
78 gi|494066 Chain A, Three-Dimensional Structure Of Class 
Pi Glutathione S- Transferase From Human 
Placenta In Complex With S- Hexylglutathione 
At 2.8 Angstroms Resolution 
536 23438 9 
79 gi|4757756 annexin A2 isoform 2 [Homo sapiens] 529 38808 10 
80 gi|4507677 heat shock protein 90kDa beta, member 1 
precursor [Homo sapiens] 
517 92696 14 
81 gi|10835792 Chain A, Crystal Structure Of The Fab Fragment 
Of A Human Monoclonal Igm Cold Agglutinin 
502 23552 11 
82 gi|5305598 vanilloid receptor-like protein [Homo sapiens] 499 86912 12 
83 gi|3978244 inhibitor of apoptosis protein-1 [Homo sapiens] 499 69631 12 
84 gi|6912286 caspase 14 precursor [Homo sapiens] 498 27947 10 
85 gi|55749577 adenine nucleotide translocator 1 [Homo 
sapiens] 
493 33271 14 
86 gi|34740335 tubulin, alpha 1B [Mus musculus] 491 50804 12 
87 gi|671527 gamma subunit of CCT chaperonin [Homo 
sapiens] 
483 60862 11 
88 gi|9857759 recombinant IgG4 heavy chain [Homo sapiens] 483 43465 67 
89 gi|223278387 calmodulin-like 5 [Homo sapiens] 483 15883 9 
90 gi|338695 beta-tubulin [Homo sapiens] 482 50240 10 
91 gi|4502141 baculoviral IAP repeat-containing protein 2 
[Homo sapiens] 
480 71109 11 
92 gi|10799664 immunoglobulin heavy chain constant region 
[Homo sapiens] 
472 36525 18 
93 gi|4504927 keratin 36 [Homo sapiens] 470 53354 11 
Appendix 
133 
 
94 gi|264672 gp39=CD40 ligand [human, hyper-IgM 
syndrome patient JW, T cells, Peptide Partial 
Mutant, 151 aa] 
470 16560 141 
95 gi|4505591 peroxiredoxin 1 [Homo sapiens] 466 22324 13 
96 gi|196049873 Chain A, Crystal Structure Of Fabox117 465 23908 91 
97 gi|4504517 heat shock protein beta-1 [Homo sapiens] 464 22826 10 
98 gi|160877748 Chain L, Neuropilin-1 B1 Domain In Complex 
With A Vegf-Blocking Fab 
463 23555 10 
99 gi|4501881 actin, alpha 1, skeletal muscle [Homo sapiens] 461 42366 17 
100 gi|13994300 transmembrane protein 120A [Homo sapiens] 453 41040 12 
101 gi|339723 ADP.ATP translocase [Homo sapiens] 451 29331 14 
102 gi|4885111 calmodulin-like 3 [Homo sapiens] 447 16937 8 
103 gi|119703753 keratin 6B [Homo sapiens] 445 60315 12 
104 gi|14124984 Chaperonin containing TCP1, subunit 3 
(gamma) [Homo sapiens] 
444 60934 11 
105 gi|238537877 Chain L, Crystal Structure Of The Fab Fragment 
Of Anti-Cd20 Antibody Ofatumumab 
440 23367 10 
106 gi|39795269 Keratin 79 [Homo sapiens] 431 58025 9 
107 gi|266618547 Chain L, Crystal Structure Of Hapten Complex 
Of Catalytic Elimination Antibody 13g5 (Wild-
Type) 
419 24248 26 
108 gi|225541 cystic fibrosis antigen 413 11002 16 
109 gi|10716563 calnexin precursor [Homo sapiens] 404 67982 13 
110 gi|32171186 B-cell receptor-associated protein 31 isoform b 
[Homo sapiens] 
404 28031 15 
111 gi|15618995 keratin 71 [Homo sapiens] 402 57769 9 
112 gi|14278227 Chain B, Nmr Structure Of Dff40 And Dff45 N-
Terminal Domain Complex 
400 16302 23 
113 gi|218512079 RecName: Full=Ig gamma-2 chain C region 392 36505 85 
114 gi|4503483 eukaryotic translation elongation factor 2 [Homo 
sapiens] 
388 96246 12 
115 gi|253722541 Chain A, Solution Structure Of The Rrm Of 
Srp20 Bound To The Rna Cauc 
387 17052 22 
116 gi|8569502 Chain A, Fc Fragment Of Human Igg1 In 
Complex With An Engineered 13 Residue 
Peptide Dcawhlgelvwct-Nh2 
386 23762 16 
117 gi|226787 Ig gamma1 378 25556 31 
118 gi|2804273 alpha actinin 4 [Homo sapiens] 373 102661 7 
119 gi|190200 porin [Homo sapiens] 364 38639 10 
120 gi|19072649 TPMsk3 [Homo sapiens] 361 28906 8 
121 gi|24158782 Chain L, Crystal Structure Of Fab Fragment 
Complexed With Gibberellin A4 
361 23942 16 
122 gi|1127248 Chain L, Opg2 Fab Fragment 358 23798 17 
123 gi|229526 protein Rei,Bence-Jones 357 23779 6 
124 gi|17028379 POF1B protein [Homo sapiens] 356 69490 8 
125 gi|4502303 mitochondrial ATP synthase, O subunit 
precursor [Homo sapiens] 
356 23377 7 
126 gi|3891470 Chain A, Crystal Structure Of Human Galectin-7 
In Complex With Galactosamine 
352 14992 9 
127 gi|6005854 prohibitin 2 isoform 2 [Homo sapiens] 350 33276 8 
128 gi|190668 psoriasin [Homo sapiens] 334 11564 11 
129 gi|119611708 protein tyrosine phosphatase, receptor type, C, 
isoform CRA_c [Homo sapiens] 
332 111614 7 
130 gi|4557581 fatty acid binding protein 5 (psoriasis-
associated) [Homo sapiens] 
331 15497 9 
131 gi|121039 RecName: Full=Ig gamma-1 chain C region 330 36596 11 
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132 gi|74271845 alpha-2-macroglobulin-like 1 precursor [Homo 
sapiens] 
322 162463 8 
133 gi|7019415 Sec61 alpha 1 subunit [Homo sapiens] 321 52687 14 
134 gi|40795897 hornerin precursor [Homo sapiens] 318 283111 10 
135 gi|16945897 chromosome 17 open reading frame 26 [Homo 
sapiens] 
317 34689 7 
136 gi|229585 Ig A1 Bur 314 74642 6 
137 gi|10999057 T200 leukocyte common antigen precursor 
[Homo sapiens] 
313 129028 7 
138 gi|4501867 aconitase 2, mitochondrial precursor [Homo 
sapiens] 
312 86113 8 
139 gi|23844 2-oxoglutarate carrier [Homo sapiens] 310 34229 10 
140 gi|62896519 SPFH domain family, member 1 variant [Homo 
sapiens] 
307 39100 5 
141 gi|187302 epithelial cell marker protein 1 [Homo sapiens] 307 27873 7 
142 gi|440308 enhancer protein [Homo sapiens] 305 22048 9 
143 gi|34189561 RanBP-type and C3HC4-type zinc finger 
containing 1 [Homo sapiens] 
295 58169 7 
144 gi|4505773 prohibitin [Homo sapiens] 295 29843 7 
145 gi|12054078 immunoglobulin heavy chain constant region 
gamma 4 [Homo sapiens] 
294 36662 53 
146 gi|4503143 cathepsin D preproprotein [Homo sapiens] 289 45037 8 
147 gi|3603230 cytochrome oxidase assembly factor [Homo 
sapiens] 
281 46315 9 
148 gi|32189 HLA-Bw72 antigen [Homo sapiens] 281 40647 6 
149 gi|51247325 Chain L, Crystal Structure Of A Humanized Fab 
(Hu3s193) In Complex With The Lewis Y 
Tetrasaccharide 
279 24313 7 
150 gi|14198272 Phosphoglycerate mutase family member 5 
[Homo sapiens] 
275 28217 9 
151 gi|229532 ubiquitin 274 8446 6 
152 gi|13375983 mitochondrial glutamate carrier 1 [Homo 
sapiens] 
273 34904 5 
153 gi|30354619 YWHAZ protein [Homo sapiens] 270 35542 6 
154 gi|68563515 keratinocyte proline-rich protein [Homo sapiens] 265 67172 7 
155 gi|4502285 ATPase, Ca++ transporting, slow twitch 2 
isoform 2 [Homo sapiens] 
263 111103 6 
156 gi|1827928 Chain L, Igg Fab (Human Igg1, Kappa) Chimeric 
Fragment (Cbr96) Complexed With Lewis Y 
Nonoate Methyl Ester 
263 24324 10 
157 gi|5032057 S100 calcium binding protein A11 [Homo 
sapiens] 
263 11847 6 
158 gi|5031839 keratin 6A [Homo sapiens] 259 60293 7 
159 gi|4176418 IgG kappa chain [Homo sapiens] 257 23690 7 
160 gi|63055057 actin, beta-like 2 [Homo sapiens] 255 42318 11 
161 gi|7706200 mesenchymal stem cell protein DSCD75 
precursor [Homo sapiens] 
254 24135 7 
162 gi|190406 profilaggrin [Homo sapiens] 253 133528 11 
163 gi|508285 Rab5c-like protein, similar to Canis familiaris 
Rab5c protein, PIR Accession Number S38625 
[Homo sapiens] 
251 23781 5 
164 gi|229597905 Chain H, Fgfr3 In Complex With A Fab 246 25241 4 
165 gi|619846 MHC class II HLA-DQ-beta-1 [Homo sapiens] 245 26532 7 
166 gi|4506371 RAB5B, member RAS oncogene family [Homo 
sapiens] 
244 23920 5 
167 gi|223069 protein Tro alpha1 H,myeloma 242 52010 5 
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168 gi|531241 2-oxoglutarate dehydrogenase precursor [Homo 
sapiens] 
241 114601 6 
169 gi|5031857 lactate dehydrogenase A isoform 1 [Homo 
sapiens] 
241 36950 4 
170 gi|31074631 keratin 1b [Homo sapiens] 239 62049 10 
171 gi|4506675 ribophorin I precursor [Homo sapiens] 238 68641 6 
172 gi|4507651 tropomyosin 4 isoform 2 [Homo sapiens] 238 28619 7 
173 gi|4757810 ATP synthase, H+ transporting, mitochondrial 
F1 complex, alpha subunit precursor [Homo 
sapiens] 
237 59828 5 
174 gi|950004 citrate transporter protein [Homo sapiens] 237 34405 6 
175 gi|4503817 3-ketodihydrosphingosine reductase precursor 
[Homo sapiens] 
236 36563 6 
176 gi|2194044 Chain L, Igg Fab Fragment (Cd25-Binding) 235 23072 6 
177 gi|5360673 anti-Entamoeba histolytica immunoglobulin 
kappa light chain [Homo sapiens] 
233 24476 6 
178 gi|6912482 leucine zipper-EF-hand containing 
transmembrane protein 1 precursor [Homo 
sapiens] 
232 83986 4 
179 gi|5453559 ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit d isoform a [Homo sapiens] 
232 18537 5 
180 gi|493869 Chain L, Crystal Structure Of A Chimeric Fab~ 
Fragment Of An Antibody Binding Tumour Cells 
231 23345 6 
181 gi|6755368 ribosomal protein S18 [Mus musculus] 230 17708 6 
182 gi|6005721 ER lipid raft associated 2 isoform 1 [Homo 
sapiens] 
228 38044 4 
183 gi|18031720 keratin protein K6irs [Homo sapiens] 224 56342 6 
184 gi|10185074 MHC class II antigen [Homo sapiens] 224 30159 7 
185 gi|425518 anti-colorectal carcinoma heavy chain [Homo 
sapiens] 
223 51254 6 
186 gi|13129110 WD repeat domain 77 [Homo sapiens] 219 37442 3 
187 gi|16751921 dermcidin preproprotein [Homo sapiens] 216 11391 4 
188 gi|4757900 calreticulin precursor [Homo sapiens] 215 48283 6 
189 gi|243169 Ig gamma 2 H chain, BUR [human, Peptide 
Mutant, 348 aa] 
215 39383 10 
190 gi|8923390 coiled-coil-helix-coiled-coil-helix domain 
containing 3 precursor [Homo sapiens] 
211 26421 3 
191 gi|37360930 KIAA2034 protein [Homo sapiens] 203 180845 3 
192 gi|4506667 ribosomal protein P0 [Homo sapiens] 201 34423 5 
193 gi|28235 MCH class I HLA-B*5104 [Homo sapiens] 200 40820 4 
194 gi|4885165 cystatin A [Homo sapiens] 200 11000 4 
195 gi|1359726 HLA-DRB1*1419 [Homo sapiens] 199 11385 6 
196 gi|6470150 BiP protein [Homo sapiens] 195 71002 4 
197 gi|131412225 keratin 13 isoform a [Homo sapiens] 195 49870 7 
198 gi|31831 glutamate--ammonia ligase [Homo sapiens] 191 42748 6 
199 gi|28336 mutant beta-actin (beta~-actin) [Homo sapiens] 191 42128 4 
200 gi|21669519 immunoglobulin lambda light chain VLJ region 
[Homo sapiens] 
185 28490 5 
201 gi|4557403 carnitine/acylcarnitine translocase [Homo 
sapiens] 
183 33264 5 
202 gi|347134 succinate dehydrogenase flavoprotein subunit 
[Homo sapiens] 
182 73670 4 
203 gi|497763 Na+, K+ -ATPase catalytic subunit [Homo 
sapiens] 
180 112987 5 
204 gi|2935281 delta7-sterol reductase [Homo sapiens] 179 55221 3 
205 gi|119577330 Fc fragment of IgG binding protein [Homo 
sapiens] 
178 330442 5 
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206 gi|186685 keratin type 16 [Homo sapiens] 174 51010 4 
207 gi|16076466 immunoglobulin kappa chain variable region 
[Homo sapiens] 
174 8553 14 
208 gi|306891 90kDa heat shock protein [Homo sapiens] 172 83584 4 
209 gi|5453539 phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase isoform 2 
[Homo sapiens] 
170 47790 4 
210 gi|35505 pyruvate kinase [Homo sapiens] 169 58411 5 
211 gi|4826659 F-actin capping protein beta subunit [Homo 
sapiens] 
160 30952 4 
212 gi|5032193 TNF receptor-associated factor 1 [Homo 
sapiens] 
157 47103 3 
213 gi|62122917 filaggrin family member 2 [Homo sapiens] 153 249296 4 
214 gi|4759026 RAS protein activator like 1 [Homo sapiens] 151 90861 3 
215 gi|177216 4F2 heavy chain antigen [Homo sapiens] 151 58155 2 
216 gi|4757732 programmed cell death 8 isoform 1 [Homo 
sapiens] 
150 67144 4 
217 gi|1065111 Chain A, High Resolution Solution Nmr Structure 
Of Mixed Disulfide Intermediate Between Mutant 
Human Thioredoxin And A 13 Residue Peptide 
Comprising Its Target Site In Human Nfkb 
149 11629 3 
218 gi|10190712 S100 calcium binding protein A14 [Homo 
sapiens] 
146 11826 2 
219 gi|47846296 keratin b20 [Homo sapiens] 145 50992 3 
220 gi|38026 Zn-alpha2-glycoprotein [Homo sapiens] 144 34942 4 
221 gi|5803227 tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, theta polypeptide [Homo 
sapiens] 
144 28032 4 
222 gi|9845297 diablo isoform 1 precursor [Homo sapiens] 144 27342 2 
223 gi|3559910 aralar1 [Homo sapiens] 143 75108 3 
224 gi|186928856 solute carrier family 25, member 19 [Homo 
sapiens] 
142 35887 6 
225 gi|463907 syntaxin [Homo sapiens] 138 34287 3 
226 gi|229751 Chain A, Structure Of Haemoglobin In The 
Deoxy Quaternary State With Ligand Bound At 
The Alpha Haems 
138 15174 6 
227 gi|1944352 IgG Fc binding protein [Homo sapiens] 134 596522 4 
228 gi|5080756 Human Fc gamma BP [AA 1-2843] [Homo 
sapiens] 
134 313925 3 
229 gi|2970538 immunoglobulin kappa light chain [Homo 
sapiens] 
134 11707 20 
230 gi|1504002 KIAA0209 [Homo sapiens] 130 214320 3 
231 gi|31853 G(M2) activator protein [Homo sapiens] 129 19798 3 
232 gi|7331176 BM88 antigen [Homo sapiens] 128 14992 2 
233 gi|33985 trypsin inhibitor [Homo sapiens] 127 107103 3 
234 gi|28614 aldolase A [Homo sapiens] 127 39706 5 
235 gi|6680045 guanine nucleotide-binding protein, beta-1 
subunit [Mus musculus] 
127 38151 3 
236 gi|3318697 Chain A, Apo-Cellular Retinoic Acid Binding 
Protein Ii 
127 15698 4 
237 gi|179665 complement component C3 [Homo sapiens] 126 188585 3 
238 gi|31873640 hypothetical protein [Homo sapiens] 126 54655 4 
239 gi|5453595 adenylyl cyclase-associated protein [Homo 
sapiens] 
126 51926 1 
240 gi|31746 glutathione-insulin transhydrogenase (216 AA) 
[Homo sapiens] 
125 25107 3 
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241 gi|90109513 Chain H, Cofactor-Containing Antibodies: 
Crystal Structure Of The Original Yellow 
Antibody 
125 23945 3 
242 gi|4506671 ribosomal protein P2 [Homo sapiens] 125 11658 2 
243 gi|4680717 CGI-39 protein [Homo sapiens] 124 15729 3 
244 gi|2098347 Chain A, Physiological Dimer Hpp Precursor 123 51920 2 
245 gi|186016 immunoglobulin kappa light chain VJ region 
[Homo sapiens] 
123 12742 5 
246 gi|58530842 desmoplakin isoform II [Homo sapiens] 121 262237 4 
247 gi|2337920 syntaxin 7 [Homo sapiens] 121 29941 3 
248 gi|438069 thiol-specific antioxidant protein [Homo sapiens] 121 22014 3 
249 gi|28935 ATP-citrate (pro-S-)-lyase [Homo sapiens] 120 122197 3 
250 gi|260436922 suprabasin isoform 1 precursor [Homo sapiens] 120 60562 2 
251 gi|14043666 ATAD3A protein [Homo sapiens] 117 66349 4 
252 gi|6468762 Pig8 [Homo sapiens] 116 41295 3 
253 gi|385225 small proline-rich protein 1 [Homo sapiens] 116 10332 2 
254 gi|551638 SSR alpha subunit [Homo sapiens] 115 32163 2 
255 gi|509291 H+-ATP synthase subunit b [Homo sapiens] 115 28933 3 
256 gi|2906146 malate dehydrogenase precursor [Homo 
sapiens] 
114 35965 4 
257 gi|5802974 peroxiredoxin 3 isoform a precursor [Homo 
sapiens] 
114 28017 2 
258 gi|13491174 MARCKS-like 1 [Homo sapiens] 114 19574 2 
259 gi|4504165 gelsolin isoform a precursor [Homo sapiens] 113 86043 3 
260 gi|4191396 putative sterol reductase SR-1 [Homo sapiens] 112 46730 2 
261 gi|181969 elongation factor 2 [Homo sapiens] 111 40264 3 
262 gi|801893 leucine-rich PPR-motif containing protein [Homo 
sapiens] 
110 146306 3 
263 gi|1710279 dihyrolipoamide acetyl transferase [Homo 
sapiens] 
110 40435 2 
264 gi|13129092 transmembrane protein 109 precursor [Homo 
sapiens] 
109 26194 3 
265 gi|41327781 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, assembly factor 3 isoform a 
precursor [Homo sapiens] 
109 20566 3 
266 gi|24987241 Chain L, Variable Light Chain Dimer Of Anti-
Ferritin Antibody 
108 12798 12 
267 gi|8131894 mitofilin [Homo sapiens] 107 68316 3 
268 gi|31645 glyceraldehyde-3-phosphate dehydrogenase 
[Homo sapiens] 
107 36202 3 
269 gi|1373019 cysteine-rich fibroblast growth factor receptor 
[Homo sapiens] 
106 138149 3 
270 gi|5733504 voltage-dependent anion channel VDAC3 
[Homo sapiens] 
105 27972 2 
271 gi|5453832 hypoxia up-regulated 1 precursor [Homo 
sapiens] 
104 111494 3 
272 gi|577295 KIAA0088 [Homo sapiens] 104 107158 3 
273 gi|29649713 protease serine 1 [Homo sapiens] 104 9218 4 
274 gi|7765076 S3 ribosomal protein [Homo sapiens] 103 26870 3 
275 gi|13194195 Mid-1-related chloride channel 1 isoform 2 
[Homo sapiens] 
101 56915 3 
276 gi|338490 52-kD SS-A/Ro autoantigen [Homo sapiens] 101 55135 3 
277 gi|2984585 P1.11659_4 [Homo sapiens] 99 38839 2 
278 gi|801893 leucine-rich PPR-motif containing protein [Homo 
sapiens] 
98 146306 2 
279 gi|188492 heat shock-induced protein [Homo sapiens] 98 70755 2 
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280 gi|31645 glyceraldehyde-3-phosphate dehydrogenase 
[Homo sapiens] 
98 36202 1 
281 gi|7661922 RAB21, member RAS oncogene family [Homo 
sapiens] 
97 24731 2 
282 gi|4503113 cystatin M precursor [Homo sapiens] 97 16785 2 
283 gi|56699492 small proline-rich protein 2D [Homo sapiens] 97 8584 3 
284 gi|19264112 SHARPIN protein [Homo sapiens] 95 34199 2 
285 gi|1050983 pHL E1F1 [Homo sapiens] 95 15088 1 
286 gi|189036 nonmuscle myosin heavy chain (NMHC) [Homo 
sapiens] 
94 145623 1 
287 gi|339527 transglutaminase [Homo sapiens] 93 90440 3 
288 gi|307141 lysozyme precursor (EC 3.2.1.17) [Homo 
sapiens] 
93 17000 2 
289 gi|114631808 PREDICTED: insulysin isoform 2 [Pan 
troglodytes] 
92 113869 3 
290 gi|234746 RAS-related protein MEL [Homo sapiens] 92 23753 2 
291 gi|238427 Porin 31HM [human, skeletal muscle 
membranes, Peptide, 282 aa] 
91 30737 2 
292 gi|300181 neutrophil gelatinase-associated lipocalin, NGAL 
[human, neutrophils, Peptide, 178 aa] 
91 20707 2 
293 gi|31791004 keratin associated protein 13-4 [Homo sapiens] 91 18883 2 
294 gi|1633054 Chain A, Cyclophilin A Complexed With 
Dipeptide Gly-Pro 
91 18098 3 
295 gi|1296662 plectin [Homo sapiens] 90 533408 3 
296 gi|183817 beta-globin [Homo sapiens] 90 19204 2 
297 gi|6841264 HSPC307 [Homo sapiens] 90 18769 2 
298 gi|4506691 ribosomal protein S16 [Homo sapiens] 90 16549 2 
299 gi|71664 calmodulin - salmon 89 16696 2 
300 gi|7657257 translocase of outer mitochondrial membrane 20 
homolog [Homo sapiens] 
89 16459 2 
301 gi|13624098 cervical cancer 1 protooncogene protein p40 
[Homo sapiens] 
88 42177 1 
302 gi|1262582 ATPase subunit 6 [Homo sapiens] 88 24727 4 
303 gi|1763665 Snk interacting protein 2-28 [Homo sapiens] 88 21875 2 
304 gi|14016 cytochrome C oxidase II subunit [Homo sapiens] 88 21095 3 
305 gi|56605994 CDGSH iron sulfur domain 2 [Homo sapiens] 88 15497 3 
306 gi|1020320 CDM protein [Homo sapiens] 86 14066 2 
307 gi|98956399 immunoglobulin kappa light chain variable 
region [Homo sapiens] 
86 12397 12 
308 gi|457464 Dsc1a precursor [Homo sapiens] 84 93668 2 
309 gi|45768728 Ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1 [Homo sapiens] 
83 29958 3 
310 gi|21748644 FLJ00400 protein [Homo sapiens] 82 88172 2 
311 gi|4689112 sec61 homolog [Homo sapiens] 82 52902 2 
312 gi|6631112 synaptogyrin 3 [Homo sapiens] 82 24768 2 
313 gi|4759158 small nuclear ribonucleoprotein D2 isoform 1 
[Homo sapiens] 
82 13632 2 
314 gi|188479 HLA-DPB1 [Homo sapiens] 81 29440 2 
315 gi|31791006 keratin associated protein 13-2 [Homo sapiens] 81 19912 2 
316 gi|13129018 gamma-glutamyl cyclotransferase [Homo 
sapiens] 
80 21222 2 
317 gi|4680655 CGI-08 protein [Homo sapiens] 79 34265 1 
318 gi|1228049 multifunctional protein CAD [Homo sapiens] 78 245100 2 
319 gi|16758368 RAB14, member RAS oncogene family [Rattus 
norvegicus] 
78 24140 2 
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320 gi|229858 Chain A, Crystal Structure Of Defensin Hnp-3, 
An Amphiphilic Dimer: Mechanisms Of 
Membrane Permeabilization 
78 3832 2 
321 gi|6735452 B-ind1 protein [Homo sapiens] 77 43800 1 
322 gi|6005884 signal sequence receptor gamma subunit [Homo 
sapiens] 
77 21067 2 
323 gi|17998551 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 12 [Homo sapiens] 
76 46646 2 
324 gi|338421 small proline rich protein [Homo sapiens] 75 10363 2 
325 gi|28557150 hornerin [Homo sapiens] 74 48797 3 
326 gi|119571242 hCG1642498, isoform CRA_a [Homo sapiens] 74 29605 2 
327 gi|2323410 Skb1Hs [Homo sapiens] 73 73424 2 
328 gi|177870 alpha-2-macroglobulin precursor [Homo 
sapiens] 
70 164600 3 
329 gi|5453906 CDP-diacylglycerol-inositol 3-
phosphatidyltransferase [Homo sapiens] 
69 23865 2 
330 gi|4505821 prolactin-induced protein precursor [Homo 
sapiens] 
69 16847 1 
331 gi|1143218 nonmuscle myosin heavy chain IIB [Homo 
sapiens] 
69 9273 4 
332 gi|31979 histone H2A.2 [Homo sapiens] 68 13898 2 
333 gi|14595132 Raichu404X [Homo sapiens] 67 85646 3 
334 gi|4758304 protein disulfide isomerase A4 precursor [Homo 
sapiens] 
67 73229 2 
335 gi|179832 calnexin [Homo sapiens] 67 67948 2 
336 gi|28931 beta-subunit (AA 1-312) [Homo sapiens] 67 34026 1 
337 gi|33126535 protease serine 4 isoform B [Homo sapiens] 67 28751 2 
338 gi|4504447 heterogeneous nuclear ribonucleoprotein A2/B1 
isoform A2 [Homo sapiens] 
66 36041 2 
339 gi|494066 Chain A, Three-Dimensional Structure Of Class 
Pi Glutathione S- Transferase From Human 
Placenta In Complex With S- Hexylglutathione 
At 2.8 Angstroms Resolution 
66 23438 1 
340 gi|4502205 ADP-ribosylation factor 4 [Homo sapiens] 66 20612 2 
341 gi|1065361 Chain A, Human Adp-Ribosylation Factor 1 
Complexed With Gdp, Full Length Non-
Myristoylated 
66 20610 2 
342 gi|116642885 myofibrillogenesis regulator 1 isoform 3 [Homo 
sapiens] 
65 15444 2 
343 gi|62896831 glutaminyl-peptide cyclotransferase-like variant 
[Homo sapiens] 
64 42957 1 
344 gi|14043299 YIF1B protein [Homo sapiens] 64 33926 1 
345 gi|1145799 p60 [Homo sapiens] 63 48370 2 
346 gi|337930 scar protein [Homo sapiens] 63 27614 2 
347 gi|4506145 protease, serine, 1 preproprotein [Homo 
sapiens] 
63 27111 3 
348 gi|550023 ribosomal protein S9 [Homo sapiens] 63 22615 2 
349 gi|4506697 ribosomal protein S20 isoform 2 [Homo sapiens] 63 13478 2 
350 gi|915392 fatty acid synthase [Homo sapiens] 62 275542 1 
351 gi|6672071 carboxypeptidase A3 [Homo sapiens] 62 47578 2 
352 gi|36142 ribosomal protein homologous to yeast S24 
[Homo sapiens] 
62 14821 2 
353 gi|494619 Chain I, The Refined 2.4 Angstroms X-Ray 
Crystal Structure Of Recombinant Human Stefin 
B In Complex With The Cysteine Proteinase 
Papain: A Novel Type Of Proteinase Inhibitor 
Interaction 
62 11151 1 
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354 gi|288100 initation factor 4B [Homo sapiens] 61 69240 2 
355 gi|119572363 hCG22067 [Homo sapiens] 60 30319 1 
356 gi|14042927 MLN64 N-terminal homolog [Homo sapiens] 60 26752 2 
357 gi|24308400 coiled-coil domain containing 109A [Homo 
sapiens] 
59 40127 2 
358 gi|3329386 synaptic glycoprotein SC2 spliced variant [Homo 
sapiens] 
59 36494 2 
359 gi|177198 (R)-3-hydroxybutyrate dehydrogenase [Homo 
sapiens] 
58 38511 2 
360 gi|37183226 ATWD578 [Homo sapiens] 58 29500 1 
361 gi|9910382 mitochondrial import receptor Tom22 [Homo 
sapiens] 
58 15512 2 
362 gi|313159 keratin K4a [Homo sapiens] 58 14026 1 
363 gi|433413 mitochondrial short-chain enoyl-CoA hydratase 
[Homo sapiens] 
57 31716 2 
364 gi|6005942 valosin-containing protein [Homo sapiens] 56 89950 2 
365 gi|182599 IgG Fc fragment receptor precursor [Homo 
sapiens] 
56 33812 2 
366 gi|4759160 small nuclear ribonucleoprotein polypeptide D3 
[Homo sapiens] 
56 14021 1 
367 gi|386758 GRP78 precursor [Homo sapiens] 55 72185 2 
368 gi|37492 alpha-tubulin [Homo sapiens] 55 50810 1 
369 gi|87783 Ig alpha-2 chain C region (allotype A2m(2)) - 
human  (fragment) 
55 24238 2 
370 gi|1374813 SNAP-23 [Homo sapiens] 55 23710 1 
371 gi|483910 TPO autoantibody immunoglobulin heavy chain, 
V-region (TR1.41) [Homo sapiens] 
55 13481 1 
372 gi|4506613 ribosomal protein L22 proprotein [Homo 
sapiens] 
54 14835 1 
373 gi|2245566 NADH dehydrogenase III [Homo sapiens] 54 12158 1 
374 gi|24415404 MDN1, midasin homolog [Homo sapiens] 53 638008 2 
375 gi|762885 Plakoglobin [Homo sapiens] 53 82381 2 
376 gi|5107725 Chain A, Biochemical Characterization And 
Structure Determination Of Human Heart Short 
Chain L-3-Hydroxyacyl Coa Dehydrogenase 
Provide Insight Into Catalytic Mechanism 
53 31848 1 
377 gi|5031931 nascent polypeptide-associated complex alpha 
subunit isoform b [Homo sapiens] 
53 23370 1 
378 gi|149242857 Chain A, Crystal Structure Of The Third Kh 
Domain Of Human Poly(C)- Binding Protein-2 In 
Complex With C-Rich Strand Of Human 
Telomeric Dna 
53 8112 2 
379 gi|473947 KIAA0115 [Homo sapiens] 52 50851 2 
380 gi|47825361 non-specific cytotoxic cell receptor protein 1 
homolog [Homo sapiens] 
52 30942 2 
381 gi|6166493 Peroxiredoxin 5 [Homo sapiens] 52 22262 1 
382 gi|6041669 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 4 isoform 1 [Homo sapiens] 
52 15256 1 
383 gi|1483187 inter-alpha-trypsin inhibitor family heavy chain-
related protein (IHRP) [Homo sapiens] 
51 103549 2 
384 gi|14602923 HLA-DPA1 protein [Homo sapiens] 50 29545 2 
385 gi|5032051 ribosomal protein S14 [Homo sapiens] 50 16434 1 
386 gi|83753119 Chain A, Crystal Structure Of Human Full-
Length Vinculin (Residues 1- 1066) 
49 116498 2 
387 gi|5107666 Chain A, Structure Of Importin Beta Bound To 
The Ibb Domain Of Importin Alpha 
49 98484 1 
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388 gi|387011 pyruvate dehydrogenase E1-alpha precursor 
[Homo sapiens] 
49 47098 1 
389 gi|179255 ATPase subunit 9 [Homo sapiens] 49 10480 2 
390 gi|2585772 multidrug resistance protein [Homo sapiens] 47 171113 1 
391 gi|1465733 cytosolic NADP(+)-dependent malic enzyme 
[Homo sapiens] 
47 63859 1 
392 gi|414810 epidermal granular cell layer-specific [Homo 
sapiens] 
47 47739 1 
393 gi|5454122 translocase of inner mitochondrial membrane 23 
(yeast) homolog [Homo sapiens] 
47 22100 1 
394 gi|643695 glutaredoxin [Homo sapiens] 47 12039 1 
395 gi|190238 nucleolar phosphoprotein B23 [Homo sapiens] 47 9246 1 
396 gi|3170190 antigen NY-CO-25 [Homo sapiens] 45 99347 1 
397 gi|110590597 Chain A, Apo-Human Serum Transferrin (Non-
Glycosylated) 
45 76810 2 
398 gi|119610617 hCG2036610 [Homo sapiens] 45 40050 1 
399 gi|4826643 annexin A3 [Homo sapiens] 45 36524 1 
400 gi|4092058 proteasome subunit HSPC [Homo sapiens] 45 28057 2 
401 gi|313014 vacuolar proton ATPase [Homo sapiens] 45 26271 1 
402 gi|3550427 seven transmembrane domain protein [Homo 
sapiens] 
45 25775 1 
403 gi|3342734 NUKM_HUMAN, partial CDS [Homo sapiens] 45 18321 2 
404 gi|7657532 S100 calcium-binding protein A6 [Homo 
sapiens] 
45 10230 1 
405 gi|307504 transglutaminase E3 [Homo sapiens] 44 77121 1 
406 gi|4506185 proteasome alpha 4 subunit isoform 1 [Homo 
sapiens] 
44 29750 1 
407 gi|505098 KIAA0069 [Homo sapiens] 44 26004 1 
408 gi|224342 antigen HLA DAalpha 44 21588 2 
409 gi|5031635 cofilin 1 (non-muscle) [Homo sapiens] 44 18719 1 
410 gi|4502313 ATPase, H+ transporting, lysosomal, V0 subunit 
c [Homo sapiens] 
44 15725 2 
411 gi|119638475 adenomatosis polyposis coli [Homo sapiens] 44 10473 1 
412 gi|553734 putative [Homo sapiens] 44 2269 1 
413 gi|119594965 spectrin, beta, non-erythrocytic 2, isoform 
CRA_a [Homo sapiens] 
43 144621 2 
414 gi|2546979 OXA1L [Homo sapiens] 43 55832 1 
415 gi|178995 arginase (EC 3.5.3.1) [Homo sapiens] 43 34883 1 
416 gi|20521768 KIAA1109 protein [Homo sapiens] 42 341644 2 
417 gi|181608 desmoplakin [Homo sapiens] 42 202206 1 
418 gi|2735857 cAMP-specific phosphodiesterase PDE4D5 
[Homo sapiens] 
42 84945 1 
419 gi|169169660 PREDICTED: hypothetical protein [Homo 
sapiens] 
42 51449 2 
420 gi|7271867 golgi membrane protein GP73 [Homo sapiens] 42 45346 2 
421 gi|4929671 CGI-101 protein [Homo sapiens] 42 24416 1 
422 gi|2370149 PDZ domain protein [Homo sapiens] 41 167849 1 
423 gi|288563 inter-alpha-trypsin inhibitor heavy chain H3 
[Homo sapiens] 
41 99401 1 
424 gi|485388 eukaryotic initiation factor 4AII [Homo sapiens] 41 46593 1 
425 gi|5174655 reticulon 3 isoform a [Homo sapiens] 41 25764 1 
426 gi|11139093 GrpE-like protein cochaperone [Homo sapiens] 41 24361 1 
427 gi|33609 immunoglobulin kappa light chain, A23 V-
segment [Homo sapiens] 
41 13185 1 
428 gi|189754 pyruvate dehydrogenase beta subunit [Homo 
sapiens] 
40 39566 1 
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429 gi|5730031 secretory carrier membrane protein 2 [Homo 
sapiens] 
40 37082 2 
430 gi|224052 transferase,HG phosphoribosyl 40 24590 1 
431 gi|13994362 keratin associated protein 3.1 [Homo sapiens] 40 11558 1 
432 gi|338697 thyroxine-binding globulin precursor [Homo 
sapiens] 
39 46625 1 
433 gi|4758582 isocitrate dehydrogenase 3 (NAD+) gamma 
isoform a precursor [Homo sapiens] 
39 43166 1 
434 gi|119599578 hCG2040552 [Homo sapiens] 39 9263 1 
435 gi|13021892 PGC-1 related co-activator [Homo sapiens] 38 179040 1 
436 gi|4502057 arachidonate 5-lipoxygenase [Homo sapiens] 38 78675 1 
437 gi|62084731 aberrant LSLCL [Homo sapiens] 38 33536 1 
438 gi|576556 KIAA0118 [Homo sapiens] 38 18106 1 
439 gi|253722855 Chain A, Solution Structure Of Multi-Functional 
Peptide Motif-1 Present In Human Glutamyl-
Prolyl Trna Synthetase (Eprs) 
38 6322 1 
440 gi|15528835 Fc receptor-like protein 3 [Homo sapiens] 37 81576 2 
441 gi|19111150 angiomotin isoform 2 [Homo sapiens] 37 72894 1 
442 gi|306704 1,25-dihydroxyvitamin D3 24-hydroxylase [Homo 
sapiens] 
37 59314 1 
443 gi|181192 preprocathepsin B [Homo sapiens] 37 38752 1 
444 gi|18088572 RAB, member of RAS oncogene family-like 3 
[Homo sapiens] 
37 26520 1 
445 gi|21465651 Chain J, Crystal Structure Of The Mammalian 
20s Proteasome At 2.75 A Resolution 
37 23201 1 
446 gi|4758774 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa [Homo sapiens] 
37 21048 1 
447 gi|4504963 lipocalin 1 precursor [Homo sapiens] 37 19409 1 
448 gi|1015321 alanyl-tRNA synthetase [Homo sapiens] 36 107476 1 
449 gi|1495421 mono-ADP-ribosyltransferase [Homo sapiens] 36 31020 1 
450 gi|156076910 immunoglobulin heavy chain variable region 6 
[Homo sapiens] 
36 11583 1 
451 gi|5256825 CD3e-associated protein [Homo sapiens] 35 55423 1 
452 gi|283838252 NADH dehydrogenase subunit 1 [Homo sapiens] 35 4718 1 
 
Table 7.2: Complete list of proteins found in the MassSpec analysis of 2D gels. 
Spots were taken from the 2D gel according to figure 3.16 and analysed by mass spectrometry. Grey 
fields: Proteins considered to be contaminants; white fields: protein of interest; dark grey fields: 
proteins found to be recruited to the CD40-RSC. 
 Protein 
Nr. 
Acc. Nr. Protein Description Protein 
score 
Protein 
Mass 
No. of 
hits 
Spot 1 3 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1598 66110 38 
 4 gi|55956899 keratin 9 [Homo sapiens] 1297 62255 47 
 5 gi|28317 Keratin 10 [Homo sapiens] 1256 59720 32 
 6 gi|18999435 Keratin 5 [Homo sapiens] 970 62568 27 
 7 gi|1195531 keratin 16 [Homo sapiens] 651 51548 18 
 8 gi|1147813 desmoplakin I [Homo sapiens] 479 334023 15 
 9 gi|226787 immunoglobulin lambda heavy chain [Homo sapiens] 392 25556 21 
 10 gi|28590 serum albumin [Homo sapiens] 343 71246 7 
 11 gi|3318722 Trypsin (porcine) 259 24142 21 
 12 gi|40795897 hornerin precursor [Homo sapiens] 239 283111 8 
 13 gi|21755908 keratin 5b [Homo sapiens] 140 57583 4 
 14 gi|264672 CD40 ligand [Homo sapiens] 115 16560 4 
 15 gi|6912286 caspase 14 precursor [Homo sapiens] 82 27947 2 
 16 gi|33337556 citrate synthase [Homo sapiens] 75 51942 2 
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 17 gi|535015 band-6-protein [Homo sapiens] 72 81637 2 
 18 gi|416917 desmoglein 1 [Homo sapiens] 58 114670 1 
 19 gi|16751921 dermcidin [Homo sapiens] 53 11391 2 
 20 gi|68563515 keratinocyte proline-rich protein [Homo sapiens] 52 67172 2 
Spot 2 1 gi|114667176 keratin 14 [Homo sapiens] 1312 107899 28 
 2 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1118 66110 21 
 3 gi|11935049 keratin 1 [Homo sapiens] 994 66198 24 
 4 gi|28317 Keratin 10 [Homo sapiens] 823 59720 19 
 5 gi|435476 cytokeratin 9 [Homo sapiens] 738 62320 16 
 6 gi|1195531 keratin 16 [Homo sapiens] 555 51548 12 
 7 gi|226787 immunoglobulin lambda heavy chain [Homo sapiens] 405 25556 19 
 8 gi|18999435 Keratin 5 [Homo sapiens] 330 62568 8 
 9 gi|5031839 keratin 6A [Homo sapiens] 325 60293 9 
 10 gi|3318722 Trypsin (porcine) 270 24142 21 
 11 gi|264672 CD40 ligand [Homo sapiens] 210 16560 4 
 12 gi|338490 52-kD SS-A/Ro autoantigen [Homo sapiens] 73 55135 2 
 13 gi|16751921 dermcidin [Homo sapiens] 42 11391 1 
Spot 3 1 gi|11935049 keratin 1 [Homo sapiens] 1916 66198 50 
 2 gi|114667176 keratin 14 [Homo sapiens] 1545 107899 42 
 3 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1485 66110 31 
 4 gi|1195531 keratin 16 [Homo sapiens] 959 51548 24 
 5 gi|55956899 keratin 9 [Homo sapiens] 945 62255 28 
 6 gi|28317 Keratin 10 [Homo sapiens] 835 59720 18 
 7 gi|12803709 Keratin 14 [Homo sapiens] 743 51905 18 
 8 gi|109096781 Keratin 6A [Homo sapiens] 682 60221 14 
 9 gi|119617032 keratin 6B [Homo sapiens] 673 60159 14 
 10 gi|908801 Keratin 6C [Homo sapiens] 663 60448 12 
 11 gi|18999435 Keratin 5 [Homo sapiens] 502 61138 12 
 12 gi|3318722 Trypsin (porcine) 258 24142 16 
 13 gi|14278227 Chain B, Nmr Structure Of Dff40 And Dff45 N-Terminal 
Domain Complex 
217 16302 3 
 14 gi|40795897 hornerin precursor [Homo sapiens] 207 283111 5 
 15 gi|58530842 desmoplakin I [Homo sapiens] 148 262237 4 
 16 gi|62122917 filaggrin family member 2 [Homo sapiens] 56 249296 1 
 17 gi|16751921 dermcidin [Homo sapiens] 56 11391 1 
 18 gi|416917 desmoglein 1 [Homo sapiens] 45 114670 1 
 19 gi|68563515 keratinocyte proline-rich protein [Homo sapiens] 37 67172 1 
Spot 4 1 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1534 66110 29 
 2 gi|11935049 keratin 1 [Homo sapiens] 1009 66198 26 
 3 gi|28317 Keratin 10 [Homo sapiens] 943 59720 23 
 4 gi|114667176 keratin 14 [Homo sapiens] 887 107899 19 
 5 gi|18999435 Keratin 5 [Homo sapiens] 344 62568 7 
 6 gi|7019477 HtrA serine peptidase 2 isoform 1 preproprotein [Homo 
sapiens] 
342 48868 10 
 7 gi|136429 Trypsin (porcine) 258 24142 16 
 8 gi|178995 arginase [Homo sapiens] 60 34883 1 
 9 gi|28557150 hornerin [Homo sapiens] 60 48797 2 
 10 gi|6912286 caspase 14 precursor [Homo sapiens] 44 27947 1 
 11 gi|7959223 SHROOM3 protein [Homo sapiens] 32 150746 1 
Spot 5 1 gi|114667176 keratin 14 [Homo sapiens] 1153 107899 31 
 2 gi|11935049 keratin 1 [Homo sapiens] 1033 66198 29 
 3 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 883 66110 17 
 4 gi|55956899 keratin 9 [Homo sapiens] 849 62255 26 
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 5 gi|28317 Keratin 10 [Homo sapiens] 761 59720 17 
 6 gi|136429 Trypsin (porcine) 340 24142 21 
 7 gi|18999435 Keratin 5 [Homo sapiens] 163 62568 3 
 8 gi|7019477 HtrA serine peptidase 2 isoform 1 preproprotein [Homo 
sapiens] 
196 48868 5 
 9 gi|16751921 dermcidin [Homo sapiens] 64 11391 1 
 10 gi|28557150 hornerin [Homo sapiens] 63 48797 3 
Spot 6 1 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1818 66110 47 
 2 gi|11935049 keratin 1 [Homo sapiens] 1469 66198 48 
 3 gi|114667176 keratin 14 [Homo sapiens] 1443 107899 33 
 4 gi|28317 Keratin 10 [Homo sapiens] 1124 59720 34 
 5 gi|1195531 keratin 16 [Homo sapiens] 874 51548 19 
 6 gi|435476 cytokeratin 9 [Homo sapiens] 754 62320 20 
 7 gi|18999435 Keratin 5 [Homo sapiens] 511 62568 12 
 8 gi|136429 Trypsin (porcine) 320 24142 19 
 9 gi|40795897 hornerin precursor [Homo sapiens] 250 283111 9 
 10 gi|520 beta-lactoglobulin [Bos taurus] 106 20307 3 
 11 gi|16751921 dermcidin preproprotein [Homo sapiens] 64 11391 1 
 12 gi|162794 alpha-S1-casein [Bos taurus] 64 24536 2 
 13 gi|62122917 filaggrin family member 2 [Homo sapiens] 56 249296 1 
 14 gi|416917 desmoglein 1 [Homo sapiens] 55 114670 1 
 15 gi|73964427 PREDICTED: similar to serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 12 [Canis familiaris] 
40 47050 1 
Spot 7  1 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1258 66110 24 
 2 gi|28317 Keratin 10 [Homo sapiens] 699 59720 13 
 3 gi|11935049 keratin 1 [Homo sapiens] 694 66198 16 
 4 gi|435476 cytokeratin 9 [Homo sapiens] 425 62320 7 
 5 gi|386848 keratin [Homo sapiens] 309 51916 7 
 6 gi|18999435 Keratin 5 [Homo sapiens] 255 62568 6 
 7 gi|22761713 shank-interacting protein-like 1 [Homo sapiens] 137 42403 5 
 8 gi|16751921 dermcidin preproprotein [Homo sapiens] 48 11391 1 
 9 gi|7959223 SHROOM3 protein [Homo sapiens] 32 150746 1 
 10 gi|4758582 isocitrate dehydrogenase 3 (NAD+) gamma isoform a 
precursor [Homo sapiens] 
28 43166 1 
Spot 8 1 gi|11935049 keratin 1 [Homo sapiens] 885 66198 18 
 2 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 777 66110 15 
 3 gi|28317 Keratin 10 [Homo sapiens] 772 59720 13 
 4 gi|435476 cytokeratin 9 [Homo sapiens] 533 62320 11 
 5 gi|186685 keratin type 16 [Homo sapiens] 191 51010 4 
 6 gi|18999435 Keratin 5 [Homo sapiens] 182 62568 5 
 7 gi|16751921 dermcidin preproprotein [Homo sapiens] 60 11391 1 
 8 gi|9845297 diablo isoform 1 precursor [Homo sapiens] 46 27342 1 
Spot 9 1 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1879 66110 36 
 2 gi|11935049 keratin 1 [Homo sapiens] 1857 66198 46 
 3 gi|28317 Keratin 10 [Homo sapiens] 1358 59720 30 
 4 gi|5031839 keratin 6A [Homo sapiens] 824 60293 18 
 5 gi|435476 cytokeratin 9 [Homo sapiens] 810 62320 17 
 6 gi|18999435 Keratin 5 [Homo sapiens] 742 62568 16 
 7 gi|12803709 Keratin 14 [Homo sapiens] 662 51905 15 
 8 gi|1195531 type I keratin 16 [Homo sapiens] 479 51548 12 
 9 gi|1147813 desmoplakin I [Homo sapiens] 371 334023 11 
 10 gi|31074631 keratin 1b [Homo sapiens] 278 62049 8 
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 11 gi|28592 serum albumin [Homo sapiens] 234 71316 6 
 12 gi|31873640 keratin b20 [Homo sapiens] 157 54655 4 
 13 gi|762885 Plakoglobin [Homo sapiens] 109 82381 3 
 14 gi|416917 Desmoglein-1 [Homo sapiens] 98 114670 3 
 15 gi|62122917 filaggrin family member 2 [Homo sapiens] 74 249296 1 
 16 gi|121039 immunoglobulin gamma-1 heavy chain constant region 
[Homo sapiens] 
72 36596 2 
 17 gi|68563515 keratinocyte proline-rich protein [Homo sapiens] 62 67172 2 
Spot 10 1 gi|47132620 keratin 2 [Homo sapiens] 2370 65678 57 
 2 gi|11935049 keratin 1 [Homo sapiens] 2030 66198 62 
 3 gi|28317 keratin 10 [Homo sapiens] 1584 59720 42 
 4 gi|55956899 keratin 9 [Homo sapiens] 1424 62255 34 
 5 gi|1195531 type I keratin 16 [Homo sapiens] 1285 51548 33 
 6 gi|5031839 keratin 6A [Homo sapiens] 1199 60293 28 
 7 gi|18999435 Keratin 5 [Homo sapiens] 1197 62568 28 
 8 gi|12803709 Keratin 14 [Homo sapiens] 1057 51905 26 
 9 gi|4557701 keratin 17 [Homo sapiens] 655 48361 16 
 10 gi|416917 RecName: Full=Desmoglein-1 344 114670 7 
 11 gi|31074631 keratin 1b [Homo sapiens] 332 62049 10 
 12 gi|28592 serum albumin [Homo sapiens] 284 71316 6 
 13 gi|1147813 desmoplakin I [Homo sapiens] 283 334023 8 
 14 gi|40795897 hornerin precursor [Homo sapiens] 192 283111 5 
 15 gi|762885 Plakoglobin [Homo sapiens] 189 82381 4 
 16 gi|21755908 keratin 5b [Homo sapiens] 148 57583 4 
 17 gi|4757756 annexin A2 isoform 2 [Homo sapiens] 124 38808 3 
 18 gi|31873640 keratin b20 [Homo sapiens] 117 54655 3 
 19 gi|16751921 dermcidin preproprotein [Homo sapiens] 114 11391 2 
 20 gi|178995 arginase (EC 3.5.3.1) [Homo sapiens] 101 34883 3 
 21 gi|229532 pro-ubiquitin [Homo sapiens] 96 8446 2 
 22 gi|6912286 caspase 14 precursor [Homo sapiens] 82 27947 2 
Spot 11 1 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1654 66110 33 
 2 gi|11935049 keratin 1 [Homo sapiens] 1332 66198 30 
 3 gi|28317 Keratin 10 [Homo sapiens] 1190 59720 27 
 4 gi|435476 cytokeratin 9 [Homo sapiens] 1007 62320 21 
 5 gi|12803709 Keratin 14 [Homo sapiens] 691 51905 14 
 6 gi|18999435 Keratin 5 [Homo sapiens] 550 62568 15 
 7 gi|908801 keratin type II [Homo sapiens] 305 60448 9 
 8 gi|3978244 inhibitor of apoptosis protein-1 [Homo sapiens] 264 69631 7 
 9 gi|28592 serum albumin [Homo sapiens] 229 71316 5 
 10 gi|1147813 desmoplakin I [Homo sapiens] 163 334023 4 
 11 gi|40795897 hornerin precursor [Homo sapiens] 115 283111 4 
 12 gi|457464 Dsc1a precursor [Homo sapiens] 62 93668 2 
 16 gi|4502141 baculoviral IAP repeat-containing protein 2 [Homo 
sapiens] 
31 71109 1 
 17 gi|121039 RecName: Full=Ig gamma-1 chain C region 29 36596 1 
Spot 12 1 gi|11935049 keratin 1 [Homo sapiens] 1317 66198 36 
 2 gi|181402 epidermal cytokeratin 2 [Homo sapiens] 1229 66110 24 
 3 gi|28317 Keratin 10 [Homo sapiens] 962 59720 20 
 4 gi|435476 cytokeratin 9 [Homo sapiens] 957 62320 22 
 5 gi|18999435 Keratin 5 [Homo sapiens] 587 62568 17 
 6 gi|12803709 Keratin 14 [Homo sapiens] 573 51905 13 
 7 gi|186685 keratin type 16 [Homo sapiens] 394 51010 9 
 8 gi|3978244 inhibitor of apoptosis protein-1 [Homo sapiens] 315 69631 7 
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 9 gi|28592 serum albumin [Homo sapiens] 161 71316 5 
 10 gi|16751921 dermcidin preproprotein [Homo sapiens] 129 11391 2 
 11 gi|121039 RecName: Full=Ig gamma-1 chain C region 65 36596 2 
 12 gi|37460 trypsin (EC 3.4.21.4) IV form b precursor - human 
(fragment) 
57 27329 1 
 13 gi|119572363 Trypsin [Homo sapiens] 52 30319 1 
 14 gi|12052734 spermatogenesis-associated protein 7 isoform a 
[Homo sapiens] 
52 64536 3 
 15 gi|338490 52-kD SS-A/Ro autoantigen [Homo sapiens] 52 55135 2 
 17 gi|7959223 SHROOM3 protein [Homo sapiens] 29 150746 2 
 1 gi|47132620 keratin 2 [Homo sapiens] 2179 65678 40 
 2 gi|11935049 keratin 1 [Homo sapiens] 2037 66198 46 
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7.2 Abbreviations 
53BP1   p53-binding protein 1 
A   Alanine 
aa   Amino acid 
ABIN   A20 binding inhibitor of NF-kappaB 
AID   Activation-induced cytidine deaminase 
AMP   Adenosin-monophosphate 
AMPK  AMP-activated protein kinase 
AMSH  (associatedmolecule with the SH3 (Src homology 3) domain of STAM 
(signal-transducing adaptor molecule) 
AP-1   Activator protein 1 
APC   Antigen presenting cell 
APC/C  Anaphase-Promoting Complex 
APE1   apurine/apyrimidinic endonuclease 1 
ATP   Adenosin-triphosphate 
BAFF   B-cell-activating factor 
BARD   BRCA1-associated RING domain protein 
BCR   B cell receptor 
BCA   Bicinchoninic acid 
Bcl-XL  B-cell lymphoma extra large 
BCMA  B-cell maturation antigen 
BER   Base excision repair 
BIR   Baculoviral IAP repeat 
bp   base pair 
BRCA   Breast cancer 
C   Cystein 
CD   Cluster of differentiation 
CD40L  CD40 ligand 
cFLIP   Cellular FLICE-inhibitory protein 
cIAP   Cellular inhibitor of apoptosis protein 
CIM   cIAP1/2 interacting motif 
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CMC   Critical micelle concentration 
cpdm   Chronic proliferative dermatitis 
CR   Complement receptor 
CRDs   Cysteine rich domains 
CRP   C reactive protein 
CREB   cAMP response element-binding 
CSR   Class switch recombination 
CUE   Coupling of ubiquitin conjugation to ER degradation 
CYLD   Familial Cylindromatosis Protein 
CXCL   Chemokine (C-X-C motif) ligand 
D   Aspartic acid 
Da   Dalton 
DC   Dendritic cell 
DD   Death domain 
DISC   Death inducing signalling complex 
DMEM  Dulbecco’s modified Eagle’s medium 
dsRNA  Double stranded ribonuclease acid 
DUB   Deubiquitinases 
E   Glutamic acid 
EBNA   EBV-specific nuclear antigen 
EBV   Epstein-Barr virus 
ELISA  Enzyme-linked immunosorbent assay 
ER   Endoplasmic reticulum 
ERAD   Endoplasmic-reticulum-associated degradation 
ERK   Extracellular signal related kinase 
F   Phenylalanine 
FACS   Fluorescence activated cell sorting 
FCS   Fetal calf serum 
FDC   Follicular dendritic cell 
G   Glycine 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GAT   Gga and Tom1 
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GC   Germinal centre 
GCKs   Germinal center kinases  
GCKR  Germinal centre kinase related 
GGA   Golgi-associated gamma-adaptin homologous and TOM1 
GITR   Glucocorticoid-induced TNF-R family receptor 
GLK   Germinal centre-like kinase 
GLUE   GRAM-like ubiquitin-binding in Eap45 
H   Histidine 
HBS   Hepes buffered saline 
HECT   Homologous with E6-associated protein C-terminus 
HEK   Human embryonic kidney 
HOIL-1  Haeme-oxidized IRP2 ubiquitin ligase 1 
HOIP   HOIL-1-interacting protein 
HPRT   Hypoxanthine-guanine phosphoribosyltransferase gene 
HPV   Human papillomavirus 
HRP   Horseradish-peroxidase 
I   Isoleucine 
IBR   In Between RING 
ICAM   Intercellular adhesion molecule 
IFN   Interferon 
Ig   Immunoglobuline 
IκB   Inhibitor of kappaB 
IKK   Inhibitor of kappaB kinase 
IL   Interleukin 
iNKT   invariant natural killer T cells 
iNOS   Inducible nitric oxide synthetase 
IP   Immunoprecipitation 
IRAK   IL-1R-associated kinase 
JNK   c-Jun N-terminal kinase 
K   Lysine 
KD   Dissociation constant 
kDa   kilo Dalton 
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L   Leucine 
LB   Lysogeny Broth 
LPS   Lipopolysaccharide 
LUBAC  Linear ubiquitin chain assembly complex 
M   Methionine 
MACS  Magnetic cell sorting 
MAPK  Mitogen-activated protein kinase 
MBL   mannose-binding lectin 
MHC   Major histocompatibility complex 
MKPs   MAPK phosphatases 
moTAP  Modified tandem affinity purification 
MS   Mass spectrometry 
mTOR  Mammalian target of rapamycin 
MW   Molecular weight 
N   Asparagine 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NEMO  NF-κB essential modulator 
NIK   NF-κB inducing kinase 
NF-κB  Nuclear factor kappaB 
NK   Natural Killer 
NLS   Nuclear localisation sequence 
NZF   Npl4-type zinc finger 
OPD   o-Phenylene-diaminedihydrochloride 
OPG   Osteoprotegerin 
P   Proline 
PAGE   Polyacrylamid gel electrophoresis 
PAMP  pathogen-associated molecular pattern 
PAZ   Polyubiquitin-associated zinc finger 
PCNA   Proliferating cell nuclear antigen 
PBMC  Peripheral blood mononuclear cells 
PBS   Phosphate buffered saline 
PDB   Pull-down buffer 
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PE   Phycoerythrin 
PI   Propidium iodide 
PI3K   Phosphatidylinositol-3-kinase 
PKC   Protein kinase C 
PLAD   Pre-ligand-binding assembly domain  
Pru   Plextrin receptor for ubiquitin 
PRR   pattern recognition receptor 
PS   Protease cleavage site 
PTP   Protein tyrosine phosphatase 
Q   Glutamine 
R   Arginine 
RAG   Recombination activated gene 
RANK  Receptor activator of NF-κB 
RBC   Red blood cell 
RBCK1  RBCC protein interacting with PKC 1 
RBR   RING-IBR-RING 
RHD   Rel homology domain 
RING   Really Interesting New Gene 
RIP1   Receptor interacting protein 1 
RPMI   Roswell Park Memorial Institute medium 
RSC   Receptor signalling complex 
RSF   Receptor superfamily 
RTKs   Receptor tyrosine kinases 
S   Serine 
SAPK   Stress-activated protein kinases 
SCF   Stem-cell factor 
SEM   Standard error of the mean 
SF   Superfamily 
SHARPIN  SHANK-associated RH-domain-interacting protein 
SHM   somatic hypermutation 
SM   Smac mimetic 
SP-D   Surfactant, pulmonary-associated protein D 
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ssRNA  Single stranded ribonuclease acid 
T   Threonine 
TAB   TAK1 binding protein 
TACI   Transmembrane activator and CAML interactor 
TAK1   TGF-β-activated kinase 1 
TAP   Tandem-affinity purification 
TCR   T cell receptor 
TD   Thymus dependent 
TFH   T follicular helper cells 
TH   T helper cells 
TI   Thymus independent 
TIM   TRAF-interacting motif 
TPL-2   Tumour progression locus 2 
TLR   Toll-like receptor 
TMD   Transmembrane domain 
TNF   Tumour necrosis factor 
TNP   2,4,6-Trinitrophenol 
TRADD  TNF-R1-associated death domain 
TRAF   TNF-receptor associated factor 
TRAIL  TNF-related apoptosis-inducing ligand 
TWEAK  TNF-like weak inducer of apoptosis 
UBA   Ubiquitin-associated 
UBAN   Ubiquitin-binding domains found in ABINs and NEMO 
UBD   Ubiquitin-binding domains 
UBL   Ubiquitin-like 
UEV   Ubiquitin-conjugating enzyme variant 
UIM   Ubiquitin-interacting motif 
UNG   uracil-DNA glycosylase 
UTR   Untranslated region 
V   Valine 
v/v   Volume/volume 
wt   wild-type 
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w/v   Weight/volume 
ZF   Zinc finger 
ZAP-70  Zeta-chain associated protein of 70 kDa 
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